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Eukaryotic cells contain numerous small nuclear ribonucleoproteins (RNPs) that function in 
different RNA-processing events in the nucleus. The spliceosomal U1, U2, U5 and U4/U6 snRNPs 
(small nuclear RNPs) make up one class of complexes that are catalysing a well defined process called 
pre-mRNA splicing. Pre-mRNA splicing is the process by which non-coding regions (introns) are 
removed from pre-mRNA transcripts and the protein coding elements (exons) assembled into mature 
mRNAs before the RNA leaves the nucleus. Another class comprises the box C/D snoRNPs (small 
nucleolar RNPs) that are involved in processing of the ribosomal RNA (rRNA) in the nucleolus. These 
complexes function as guides in the site-specific 2'-O-methylation of riboses in the precursor rRNA as 
well as assisting in rRNA biogenesis. 
Though the above-named U4/U6 snRNP and the box C/D snoRNP complexes are distinct in 
both composition and function, they share a similar RNA component and protein composition. Their 
RNA component can form a so called kink-turn (k-turn) motif (in the U4 5′ stem-loop and box C/D 
and B/C motif in box C/D snoRNAs), which is bound by a 15.5 kilodalton protein (15.5K).  
Besides protein 15.5K, the U4/U6 snRNP and the box C/D snoRNP complexes possesses 
several complex-specific proteins. In addition to seven Sm and seven LSm proteins that bind the Sm 
site of the U4 snRNA and the 3' end of U6 snRNA respectively, four proteins have been found to be 
associated with the human U4/U6 snRNP. These include the hPrp31 protein (also called 61K) and 
three proteins with molecular weights of 20, 60 and 90 kDa that form a biochemically stable, 
hCypH/hPrp4/hPrp3 (also 20/60/90K) protein complex. As well the box C/D snoRNPs are associated 
with a number of complex-specific proteins, which practically perform processing of the rRNA. The 
box C/D snoRNPs, like the U8 and U14 box C/D snoRNA, have been shown to bind proteins NOP56, 
NOP58, TIP48, TIP49 and fibrillarin. Lastly, the 15.5K protein and the hU3–55K protein belong to the 
complex assembled on the U3-box B/C motif of the U3 box C/D snoRNA. 
The assembly of the RNP complexes is a multiple-stage process that is initiated by 15.5K 
protein binding to the respective k-turn motif. Protein 15.5K is unique in that it is essential for the 
hierarchical assembly of the above-named three RNP complexes. Protein 15.5K interacts with the 
cognate RNAs via an induced-fit mechanism, which results in the folding of the surrounding RNA to 
create binding site(s) for the RNP-specific proteins. It has been shown that protein-RNA interactions 
are essential for the binding of complex-specific proteins to the U4/U6 snRNP, C/D snoRNP, and the 
RNP complex assembled on the U3-box B/C motif. However, at the beginning of this work it was 
unknown whether protein 15.5K also mediates RNP formation through direct protein-protein 
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interactions with the complex-specific proteins. To investigate this possibility, a series of protein 
15.5K mutations were created in which the surface properties of the protein had been changed. Within 
the scope of this work, their ability to support the formation of the three distinct RNP complexes was 
assessed and the formation of each RNP was found to require a distinct set of regions on the surface of 
the 15.5K protein. This implies that protein-protein contacts are essential for RNP formation in each 
complex. Further supporting this idea, direct protein-protein interaction was observed between 
hU3-55K and 15.5K. In conclusion, the data obtained suggest that the formation of each RNP involves 
the direct recognition of specific elements in both 15.5K protein and the specific RNA. 
The U4/U6 snRNP-specific protein hPrp31 and the box C/D snoRNP-specific proteins NOP56 
and NOP58 have been shown to be homologous, sharing a conserved domain, the so-called Nop 
domain. At the beginning of this work, it was unclear how protein hPrp31 and proteins 
NOP56/NOP58 assemble specifically onto the U4/U6 snRNP and box C/D snoRNPs, respectively. To 
address this question, structural requirements for the association of protein hPrp31 with the U4 snRNP 
in vitro were analysed. By employing point and deletion mutants of the U4 snRNA, structural features 
within the U4 snRNA necessary for binding of protein hPrp31 to the U4/U6 snRNP were determined. 
The findings indicate that the specificity of hPrp31 binding is provided by stems I and II of the 
U4 snRNA and suggest a way in which protein hPrp31 and proteins NOP56/NOP58 may specifically 
assemble onto the U4/U6 snRNP and box C/D snoRNPs, respectively. Furthermore, the results 
presented here provide evidence that the Nop domain on its own is necessary and sufficient for hPrp31 
binding to the U4 snRNP, thus suggesting that this domain may be a novel RNA-binding domain.  
Recently it has been shown that protein hPrp31 is also of clinical interest. Two mutations 
(A194E, A216P) in the human hPrp31 gene (PRPF31) are correlated with the autosomal dominant 
form of retinitis pigmentosa, a disorder that leads to degeneration of the photoreceptors in the retina of 
the eye. It has been shown that hPrp31 plays a key role in U4/U6.U5 tri-snRNP formation, which is 
assumed to take place in Cajal bodies (CBs), subnuclear organelles of animal and plant cells. 
Nevertheless, it is so far unknown whether the mutations in protein hPrp31 affect the stability of the 
tri-snRNP. Using fluorescence microscopy and biochemical methods it has been shown here how 
hPrp31 mutations influence the localisation of protein hPrp31 in vivo and how they influence 
U4/U6.U5 tri-snRNP formation. 
1.2. Zusammenfassung 
Eukaryotische Zellen enthalten eine Vielzahl kleiner Ribonukleoproteinkomplexe (engl. 
Ribonucleoproteins, RNPs), die an verschiedenen RNA-Prozessierungsereignissen im Zellkern 
teilnehmen. Die spleißosomalen U1, U2, U5 und U4/U6 snRNP (engl. small nuclear RNPs) Partikel 
stellen hierbei eine Gruppe dar und katalysieren in einem definierten und dynamischen Prozess die 
Spleißreaktion. Bei dieser Reaktion werden die nichtcodierenden Bereiche (Introns) aus der Prä-
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mRNA herausgeschnitten und die codierenden Bereiche, die so genannten Exons, zu einer reifen 
mRNA verknüpft. Eine andere Gruppe wird von den C/D Box snoRNPs (engl. small nucleolar RNPs) 
des Nukleolus gebildet. Diese steuern die Prozessierung der ribosomalen RNA (rRNA) und sind an 
der ortsspezifischen 2'-O-Methylierung von Ribosen beteiligt. Obwohl der U4/U6 snRNP Partikel und 
die C/D Box snoRNPs an unterschiedlichen Prozessen in der Zelle beteiligt sind, teilen sie sowohl eine 
ähnlich RNA Komponente als auch identische und ähnliche Proteine. Ihre RNA Komponente kann ein 
so genanntes kink-turn (k-turn) Motiv bilden (in der U4 5′ stem-loop; C/D und B/C Box Motiv in den 
C/D Box snoRNAs), das von dem allen RNPs gemeinsamen 15.5K Protein gebunden wird. 
Zusätzlich zu dem 15.5K Protein besitzt der U4/U6 snRNP Partikel und die C/D Box 
snoRNPs partikelspezifische Proteine. Der spleißosomale U4/U6 snRNP Partikel enthält neben sieben 
Sm- und sieben Lsm-Proteine, die jeweils mit der Sm-Bindungsstelle der U4 snRNA und dem 3' Ende 
der U6 snRNA assoziiert sind, vier weitere Proteine. Hierzu zählen das Protein hPrp31 (auch 61K) 
und drei weitere Proteine mit einem Molekulargewicht von 20, 60 und 90 kDa, welche den 
heteromeren hCypH/hPrp4/hPrp3 (auch 20/60/90K) Proteinkomplex bilden. Die C/D Box snoRNPs 
sind ebenfalls mit unterschiedlichen Proteinen assoziiert, welche die eigentliche rRNA 
Modifikationsreaktion durchführen. Sie besitzen sie die Proteine NOP56, NOP58, TIP48, TIP49 und 
Fibrillarin, die z.B. an die U8 und U14 C/D Box snoRNA binden. Die Proteine 15.5K und hU3-55K 
bilden den RNP-Komplex, der sich auf dem U3 C/D Box snoRNA-spezifischen B/C Box Motiv 
zusammenlagert. 
Die Zusammenlagerung der RNPs ist ein mehrstufiger Prozess, der von der Bindung des 
15.5K Proteins an das jeweilige kink-turn Motiv initiiert wird. Das 15.5K Protein ist einzigartig in 
seiner Funktion als Komplexbildner für die hierarchische Zusammenlagerung der drei RNP 
Komplexe. Es interagiert mit dem verwandten k-turn Motiv über einen „induced-fit“ Mechanismus, 
der in einer Faltung der umliegenden RNA und der Bildung von Bindungsstellen für die RNP-
spezifischen Proteine resultiert. Folglich spielen Protein-RNA Interaktionen, für die Bindung der 
assoziierten Proteine an den U4/U6 snRNP, den C/D Box snoRNP und den Partikel, der sich auf dem 
U3-spezifischen B/C Box Motiv zusammenlagert, eine wesentliche Rolle. Ob das 15.5K die RNP 
Bildung jedoch auch durch direkte Protein-Protein Wechselwirkungen mit den komplexspezifischen 
Proteinen vermittelt, war zu Beginn der vorliegenden Arbeit unklar. Um dieser Möglichkeit 
nachzugehen, wurde eine Reihe von Mutationen generiert, bei denen die Oberflächeneigenschaften 
des 15.5K Proteins verändert wurden. Im Rahmen dieser Arbeit wurde der Effekt der Mutationen auf 
die Zusammenlagerung der RNPs hin untersucht. Es zeigte sich, dass die Zusammenlagerung der drei 
untersuchten RNP Partikel eine Reihe verschiedener Regionen auf der 15.5K Oberfläche benötigt. Die 
dargestellten Ergebnisse legen daher nahe, dass direkte Protein-Protein-Interaktionen zwischen 15.5K 
und den verschiedenen komplexspezifischen Proteinen von Bedeutung sind. Diese Theorie wird ferner 
dadurch unterstützt, dass in den Studien eine direkte Interaktion zwischen dem 15.5K Protein und dem 
B/C Box-assoziierten Protein hU3-55K beobachtet werden konnte. Zusammenfassend legen die 
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gewonnenen Daten nahe, dass die Zusammenlagerung der jeweiligen RNP Partikel eine direkte 
Erkennung von spezifischen Elementen – sowohl auf der 15.5K Proteinoberfläche als auch 
spezifischer RNA Elemente –einbezieht. 
Bei dem U4/U6-spezifischen Protein hPrp31 und den C/D Box-spezifischen Proteinen NOP56 
und NOP58 handelt es sich um homologe Proteine, welche eine konservierte Domäne – die so 
genannte Nop-Domäne – gemeinsam haben. Zu Beginn dieser Arbeit war nicht bekannt wie hPrp31 
und NOP56/NOP58 spezifisch jeweils an den U4/U6 snRNP und die C/D Box snoRNP Partikel 
binden können. Um diese Fragestellung zu behandeln, wurden die strukturellen Anforderungen für die 
Assoziation von Protein hPrp31 an den U4 snRNP Partikel untersucht. Unter Verwendung von U4 
snRNA Punkt- und Deletionsmutanten wurden strukturelle Merkmale in der U4 snRNA bestimmt, 
welche für die Bindung des Proteins hPrp31 and den U4/U6 snRNP Partikel essentiell sind. Die 
Ergebnisse zeigen, dass die spezifische Bindung von hPrp31 an den U4 snRNP Partikel durch die 
RNA-Elemente „stem I“ und „stem II“ der U4 snRNA bestimmt wird, und legen einen Weg nahe, 
durch den hPrp31 und NOP56/NOP58 jeweils spezifisch an den U4/U6 snRNP und C/D Box snoRNP 
Partikel binden könnten. Die Ergebnisse erbrachten ferner den Nachweis, dass die Nop-Domäne für 
sich notwendig und darüber hinaus ausreichend für die Bindung des Proteins hPrp31 an den 
U4 snRNP Partikel ist. Sie legen zudem nahe, dass es sich bei dieser Domäne um eine neuartige RNA-
bindende Domäne handelt.  
Es konnte kürzlich gezeigt werden, dass das Protein hPrp31 auch von klinischem Interesse ist, 
da zwei Mutationen (A194E, A216P) im humanen hPrp31 Gen (PRPF31) mit der autosomal 
dominanten Form der Retinitis Pigmentosa in Zusammenhang gebracht werden konnten. Die Retinitis 
Pigmentosa ist eine Erkrankung, welche zu einer Degeneration der Photorezeptoren in der Netzhaut 
(Retina) des Auges führt. Es wurde kürzlich gezeigt, dass Protein hPrp31 eine Schlüsselrolle bei der 
U4/U6.U5 tri-snRNP Assemblierung spielt, welche vermutlich in den Cajal Bodies (sphärischen 
Unterorganellen des Nukleus) stattfindet. Dennoch ist bis jetzt unklar, ob die hPrp31 Mutationen die 
Stabilität des tri-snRNP beeinträchtigen. Unter Verwendung von Fluoreszenzmikroskopie und 
biochemischen Methoden wird in der vorliegenden Arbeit gezeigt, wie die hPrp31 Mutationen sowohl 




Eukaryotic cells contain many types of ribonucleoproteins (RNPs) which are 
complexes formed by RNA molecules associated with proteins. The majority of these RNPs 
are in the nucleus and can be classified in two groups, the small nuclear RNPs (snRNPs) that 
function in the maturation of messenger RNAs (pre–mRNA splicing), and the small nucleolar 
RNPs (snoRNPs) that reside in the cell nucleolus and are required for maturation of the 
ribosomal RNAs. Although both types of RNPs function in two different processes it was 
shown, that the complex assembly of some members of the snRNP and snoRNP family 
requires similar protein components. The assembly of multiprotein RNPs is complex and 
commonly involves a hierarchical assembly pathway. As the assembly of spliceosomal 
snRNPs and that of the snoRNPs are the objects of the work presented here. Current state of 
knowledge on their function, composition and assembly are reviewed in the following 
sections. 
2.1. Spliceosomal snRNPs 
Eukaryotic pre–mRNAs must undergo several post-transcriptional modifications 
before their export to the cytoplasm as functional mRNAs. Most pre–mRNAs have 
intervening non–coding sequences (introns) that must be removed, in order to connect 
precisely the coding sequences (exons), to generate a mature and functional mRNA. The 
mechanism of this critical processing event – called pre–mRNA splicing – has been studied in 
detail (reviewed in Brow, 2002). It has now been known for a long time that intron removal 
and ligation of exons occur through two sequential transesterification steps (Figure 2-1) that 
are carried out by a megaDalton RNP enzyme known as the spliceosome. Most introns have 
common consensus sequences near their 5' and 3' ends that are recognized by spliceosomal 
components and are required for spliceosome formation (5' and 3' splice site). The 5' splice 
site in higher eukaryotes is represented by the eight-nucleotide long consensus sequence 
AG/GURAGU. The nucleotides GU on the left always correspond to the beginning of the 
intron. The area of the 3' splice site is defined by the following three sequence elements 
(Reed, 1989): (i) the branch point, comprising the consensus sequence YNYURAC in which 
the adenosine represents the highly conserved branch-point adenosine; (ii) the polypyrimidine 
tract (Yn), consisting of 10-15 pyrimidines; (iii) the 3' splice site, consisting of the consensus 





Figure 2-1 Schematic depiction of the two-step transesterification splicing reaction.  
In the first step, the 2' hydroxyl group of the conserved adenosine within the branch site attacks the conserved 
guanine of the 5' splice site at the exon I-intron junction. A 2'-5' phosphodiester bond is made between the two 
residues, and the junction between exon I and the intron is cleaved. The products are a 2'-5' phosphodiester RNA 
lariat structure and a free 3'-OH that arises from the upstream exon. In the second step, the 3'-OH end of the 
released exon I then attacks the phosphodiester bond of the conserved guanine of the 3' splice site at the intron-
exon II junction. This reaction liberates the 3'-OH of the intron, resulting in a free lariat and spliced exons. The 
two-exon sequences are joined together, while the intron sequence is released as a lariat structure. The intron 
RNA is later degraded in the nucleus. 
The assembly of a spliceosome onto a pre–mRNA is an ordered process that involves 
five uridine-rich RNA molecules, the so-called U snRNAs. U snRNAs are characterized by 
their small size (between 106 and 187 nucleotides). These are associated with proteins 
forming small nuclear ribonucleoprotein particles (snRNPs) (Burge, 1999; Brow, 2002; Jurica 
and Moore, 2003). 
These snRNPs associate dynamically with each other and with pre–mRNA substrates 
through a multitude of RNA–RNA, RNA–protein and protein-protein interactions during 
spliceosome assembly and splicing catalysis to excise each intron precisely and to join the 
exons in the correct order in a concerted action.  
At present, two distinct spliceosomes have been identified (reviewed by Padgett and 
Shukla (2002) and Will and Lührmann (2005)). The large majority of introns are called U2-
dependent introns and are spliced by the U1, U2, U4, U5 and U6 snRNPs, which form the 
major spliceosome. A further, minor class of introns has been identified in eukaryotes, 
including Arabidopsis, Drosophila, Xenopus, mouse and humans (Burge, 1999). This class of 
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introns was initially identified by their unusual intron termini which consisted of 
dinucleotides AT–AC at their 5' and 3' ends. For this reason, they were originally referred to 
as ATAC introns. These introns were later found to be spliced by a group of less abundant 
snRNPs including U11, U12, U5 and U4atac/U6atac, which form the minor spliceosome, and 
an unknown number of non–snRNP proteins (Hall and Padgett, 1996; Tarn and Steitz, 1996; 
Tarn and Steitz, 1996). Thus, of the main spliceosomal subunits (i.e. the snRNPs), only the 
U5 snRNP is common to the two spliceosomes. 
As the major spliceosomal snRNPs, the minor spliceosomal snRNPs interact stepwise 
and in a highly ordered manner with the pre–mRNA. 
2.1.1. The spliceosome cycle 
The splicing reaction is a co-ordinated, dynamic process including the stepwise 
assembly of a spliceosome on the pre–mRNA, the splicing catalysis as well as the subsequent 
dissociation and recycling of splicing factors (Nilsen, 1998; Staley and Guthrie, 1998; Burge, 
1999). The stepwise assembly of the spliceosome involves the co-ordinated binding of pre-
assembled U snRNPs and numerous non–U snRNP splice factors onto the pre–mRNA (Figure 
2-2). 
The first step includes the recognition of the 5' splice site by the 5' end of the U1 
snRNP through base pairing with the intronic sequences of the pre–mRNA, initiating thus the 
early (E) complex formation. This initial step does not require energy (ATP) for formation. 
U1 is the only component that can bind in the absence of ATP, and its interaction with the 
pre–mRNA is in general required for the other snRNPs to bind. After the association of the 
U1 snRNP with the 5' splice site, the U2 snRNP recognizes and binds to the branch point to 
form complex A. Addition of the U2 snRNP is the first energy-dependent step in the splicing 
pathway. Binding of U2 snRNP is mediated in part by U1 snRNP, as well as additional non–
snRNP factors that bridge the two components. The U4/U6 di–snRNP, in turn, associates with 
the U5 snRNP and thus the 25S U4/U6·U5 tri-snRNP is formed, which is then integrated into 
the spliceosome to form complex B. In the subsequent steps, a base-paired region is formed 
between the U6 snRNA and the U2 snRNA, which leads to the formation of the catalytically 
active centre (Staley and Guthrie, 1998; Brow, 2002; Nilsen, 2003) (Figure 2-3). During the 
rearrangement of the fully assembled spliceosome to a catalytically active machine, the 
intermolecular base pairing between the U4 and U6 snRNAs becomes disrupted and the 
U4 snRNP particle is released from the spliceosome. Subsequently, the catalytically active 
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Figure 2-2 Schematic depiction of the spliceosome assembly.  
The first step of spliceosome assembly includes the ATP-independent recognition of the 5' splice site by U1 
snRNP (E complex). Subsequently, U2 snRNA base pairs with the branch site (A complex). The U4/U6.U5 
tri-snRNP binds, giving rise to the B complex. After major RNA-RNA rearrangements, the catalytically 
activated spliceosome is formed (complex B*). During these rearrangements, the U4 and U6 snRNAs dissociate 
and the 5' end of U2 enters into base-pairing interactions with U6, forming part of the spliceosomes catalytic 
core. The activated spliceosome catalyses the first transesterification step of splicing and complex C is formed. 
After the second step of splicing, the mRNA is released and the post-spliceosomal complex, containing the 
excised intron and the U2, U5, and U6 snRNPs, dissociates and the snRNPs are then recycled for a new round of 
splicing (modified from Staley and Guthrie, 1998). 
In the course of the splicing reaction, exon I and exon II are linked, generating a 
mature mRNA, and the intron lariat is released. Following the processing of the pre–mRNA, 
the spliceosome dissociates, and the snRNPs are recycled for new rounds of splicing (Nilsen, 
1998; Staley and Guthrie, 1998). 
The U4 and U6 snRNP form a heterodimer through intermolecular base-pairing 
between the U4 and the U6 snRNA (Bringmann et al., 1984; Hashimoto and Steitz, 1984; 
Rinke et al., 1985; Brow and Guthrie, 1988). This 13S U4/U6 di–snRNP associates with the 
20S U5 snRNP to generate the 25S U4/U6.U5 tri-snRNP particle, which is then integrated 
into the spliceosome (Black and Pinto, 1989). As the U4/U6 di–snRNP and the U4/U6.U5 
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tri-snRNP particle are in part object of the presented work, I will focus on this particle in the 
following sections. 
 
Figure 2-3 Proposed mechanism for disruption of U4/U6 di–snRNA base-pairing during activation of the 
spliceosome.  
Before activation of the spliceosome, the U6 snRNA base-pairs with the U4 snRNA, forming helices I and II of 
the U4/U6 snRNA duplex. Spliceosome activation is accompanied by the dissociation of U4 snRNA from the 
U4/U6 duplex, allowing U6 snRNA to pair with U2 snRNA, forming helix Ia, Ib and II. The intramolecular 
hairpin loop of the U6 snRNA co-ordinates the magnesium ion essential for the first step of splicing catalysis. 
The pre–mRNA 5' splice site is recognised by the ACAGA box of U6 snRNA before catalysis. The first 
transesterification step is indicated by the dashed red arrow. The formed network is essential for the structure 
formation of the catalytically active centre of the spliceosome (Datta and Weiner, 1991; Hausner, 1992; Madhani 
and Guthrie, 1992; Sun and Manley, 1995). The interaction of the U5 snRNA with the pre–mRNA in the 
catalytically active centre of the spliceosome is not depicted here for clarity. The U5 snRNP is essentially 
involved in structural rearrangements of the RNA-RNA network within the spliceosome during its activation.  
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2.1.2. The spliceosomal U4/U6.U5 tri-snRNP 
2.1.2.1. The RNA components of the U4/U6.U5 tri-snRNP 
Like the U1 and the U2 snRNA the U4, U5 and the U6 snRNA are characterized by a 
high content of uracil bases, small size and a phylogenetically conserved primary and 
secondary structure. The U6 snRNA shows the strongest conservation in sequence and size. 
The U4 and U5 snRNA are – like the U1 and U2 snRNA – transcribed by RNA 
polymerase II and modified at their 5' end by a N7-methylguanosine (m7G) cap. In the course 
of U snRNP assembly, which occurs in the cytoplasm, this cap is transformed by 
hypermethylation into a 2,2,7-trimethyl guanosine (m3G) cap. The U6 snRNA is an 
exception: it is transcribed by RNA Polymerase III and carries a γ–monomethylphospate at its 
5' end (Kunkel et al., 1986; Reddy et al., 1987; Brow and Guthrie, 1988; Guthrie and 
Patterson, 1988; Singh and Reddy, 1989; Tarn and Steitz, 1996). 
A group of less abundant snRNPs, U11, U12, U4atac, and U6atac, together with U5, 
are subunits of the so-called minor spliceosome which catalyses the removal of an untypical 
class of spliceosomal introns (U12-type) from eukaryotic messenger RNAs in plant, insects, 
vertebrates and some fungi. The U11, U12 and U4atac/U6atac snRNPs are orthologs of the 
U1, U2 and U4/U6 snRNPs in the major spliceosome (Hall and Padgett, 1996; Tarn and 
Steitz, 1996; Kolossova and Padgett, 1997; Yu and Steitz, 1997; Incorvaia and Padgett, 1998). 
Even though the minor U4atac and U6atac snRNAs are orthologs of U4 and U6, respectively, 
they share limited sequence homology (~ 40%). In addition, the sequence of U11 in 
comparison with U1, as well as U12 compared with U2, are completely unrelated. Even so, 
the minor U11, U12, U4atac and U6atac snRNAs can be folded into structures similar to U1, 
U2, U4 and U6, respectively (Tarn and Steitz, 1996). 
Moreover, spliceosomal U snRNAs contain post-transcriptionally modified 
nucleotides that are 2’-O-methylated or pseudouridylated (reviewed in Massenet (1998)). 
These modifications are made by the small nucleolar RNPs (snoRNPs), the function and 
composition of which are described in section 2.2. While the U6 snRNA transiently cycles 
through the nucleolus, the U4 and U5 snRNA are modified like the U1 and U2 snRNA in so-
called Cajal bodies, which are located in the nucleoplasm (Ganot et al., 1999; Lange and 
Gerbi, 2000; Kiss, 2001; Filipowicz and Pogacic, 2002). 
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Spliceosomal U snRNAs form extensive secondary structures characterised by 
numerous single- and double-stranded regions and stem-loop structures. Postulated secondary 
structures are represented in Figure 2-4. 
Except for the U6 snRNA, all U snRNAs contain the uridine-rich Sm binding-site 
(consensus sequence RAU3-6GR), which is essential for the association of the common Sm 
proteins (Branlant et al., 1982; Jones and Guthrie, 1990; Jarmolowski and Mattaj, 1993; 
Raker et al., 1996; Raker et al., 1999). 
 
Figure 2-4 Postulated secondary structure of the single U4 and U6 snRNA and the base-paired U4/U6 di–
snRNA.  
The Sm protein-binding site is depicted by grey shaded capitals. In the U6 snRNA, the Sm consensus sequence 
is absent (modified from Myslinski and Branlant (1991) and Achsel et al. (1999)). 
At the beginning of the splicing cycle, (see Figure 2-2) the U4 snRNA and the 
U6 snRNA are associated firmly with one another by two extended stretches of RNA-RNA 
base pairs (Figure 2-4). Two intermolecular helices (helix I and helix II) of the U4/U6 snRNA 
are separated by an intramolecular 5'-terminal hairpin loop (5' stem-loop) of the U4 snRNA 
(Bringmann et al., 1984; Hashimoto and Steitz, 1984; Rinke et al., 1985; Brow and Guthrie, 
1988). Mutational analysis of U4 snRNA in Xenopus oocytes and in the HeLa in vitro 
splicing system demonstrated that the 5' stem-loop is essential for spliceosome assembly and 
pre–mRNA splicing (Vankan et al., 1992; Wersig and Bindereif, 1992). Since the U4 snRNA 
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5' stem-loop is not needed for U4/U6 base pairing in vitro, it was suggested that it functions in 
spliceosome assembly at a stage subsequent to U4/U6 snRNP formation (Wersig et al., 1992). 
The 5' stem-loop of the U4 snRNP can form a conserved stem-internal loop-stem structure 
(Vidovic et al., 2000). This element is found repeatedly in the high-resolution structures of 
large and small ribosomal subunits, as well as in the box C/D snoRNAs (see section 2.2.3) 
and is described in more detail in section 2.3. 
2.1.2.2. The protein composition of the U4/U6.U5 tri-snRNP 
The protein composition of the major spliceosomal snRNPs has been best 
characterized in HeLa cells and yeast. Proteins associated with the snRNPs can be subdivided 
into two classes. The first class consists of the so-called common or Sm proteins, which are 
tightly associated with all snRNP particles. The second class comprises the particle-specific 
proteins, which associate with a particular snRNP particle or complex. The protein 
composition of the U4/U6 di–snRNP, the U5 snRNP, and the U4/U6.U5 tri-snRNP is 
summarised in Table 2-1 Protein composition of the U4/U6.U5 tri-snRNP (modified from 
Kastner (1998)).  
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Table 2-1 Protein composition of the U4/U6.U5 tri-snRNP (modified from Kastner (1998)) 
In addition to seven Sm proteins that bind the Sm site of the U4 snRNA, and seven 
LSm proteins, which are associated with U6 snRNA the 13S U4/U6 snRNP contains five 
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particle-specific proteins, namely 15.5K, hPrp31 (61K), hPrp3, hPrp4, and hCypH (reviewed 
in Will and Lührmann (2001)).  
The highly conserved protein 15.5K possesses a RNA-binding domain and binds 
directly to U4 snRNA (Nottrott et al., 1999). It is the first U4/U6-specific protein identified as 
interacting directly with the U4 snRNA. Protein 15.5K has been shown to be associated with 
the box C/D snoRNPs. It is unique in its function, as it is essential for the hierarchical 
assembly of these RNP complexes, which are different in both composition and function. The 
structure and function of 15.5K within the U4/U6 snRNP and the box C/D snoRNPs is 
described in more detail in section 2.3. 
Protein hPrp31 (hPrp31; human pre–mRNA processing factor 31) possesses a so-
called Nop domain in its central region, which shows clear homology to a domain of the 
box C/D snoRNP-associated proteins NOP56 and NOP58 (Gautier et al., 1997; Vithana et al., 
2001; Makarova et al., 2002) (see section 2.3 for more detail). 
 
Figure 2-5 Schematic representation of hPrp31 and the box C/D snoRNP-core proteins NOP56 and 
NOP58.  
The homologous Nop domain is indicated in green. 
The proteins hCypH, hPrp4, and hPrp3 (or, in the “human” nomenclature, 20K, 60K 
and 90K) form a biochemically stable, heteromeric complex (Horowitz et al., 1997; 
Teigelkamp et al., 1998). Protein hCypH belongs to the cyclophilin family of peptidyl-prolyl 
isomerases, termed cyclophilin H (CypH) (Horowitz et al., 1997; Teigelkamp et al., 1998). 
The crystal structure of CypH shows a typical cyclophilin fold (Reidt et al., 2000). 
Except for the hCypH protein, orthologous proteins termed Snu13p (15.5K in human), 
Prp4, Prp3 and hPrp31 are also associated with the yeast U4/U6 snRNP particle (Banroques 
and Abelson, 1989; Petersen-Bjorn et al., 1989; Anthony et al., 1997; Weidenhammer et al., 
1997; Gottschalk et al., 1999; Stevens and Abelson, 1999). Like their human counterparts, 
Prp4 and Prp3 bind directly to each other (Wang et al., 1997; Ayadi et al., 1998; Gonzalez-
Santos et al., 2002). The p110 (SART3) protein is required for recycling of the U4/U6 snRNP 
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from single U4 and U6 snRNPs and associates only transiently with U6 and U4/U6 (Bell et 
al., 2002). 
Interestingly, recent biochemical evidence has indicated that the U4/U6 snRNP-
specific proteins are also associated with the HeLa U4atac/U6atac snRNP of the minor 
spliceosome (Schneider et al., 2002). The part played by the U4/U6 snRNP-specific proteins 
in spliceosome assembly and activation is not yet entirely understood. Therefore, further 
analysis of the function of each protein is required. 
One part of the tri-snRNP is the U5 snRNP which is essentially involved in structural 
rearrangements of the RNA-RNA network within the spliceosome during its activation (see 
Figure 2-2). The 20S U5 snRNP possesses, in addition to the seven common Sm proteins, a 
total of eight particle-specific proteins, referred to as U5-15K, U5-40K, U5-52K, hPrp28 
(100K), hPrp6 (102K), hSnu114 (116K), U5-200K and hPrp8 (220K) proteins (Bach et al., 
1989; Will et al., 1993). 
Most of the U5-specific proteins display significant domain features, and play central 
roles in the splicing machinery (reviewed in Will and Lührmann (1997)). For example, 
protein U5-200K (in yeast Brr2p) and hPrp28 (in yeast Prp28p) contain the RNA helicase 
domain (Lauber et al., 1996; Teigelkamp et al., 1997). Protein hSnu114 (in yeast Snu114p) is 
the sole GTPase identified in the spliceosome to date and is related to translation elongation 
factor EF-2 (Fabrizio et al., 1997; Stevens et al., 2001; Jurica and Moore, 2003). 
By cross-linking experiments it has been demonstrated that only a few proteins are in 
direct contact with the U5 snRNA in the reconstituted yeast U5 snRNP (Dix et al., 1998). 
Some additional data further support the observation that U5 snRNP formation is mainly 
based upon protein-protein interactions. For example, the U5-hPrp6 protein does not bind to 
either U5 snRNA or the U5 core snRNP when this contains only U5 snRNA and Sm proteins; 
instead, it binds stably to the 20S U5 snRNP. This result suggested that one or more of the 
U5-specific proteins are required for the association of the protein hPrp6 (Makarov et al., 
2000). Protein hPrp6 contains several 34-amino-acid TPR motifs. TPR domains supply a 
structural unit of two antiparallel α-helices, building a platform for specific protein-protein 
interactions (reviewed in Blatch and Lassle (1999)). Interestingly, it was demonstrated by 
yeast two-hybrid studies that hPrp6 interacts directly with the U4/U6 di–snRNP-specific 
hPrp31 protein and, through this, connects the U4/U6 di–snRNP and the U5 snRNP 
(Makarova et al., 2002). 
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2.1.3. Assembly of the tri-snRNP 
Assembly studies in vitro have shown that both the U4/U6-specific hPrp31 protein and 
the heterotrimeric hCypH/hPrp4/hPrp3 protein complex do not bind on their own to the 
U4/U6 di–snRNP (Nottrott et al., 2002). In both cases, the 15.5K protein must bind first to the 
k-turn motif of the 5' stem-loop of the U4 snRNA. Protein 15.5K thus functions as a 
nucleation factor, inducing a hierarchical assembly of the U4/U6 di–snRNP (Figure 2-6). 
However, hPrp31 and hCypH/hPrp4/hPrp3 bind independently of one another. The situation 
just described for the U4/U6 di–snRNP particle is the same for the binding of hPrp31 to the 
alternative U4atac/U6atac snRNAs (Schneider et al., 2002). 
A key part in maintaining the stability of the tri-snRNP and in its formation from the 
U4/U6 di–snRNP and the U5 snRNP is played by the U4/U6-specific protein hPrp31, as 
demonstrated in vitro. Studies with HeLa nuclear extract depleted of hPrp31 showed that 
hPrp31 is essential for the splicing of pre–mRNA and for the formation of the human 
tri-snRNP particle (Makarova et al., 2002). Protein hPrp31 performs a dual function in the 
tri-snRNP particle. On the one hand, hPrp31 binds to the U4 snRNP in the U4/U6 di–snRNP 
(Nottrott et al., 2002). On the other hand, hPrp31 forms a bridge between the U4/U6 di–
snRNP and the U5 snRNP by binding to the U5-specific protein hPrp6 (Makarova et al., 
2002). The importance of the bridging function of hPrp31 between the U4/U6 di–snRNP and 
the U5 snRNP particle is also supported by the observation that, in the course of the catalytic 
activation of the spliceosome, the association of the U4 snRNP with the U6 snRNP on the one 
hand and the U5 snRNP on the other hand is weakened and the hPrp31 dissociates along with 
the U4 snRNP (Makarov et al., 2002).  
In order to restore the tri-snRNP so that it can participate in another round of splicing, 
the U4/U6 duplex must be reformed (Raghunathan and Guthrie, 1998). The human protein 
p110 (hPrp24 in yeast) has been found to be a U4/U6-recycling factor and a specific 
component of the U4/U6 di–snRNP (see Table 2-1) (Bell et al., 2002). 
The assembly of the tri-snRNP probably takes place in the Cajal bodies, which are 
subnuclear organelles of animal and plant cells, and which have been proposed to be involved 
in the assembly and maturation of snRNPs. It has been shown that after knock-down of the 
U4/U6-specific hPrp31 or the U5-specific hPrp6 protein in HeLa cells, tri-snRNP formation is 
inhibited, U4/U6 di–snRNPs containing U4/U6 proteins accumulate in Cajal bodies and the 




Figure 2-6 Schematic representation of the assembly of the U4/U6.U5 tri-snRNP.  
The hierarchical assembly pathway of the U4/U6.U5 tri-snRNP is initiated by the 15.5K protein. The 15.5K 
protein binds to the kink-turn motif of the U4 5' stem-loop and induces the association of the U4/U6-spcific 
hPrp31 protein and the heterotrimeric hCypH/hPrp4/hPrp3 protein complex. The U4/U6-specific protein p110 
plays an important role in U4/U6 di–snRNP recycling. However, p110 leaves the complex upon, or after, 
association of the U5 snRNP with the di–snRNP. The U4/U6 di–snRNP and the U5 snRNP are bridged by 
proteins hPrp31 and hPrp6. The U4/U6.U5 tri-snRNP formation is believed to take place in the Cajal bodies, 
within the nucleus (Schaffert et al., 2004). 
2.1.4. U4/U6.U5 tri-snRNP proteins and retinitis pigmentosa 
Recently it was shown that the tri-snRNP is also of clinical interest (McKie et al., 
2001; Vithana et al., 2001; Chakarova et al., 2002). It was demonstrated that two missense 
mutations (A194E, A216P) in the human hPrp31 gene (PRPF31) are correlated with the 
autosomal dominant form of retinitis pigmentosa (adRP), a disorder that leads to degeneration 
of the photoreceptors of the eye (Vithana et al., 2001). The mutations are located within 
(A216P) and adjacent (A194E) to the Nop domain (see Figure 2-7) shared with 
box C/D snoRNP-core proteins NOP56 and NOP58 (see Table 2-2). It is so far unknown 




Figure 2-7 Schematic representation of hPrp31 mutations A194E and A216P.  
The Nop domain shared with NOP56 and NOP58 is indicated in green. 
However, a splicing defect of A216P was demonstrated in yeast by the finding that the 
expression of yeast hPrp31 with the corresponding A216P mutation failed to complement 
hPrp31 function in a temperature-sensitive Prp31-deficient yeast strain at the high restrictive 
temperature (Deery et al., 2002). Mutations in hPrp31 may indirectly affect splicing by 
inhibiting the translocation of hPrp31 protein into the nucleus (Deery et al., 
2002).Furthermore, mutations of several highly conserved residues in the C-terminal part of 
U5-specific hPrp8p (McKie et al., 2001) and mutations of the gene encoding the U4/U6-
specific hPrp3 (Chakarova et al., 2002) are associated with adRP. 
It has been suggested that the rod photoreceptors present in the retina have a high 
demand for splicing of important molecules such as opsin mRNA. Defects in splicing due to 
loss of function of proteins hPrp31, hPrp3 and hPrp8p may cause a disease in this system. 
However, the molecular mechanism of adRP associated with mutations in these three 
tri-snRNP proteins is unclear at present. 
2.2. Small nucleolar RNPs (snoRNPs) 
2.2.1. Pre-rRNA processing 
To satisfy the demand for transcription of large numbers of ribosomal RNA (rRNA) 
molecules, all cells contain multiple copies of the rRNA genes. Ribosomal RNA –rRNA– 
genes are arranged in large clusters of, usually, many hundreds of genes. For instance, the 
human genome contains 150-300 copies of genes that encode the 5.8S, 18S and 28S rRNAs. 
The genes coding for the 5.8S, 18S, and 28S rRNAs, which are clustered in tandem arrays on 
five different human chromosomes (chromosomes 13, 14, 15, 21, and 22); the 5S rRNA genes 





Figure 2-8 Schematic representation of pre-rRNA processing in human.  
The 18S (S = sedimentation coefficient), 5.8S, and 28S rRNAs are transcribed as a single precursor (47S), which 
is cleaved at the primary processing site (PPS) in the 5' external transcribed spacers (ETS) and the second 
processing site (SPS) in the 3' external transcribed spacers, generating the 45S pre-rRNA. For further processing 
steps, the pathway depends on the chronological order of the cleavages at sites 1 and 2. Cleavage events result in 
the generation of the 18S, 5.8S, and 28S rRNAs, which are further modified by of base modifications. The 
schematic representation was modified from Bowman et al. (1981) and Hadjiolova et al. (1993). 
Each gene unit containing the gene for the 18S, 5.8S and 28S rRNAs is transcribed 
within the nucleolus by RNA polymerase I as a single 47S precursor rRNA (pre-rRNA) 
containing external transcribed spacers (ETS) at the 5' and 3' ends, and internal transcribed 
spacers (ITSs) separating the genes (see Figure 2-8). The 47S pre-rRNA is processed to give 
the 18S rRNA of the 40S (small) ribosomal subunit and to the 5.8S and 28S rRNAs of the 
60S (large) ribosomal subunit. Transcription of the 5S rRNA, which is also found in the large 
ribosomal subunit, occurs outside the nucleolus and is catalysed by RNA polymerase III 
(reviewed in Granneman and Baserga (2004)). 
The first processing step of the 47S pre-rRNA is a cleavage event within the 5' ETS of 
the pre-rRNA during the early stages of transcription (Figure 2-8). Moreover, the processing 
of pre-rRNA involves an extensive amount of base modifications, resulting in the addition of 
methyl groups to specific bases and ribose residues and also in the conversion of uridine to 
pseudouridine. In human cells, pre-rRNA processing involves the methylation of about a 
hundred ribose residues and ten bases, as well as the formation of about a hundred 
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pseudouridines (Maden, 1998; McCloskey and Crain, 1998). Most of these modifications 
occur during or soon after synthesis of the pre-rRNA, even if a few take place at later stages 
of pre-rRNA processing. 
2.2.2. Small nucleolar RNP are involved in pre-rRNA 
processing 
The processing of pre-rRNA requires the action of proteins and RNAs in the 
nucleolus. Nucleoli contain a large number (approximately 200) of small nucleolar RNAs 
(snoRNAs) which function in pre-rRNA processing (Kiss-Laszlo et al., 1996) (Figure 2-8). 
SnoRNAs contain a conserved sequence motifs (‘boxes’) termed C, D, H and ACA, 
respectively, and they are classified, according to which boxes are present, as C/D-type or 
H/ACA-type. Like the spliceosomal snRNAs, the snoRNAs are complexed with proteins, 
forming snoRNPs. Individual snoRNPs consist of single snoRNAs associated with eight to 
ten proteins. The snoRNPs then assemble on the pre-rRNA to form processing complexes in a 
manner analogous to the formation of the spliceosome on the pre–mRNA (see section 2.1.1). 
Most C/D-type snoRNPs direct the methylation of the ribose 2’-O-hydroxyl group, and most 
H/ACA-type snoRNPs direct the conversion of uridines into pseudouridines. A few snoRNPs 
of both types are necessary for certain cleavage events of pre-rRNAs, probably because they 
assist the folding of these RNAs in a crucial way. Like the spliceosomal snRNAs, the 
snoRNAs are complexed with proteins, forming snoRNPs. Individual snoRNPs consist of 
single snoRNAs associated with eight to ten proteins. The snoRNPs then assemble on the pre-
rRNA to form processing complexes in a manner analogous to the formation of the 
spliceosome on the pre–mRNA (see section 2.1.1). 
A small number of both H/ACA-type and box C/D-type snoRNPs are necessary for 
the cleavage of pre-rRNAs into 18S, 5.8S, and 28S products (Tycowski et al., 1994; Liang 
and Fournier, 1995; Peculis, 1997; Borovjagin and Gerbi, 1999). This is probably because 
they assist the folding of these RNAs in a critical way. For instance, the most abundant 
nucleolar snoRNA is U3, which is present in about 200,000 copies per cell and is required for 
the initial cleavage of pre-rRNA within the 5' ETS sequences (see 2.2.1). Likewise, the 
U8 snoRNA is responsible for cleavage of pre-rRNA to the 5.8S and 28S rRNAs, while the 
U22 snoRNA is responsible for cleavage of the pre-rRNA to the 18S rRNA. 
However, the majority of snoRNAs function in directing the base modifications of 
pre-rRNA. Most of the snoRNAs contain short sequences of about 15 nucleotides that are 
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complementary to 18S or 28S rRNA (Figure 2-9) (Ganot et al., 1997; Ni et al., 1997; Kiss-
Laszlo et al., 1998). These complementary regions contain the sites of base modification in 
the rRNA. By base-pairing with specific regions of the pre-rRNA, snoRNAs act as guide 
RNAs, targeting the enzymes responsible for ribose methylation or pseudouridylation to the 
exact site on the pre-rRNA molecule. 
Interestingly, the spliceosomal snRNAs contain many post-transcriptionally modified 
nucleotides (Reddy and Busch, 1988). The U6 snRNA, for example, contains eight 2'-O-
methyl groups and three pseudouridines, whose generation is directed by snoRNAs 
(Tycowski et al., 1998; Ganot et al., 1999). The snoRNAs that guide the modification of U6 
snRNA are structurally and functionally indistinguishable from snoRNAs that direct the 
modification of the 18S, 5.8S and 28S rRNAs (Kiss, 2001; Filipowicz and Pogacic, 2002; 
Terns and Terns, 2002).  
As the box C/D snoRNPs are among the objects of the investigation presented in this 
dissertation, they will be described in more detail in the following two sections. 
2.2.3. Structure and function of the box C/D snoRNPs. 
The RNA component of each box C/D snoRNP particle directing the 2'-O-methylation 
of the ribose in the pre-rRNA is central to RNP formation, trafficking, and function. It 
provides binding sites for specific proteins and contains one or several sequences that base-
pair with the substrate RNA. The RNA component has no catalytic function on its own, but it 
assists in accurately positioning the putative methylase relative to the RNA substrate for 




Figure 2-9 Structure and function of the box C/D snoRNAs.  
A. Methylation of the 2'–hydroxyl in the ribose moiety according to Lafontaine and Tollervey (1998). B. 
Secondary-structure model for the U14 box C/D snoRNA base-paired with the 18S pre-rRNA (according to Kiss 
(2001)). The consensus sequences for boxes C, C', D, and D' are indicated by grey shading. The box C/D 
interaction with the pre-rRNA generates a conserved structure in which the box D is positioned five nucleotides 
from the ribose moiety to be 2’-O-methylated. The C'/D' motif does not direct nucleotide methylation, but 
functions in pre-rRNA processing and 18S rRNA production. C. Schematic representation of the human 
U3 snoRNA secondary structure (according to Parker and Steitz (1987), Jeppesen et al. (1988), Mereau et al 
(1997), Borovjagin and Gerbi (1999) and Watkins et al. (2000)) base-paired with the 18S pre-rRNA. The 
consensus sequences for boxes C'/D, and B/C are indicated by the grey shading. The 5' external transcribed 
spacer (5' ETS) is indicated in grey. 
Canonical box C/D snoRNAs possess conserved boxes C (consensus sequence 5'-
PuUGAUGA-3') and D (consensus sequence 5'-CUGA-3') close to the 5' and 3' termini of the 
RNA, respectively. The box C/D snoRNAs contain next to the conserved box C/D motif often 
a less clearly homologous copy of this element termed the box C'/D' motif (Kiss-Laszlo et al., 
1998; Gaspin et al., 2000; Omer et al., 2000; Henras et al., 2004). Both motifs direct 2’-O-
methylation of the target nucleotide positioned within the guide RNA:substrate RNA duplex 
and situated five nucleotides upstream from the D or D' box (Box D-plus five-selection rule) 
(Kiss-Laszlo et al., 1996). In some eukaryotic snoRNAs such as U14 box C/D snoRNA (see), 
the C'/D' motif does not direct nucleotide methylation but functions in pre-rRNA processing 
and 18S rRNA production (Liang and Fournier, 1995). The complete secondary structure of 
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box C/D snoRNA is still not entirely known. However, it has been shown that boxes C and D 
form a k-turn motif (Caffarelli et al., 1996; Cavaille and Bachellerie, 1996; Watkins et al., 
1996; Xia et al., 1997; Darzacq and Kiss, 2000; Villa et al., 2000), which is described in more 
detail in section 2.3. This box C/D motif is crucial for box C/D snoRNP assembly and 
function (Caffarelli et al., 1996; Cavaille and Bachellerie, 1996; Watkins et al., 1996; Lange 
et al., 1998; Samarsky et al., 1998). 
The box C/D snoRNPs are associated with four core proteins, namely 15.5K, NOP56, 
NOP58 and fibrillarin (see Table 2-2; Schimmang et al., 1989; Wu et al., 1998; Lafontaine 
and Tollervey, 1999; Lafontaine and Tollervey, 2000; Watkins et al., 2000). It was shown 
recently that the assembly of the box C/D snoRNP follows a hierarchical pathway. The 
binding of protein 15.5K to the k-turn motif in the box C/D motif is essential for the 
subsequent association of the box C/D snoRNP-specific proteins NOP56, NOP58 and 
fibrillarin, as well as for the binding of the two assembly factors TIP48 and TIP49 (Watkins et 
al., 2002) (see section 2.3 for more detail).  
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Table 2-2 Proteins associating with the box C/D and Box B/C RNPs. 
The 2’-O-Methylation of the ribosomal RNA is catalysed by fibrillarin, which shares 
structural features with methyltransferases, and is guided by the associated snoRNAs 
(Tollervey et al., 1993; Niewmierzycka and Clarke, 1999). The box C/D motif probably plays 
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a key role in the correct positioning of fibrillarin, in such a way that it methylates the correct 
ribose of the substrate RNA nucleotide (see 2.2.2). 
The U3 box C/D snoRNA, which functions in processing and not in modification, 
contains a U3-specific k-turn motif, termed the box B/C motif, which also binds protein 
15.5K (Watkins et al., 2000). Binding of 15.5K to the B/C motif (see section 2.3 for more 
detail) are also essential for the recruitment of the U3-specific hU3–55K (see Figure 2-13) 
(Granneman et al., 2002). The box B/C motif, and therefore probably the 15.5K and hU3–
55K, is essential for the formation of the 80S SSU (small subunit) processome and 
consequently for processing of the 18S rRNA and production of the small subunit of the 
ribosome (Granneman et al., 2004). 
2.3. Similarities between the U4/U6 snRNP and 
box C/D snoRNPs  
The U4/U6 snRNP and the box C/D snoRNPs are though distinct in both composition 
and function, are sharing a similar RNA component and protein composition. Their RNA 
component can form a so called kink-turn motif (in the U4 5′ stem-loop and box C/D and B/C 
motif in box C/D snoRNAs), which is bound by the 15.5K protein.  
 
Figure 2-10 Crystal structure of the kink-turn motif present in the 5' stem-loop of the U4 snRNA.  
The kink in the phosphate-sugar backbone culminates with the flipped out U31 nucleotide, which is highlighted 
in red. Sheared G-A base pairs are indicated by the open circles. The conformation of the terminal penta-loop of 
the 5' stem-loop shown here was not resolved in the crystal structure (modified from Vidovic et al., 2000). 
This RNA motif has a kink in its phosphodiester backbone that causes a sharp turn in 
the RNA helix. Therefore, it has been initially called kink-turn (k-turn) motif (see Figure 
2-10) (Klein et al., 2001). In the 5' stem-loop of the U4 snRNA, two stems – stem I and stem 
II – are connected by an internal asymmetric loop. In the 5' stem-loop of the U4 snRNA, stem 
I consists of three Watson-Crick G-C base pairs and stem II consists of two Watson-Crick G-
C base pairs. Two tandem-sheared G-A base pairs are formed in the internal loop. A terminal 
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penta-loop is attached to stem II. The flipped-out uridine (U31), the unpaired adenines (A29, 
A30), and the guanine (G32) are involved in hydrogen bonds and hydrophobic interactions. 
Unpaired nucleotides and the tandem-sheared G-A base pairs are critical for binding of the 
15.5K protein to the U4 snRNA (Nottrott et al., 1999; Vidovic et al., 2000). 
The highly conserved protein 15.5K possesses a RNA-binding domain and binds 
directly to U4 snRNA (Nottrott et al., 1999), to the box C/D and B/C motif of the box C/D 
snoRNPs (Watkins et al., 2000, Granneman et al., 2002). It belongs to a family of 
homologous RNA-binding proteins that includes the ribosomal proteins S12, L7a, L30 as well 
as the H/ACA snoRNP protein NHP2 (Koonin et al., 1994). A common feature of these 
proteins is that they all recognise a k-turn motif (Figure 2-10). Members of this family of 
proteins have been shown to bind the k-turn motif using an induced fit interaction with 
changes in the structure of both the RNA and protein components (Nottrott et al., 1999; Reidt 
et al., 2000; Williamson, 2000; Turner et al., 2005; Wozniak et al., 2005). Protein 15.5K is 
the first U4/U6-specific protein identified as interacting directly with the U4 snRNA. 
 
Figure 2-11 Crystal structure of the 15.5K protein bound to the 5' stem-loop of the U4 snRNA.  
The crystal structure of the 15.5K protein displays a protein folds into a compact globular domain consisting of 
alternating α-helices and β-sheets (a so-called α-β-α sandwich). The flipped out U31 of the kink-turn motif 
locates in a binding pocket of the 15.5K. 
The structure of protein 15.5K in complex with the 5' stem-loop of U4 snRNA was 
determined by X-ray crystallography to a resolution of 2.9 Å (Vidovic et al., 2000) (see 
Figure 2-11 15.5K crystal structure). The 128 amino acid residues of the 15.5K protein fold 
into a single, compact globular domain of alternating α-helices and β-strands that form a α-β-
α sandwich structure. In the 15.5K protein, the RNA binding surface consists of amino acid 
residues located in two α-helices (α2 and α4), one β-strand (β1), and three different loops (β
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1-α2, β2-α3, and α4-β4). These residues interact predominantly with the nucleotides of the 
U4 snRNA k-turn motif, whose nucleotide U31 is tightly bound in a pocket of the protein. 
The 15.5K protein has been found to perform a similar function in the minor 
spliceosome (Nottrott et al., 1999), the RNA-binding site adopting a structural organisation 
similar to that observed in the major spliceosome. Interestingly, a recent study has shown that 
the 15.5K protein is, in addition, a component of both the box C/D snoRNPs and the U3-
specific box B/C motif, providing thus a link between the pre–mRNA and pre–rRNA 
processing machineries (Watkins et al., 2000). These findings raised the interesting possibility 
that the U4/U6 snRNP and the box C/D RNPs share a common ancestral snRNP. 
The box C/D motif is a two-part protein-binding element with internal loop 
nucleotides, forming a k-turn motif, that is essential for binding protein 15.5K, while the 
strongly conserved sequence of stem II is required for the binding of the remaining 
box C/D snoRNA-associated proteins (Szewczak et al., 2002; Watkins et al., 2002) (See 
Figure 2-13). This suggests that the stem II nucleotides form part of a binding site for proteins 
other than 15.5K. Consistent with this idea, substitutions of stem II nucleotides that establish 
or preserve Watson-Crick base-pairing do not inhibit the binding of protein 15.5K. On the 
other hand, these stem II substitutions restrain the association of the remaining C/D RNP core 
proteins with the C/D box motif (Watkins et al., 2002). Recently, it was shown by cross-
linking experiments that the NOP58 protein can be cross-linked to the 3' uridine residue in 
stem II of the C box, whereas fibrillarin can be cross-linked to the 5' uridine residue of the D 
box in stem II (Cahill et al., 2002).  
The U3 box C/D snoRNA, which functions in processing and not in modification, 
contains a U3-specific k-turn motif, termed the box B/C motif, which also binds protein 
15.5K (Watkins et al., 2000). Interestingly, the sheared G-A base pairs do not form in an 
isolated B/C motif, suggesting that protein 15.5K induces k-turn formation upon binding the 
B/C motif (induced fit; see also section 2.3). Binding of 15.5K and the small internal loop 
adjacent to stem I in B/C motif also essential for the recruitment of the U3-specific hU3–55K 
(see Figure 2-13) (Granneman et al., 2002). The box B/C motif, and therefore probably the 
15.5K and hU3–55K, is essential for the formation of the 80S SSU (small subunit) 
processome and consequently for processing of the 18S rRNA and production of the small 




Figure 2-12 The box C/D and box B/C motifs of snoRNAs. 
The box C/D and box B/C motifs present in the U14 and U3 snoRNA, respectively, can be folded into a structure 
similar to that of the 15.5K binding site within the U4 snRNA 5' stem-loop. Sheared G-A base pairs are indicated 
by the open circles. Remaining non–Watson-Crick base pairs are indicated by black dots. The consensus 
sequences for boxes C/D, and B/C are indicated by grey shading. 
Similarly as described for binding of the box C/D snoRNP-specific proteins, protein 
hPrp31 and the hCypH/hPrp4/hPrp3 complex do not only require the presence of 15.5K for 
interaction with U4/U6 snRNA, but as well certain RNA elements within the U4 and U6 
snRNA. The hCypH/hPrp4/hPrp3 heteromer requires helix II but not helix I of the U4/U6 
duplex for binding (see Figure 2-13), and this interaction involves a direct contact between 
protein 90K and U6 also requires the U4 5' stem-loop, and is observed only when stem II of 
the U4/U6 duplex is formed. Protein hPrp31 directly contacts the 5' portion of U4 snRNA via 
a novel RNA-binding domain and requires at least the U4 snRNA 5' stem-loop for interaction 
with the U4/U5 snRNP (Nottrott et al., 2002).  
Protein hPrp31 (hPrp31; human pre–mRNA processing factor 31) possesses a so-
called Nop domain in its central region, which shows clear homology to a domain of the 
box C/D snoRNP-associated proteins NOP56 and NOP58 (Gautier et al., 1997; Vithana et al., 
2001; Makarova et al., 2002) (see also 2.2.3 and 2.3). The structure of this domain was 
recently determined by X-ray crystallography for the archaeal NOP56/58 homologue Nop5p 
(Aittaleb et al., 2003). Interestingly, hPrp31 also shows functional homology to NOP56 and 
NOP58. Here too, the binding of protein 15.5K to the k-turn motif is a requirement for the 




Figure 2-13 Schematic representation of box C/D and box B/C snoRNP assembly.  
The U4/U6 snRNP, the box C/D and box B/C snoRNA are shown here schematically with the conserved 
nucleotides of the box C/D and box B/C motif indicated by grey shading. As the primary snoRNA binding 
protein, 15.5K binds to the kink-turn, while the remaining U4/U6 snRNP proteins hPrp31, hCypH/hPrp4/hPrp3, 
the box C/D snoRNP proteins NOP56, NOP58, fibrillarin, TIP48 and TIP49 and the box B/C-specific hU3–55K 
protein bind the 15.5K-snoRNA complex. Box C/D snoRNP and box B/C-specific proteins specifically 
recognize the conserved sequence of stem II and the small internal loop adjacent to stem I respectively. 
Interestingly, an identified cross-link between the U4atac snRNA and protein hPrp31, 
which mapped to an amino acid within the Nop homology domain (see Figure 2-5), indicates 
that this could function as an RNA-binding motif (Nottrott et al., 2002; Kühn-Hölsken et al., 
2005). By ultraviolet irradiation of the U4atac snRNP and the native purified U4/U6·U5 
tri-snRNP particle, hPrp31 was cross-linked to single-stranded nucleotide regions at the three-
way junction and the terminal penta-loop of the U4atac and the U4 snRNA (Nottrott et al., 
2002; Kühn-Hölsken et al., 2005). This argues for the existence of direct contacts between 
hPrp31 and the U4 snRNA. The formation of the U4-15.5K complex suffices for the stable 
binding of hPrp31. However, it remains unclear which regions of the U4 snRNA are required 
for this stable binding, and what factors determine its specificity. The corresponding 
determinants in hPrp31 are likewise unknown. 
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2.4. Aim of the work presented in this dissertation 
The k-turn-binding protein 15.5K is unique in that it is essential for the hierarchical 
assembly of three RNP complexes distinct in both composition and function, namely the 
U4/U6 snRNP, the box C/D snoRNP, and the RNP complex assembled on the U3-box B/C 
motif. The assembly of each of these complexes requires unique sequence elements found in 
the cognate RNA. Furthermore, changes in the RNA structure mediated by the binding of 
protein 15.5K are proposed to create the binding site for the complex-specific proteins. 
However, it is possible that protein 15.5K also mediates RNP formation by protein-protein 
interactions with the complex-specific proteins. The 15.5K protein is evolutionarily highly 
conserved throughout its entire sequence. However, only ~10% of its surface is directly 
involved in RNA-binding. This suggests that protein 15.5K may perform tasks other than just 
RNA-binding in either the assembly and/or the function of one or more of the different 
complexes. In addition, the close proximity of the binding sites for the box C/D proteins and 
hPrp31 to the 15.5K binding site makes it highly likely that protein-protein contacts exist 
between these components. To broaden our understanding of RNP complex formation, one 
aim of the work presented here was therefore to find out whether protein 15.5K nucleates 
complex assembly, entirely or in part, through direct protein-protein interactions. In order to 
test this possibility, the published crystal structure of protein 15.5K bound to the U4 5' stem-
loop was used to identify conserved amino acids on the surface of protein 15.5K for 
subsequent mutagenesis. The mutants generated were to be tested for their ability to support 
the formation of the U4/U6 snRNP, the box C/D snoRNP, and the U3 box B/C complex. 
It was already known that the 15.5K protein associates with the U4 snRNA in vitro. 
Therefore, the examination of its nuclear localisation pattern and its association in vivo with 
the U4 snRNA and the box C/D snoRNAs were of further interest to gain more information 
about the site of U4/U6 di-snRNP and box C/D snoRNP assembly. In addition, it was of 
interest whether the conserved 15.5K surface has any influence on complex assembly and 
localisation of the U4/U6 snRNP and the box C/D snoRNPs in vivo.  
The U4/U6-specific protein hPrp31 plays a key part in the stability of the tri-snRNP 
and in its formation from the U4/U6 di–snRNP and the U5 snRNP. As mentioned above, the 
association of the hPrp31 protein requires not only the binding of the 15.5K protein to the U4 
snRNA, but also elements located within the U4snRNA. Recently, by ultraviolet irradiation of 
the U4atac snRNP and the native purified U4/U6.U5 tri-snRNP particle, hPrp31 was cross-
linked to single-stranded nucleotide regions at the three-way junction and the terminal penta-
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loop of the U4atac and the U4. Furthermore, by hydroxyl-radical footprinting analysis, 
nucleotides within the U4 snRNA specifically contacted by protein hPrp31 have been 
identified. However, at the beginning of this work, structural requirements within the U4 
snRNA necessary for binding of protein hPrp31 to the U4/U6 snRNP were unknown. 
Therefore, it was of major interest to identify RNA elements within the U4 snRNA required 
for its binding and to learn more about the molecular interactions involved in binding of 
protein hPrp31 to the U4/U6 snRNP.  
The corresponding determinants in the hPrp31 protein are likewise unknown. Clues to 
structural requirements for the association of the hPrp31 protein were the more interesting as 
hPrp31 shows functional and structural homology with NOP56 and NOP58. Protein hPrp31 
possesses a so-called Nop domain in its central region, which shows clear homology with a 
domain of the box C/D snoRNP-associated proteins NOP56 and NOP58. This raises the 
question of how the specificity of the binding of hPrp31 to the U4 snRNA (i.e., and not to the 
box C/D snoRNA) is achieved. Interestingly, a cross-link (see above) identified between the 
U4atac snRNA and protein hPrp31, which mapped to an amino acid within the Nop 
homology domain, indicates that this could function as an RNA-binding motif (Nottrott et al., 
2002; Kühn-Hölsken et al., 2005). However, at the beginning of this work it was unclear 
whether this Nop homology domain is sufficient for the binding to the U4 snRNP. Therefore, 
the minimal requirements on the side of the hPrp31 protein for binding to the U4 snRNP were 
to be analysed by using a number of protein hPrp31 deletion mutants. 
As described before, Prp31 is also of clinical interest. Mutations in its gene (PRPF31), 
located in and around the conserved hPrp31 Nop domain, are correlated with the autosomal 
dominant form of retinitis pigmentosa (Vithana et al., 2001). However, the molecular 
mechanisms underlying this disease are so far unknown. Thus, it was of interest to investigate 
the molecular effect of these mutations on stability of the U4/U6.U5 tri-snRNP and to analyse 
their influence on hPrp31 localisation in vivo. 
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3. Materials and Methods 
3.1. Materials 
3.1.1. Fine Chemicals 
Standard chemicals, organic substances, and solvents used in this work were obtained 
from Merck (Darmstadt) or Serva (Heidelberg). Their degree of purity is „pro analysis“. The 
best supplier has been chosen respectively.  
Product Manufacturer 
Acrylamide 30% (0.8% Bis–Acrylamide) Roth, Karlsruhe 
Agarose (Type II) Sigma, Deisenhofen 
Amplify™ Amersham Biosciences, Freiburg 
APS (Ammonium persulfate ) Merck, Darmstadt 
Bio–Rad Protein Assay Bio–Rad, Munich 
Bromophenol Blue Bio–Rad Lab., USA 
Bovine Serum Albumin (BSA) Sigma, Taufkirchen 
CASYton (isotonic sodium chloride solution) Schaerfe System, Reutlingen 
Calcium chloride Merck, Darmstadt 
Coomassie Brilliant Blue R250 Serva, Heidelberg 
Coomassie Brilliant Blue G250 Serva, Heidelberg 
Denhardt´s reagent Invitrogen, Karlsruhe 
ddH2O Millipore 
DTT (Dithiothreitol) Roth, Karlsruhe 
DMSO (Dimethyl sulfoxide) Merck, Darmstadt 
Dulbecco’s modified eagle medium (DMEM) Gibco RBL, Eggenstein 
EDTA (Ethylene–diamine–tetraacetic acid) Roth, Karlsruhe 
Ethanol Merck, Darmstadt 
Ethidium bromide Roche, Switzerland 
Fetal Calf Serum (FCS) GibcoBRL, Karlsruhe 
Ficoll 400 Amersham Pharmacia, Freiburg 
Formaldehyde Riedel-de Haën, Seelze 
Glucose Sigma, Taufkirche 
Glutathion (reduced)  Sigma, Deisenhofen 
Glycerol (bonded to Tridodecylmethylammonium 
chloride) 
Merck, Darmstadt 
Glycogen Roche, Switzerland 
Glycine Roth, Karlsruhe 
Heparin Sigma, Deisenhofen 
HEPES (N-2-hydroxyethylpiperazine-N -2- Calbiochem, USA 




Imidazol Merck, Darmstadt 
Isopropyl–β–D–thiogalactoside (IPTG) Sigma, Deisenhofen 
LB medium (capsules) Bio 101, USA 
LB agarose media (capsules) Bio 101, USA 
Potassium phosphate Sigma, Deisenhofen 
Milk powder Naturaflor, Dietmannsried 
Magnesium chloride J.T. Baker, Holland 
2'–Mercaptoethanol Roth, Karlsruhe 
Mowiol 4–88 Calbiochem, USA 
OptiMEM 1 GIBCO, New Zealand 
Paraformaldehyde Merck, Darmstadt 
PMSF (Phenyl methane sulfonyl fluoride) Roche, Mannheim 
Polyvinyl pyrrolidon Merck, Darmstadt 
Ponceau S Serva, Heidelberg 
Protein–A–Sepharose CL–4B Amersham Pharmacia, Freiburg 
Roti–Phenol/Chloroform Roth, Karlsruhe 
Salmon Sperm DNA (10 mg/ml) Stratagene, USA 
Sodium acetate Sigma, Deisenhofen 
Sodium–carbonate J.T. Baker, Holland 
Sodium–chloride Roth, Karlsruhe 
Sodium dehydrogenate phosphate Merck, Darmstadt 
Sodium dodecyl sulfate (SDS) Serva, Heidelberg 
Poly(vinylidene difluoride) membrane, Hybond–P Amersham Pharmacia Biotech, 
Freiburg 
Phenol–Chloroform–Isoamylalcohol (PCA) Roth, Karlsruhe 
Bovine serum albumin (BSA) Roche, Switzerland 
TEMED (N,N,N',N'–Tetra methyl ethylendiamine) Sigma, Deisenhofen 
Tris–(hydroxymethyl)amino methane Roth, Karlsruhe 
Triton X–100 Sigma, Deisenhofen 
tRNA, E. Coli MRE 600 Boehringer; Mannheim 
Tween20 Sigma, Deisenhofen 
Urea Roth, Karlsruhe 
Xylencyanol FF Fluka, Switzerland 




Mark 12, protein marker (range 2.5-200 kDa) Invitrogen, Netherlands 
DNA–molecular weight marker III (sizes DNA fragments 
between 0.12 and 21.2 kbp) 
Roche Applied Science, 
Mannheim 
DNA–molecular weight marker VI (sizes DNA fragments 
between 0.15 and 2.1 kbp) 
Roche Applied Science, 
Mannheim 
Rainbow Prestained Protein standard (range 10-250 kDa) Bio–Rad, Munich 
Precision Unstained protein standard (range 10-250 kDa) Bio–Rad, Munich 
3.1.3. Radio Chemicals 
Product Manufacturer 
[α–³²P] pCp; 3000 Ci/mmol Amersham Pharmacia Biotech, Freiburg 
[35S] Methionine; 1000 Ci/mmol Amersham Pharmacia Biotech, Freiburg 
[α–³²P] UTP; 3000 Ci/mmol Amersham Pharmacia Biotech, Freiburg 
[γ-³²P] ATP; 6000 Ci/mmol Amersham Pharmacia Biotech, Freiburg 
[α–³²P] dATP; 3000 Ci/mmol Amersham Pharmacia Biotech, Freiburg 
3.1.4. Enzymes und Inhibitors 
Product Manufacturer 
Alkaline Shrimp Phosphatase Roche, Switzerland 
Restriction Endonucleases New England Biolabs, Schwalbach 
Pfu DNA Polymerase (2.5 U/µl) Stratagene, Heidelberg 
T7 RNA Polymerase New England Biolabs, Schwalbach 
SP6 RNA Polymerase Promega, USA 
T4 DNA Ligase New England Biolabs, Schwalbach 
T4 Polynucleotide kinase New England Biolabs, Schwalbach 
T4 RNA Ligase New England Biolabs, Schwalbach 
Thrombin Amersham Pharmacia Biotech, Freiburg 
PreScission Protease Amersham Pharmacia Biotech, Freiburg 
complete™ EDTAfree Protease Inhibitor tablets Roche, Switzerland 
DNase I Roche, Switzerland 
Proteinase K (10 mg/ml) Sigma, Deisenhofen 
RNase A (1 mg/ml) Ambion, USA 
RNasin (40 U/µl) Promega, USA 
RQ DNase I (1 U/µl) Promega, USA 
Taq DNA Polymerase (5U/µl) Promega, USA 
Trypsin-EDTA GIBCO, New Zealand 
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3.1.5. Used Organisms 
Product Manufacturer 
Epicuran Codon Plus E.coli BL21(DE3)– RIL Stratagene, Heidelberg 
Epicuran Codon Plus E.coli BL21–RIL Stratagene, Heidelberg 
Epicuran Codon Plus E.coli BL21(DE3)– RP Stratagene, Heidelberg 
Epicuran Codon Plus E.coli BL21–RP Stratagene, Heidelberg 
Epicuran Codon Plus E.coli BL21(DE3)– LysS Stratagene, Heidelberg 
XL1–blue E. coli  Stratagene, USA 
HMS 174 (DE3) E. Coli Novagen, USA 
XL1–blue super competent E.coli Stratagene, USA 
One Shot DH5a–T1 Invitrogen, Netherlands 
HeLa SS6 cells (human cervix carcinoma cells) Shooter and Grey, 1952 
YFP–Fibrillarin expressing stable cell line (HeLa) Lamond Lab, UK (Leung and 
Lamond, 2002) 
3.1.6. Plasmids and Vectors 
Plasmid Description Source, Reference 
pGex–hPrp31 pGex–6–P–1 vector expressing the human 
hPrp31 protein with a GST–tag; AmpR; 
restriction sites BamHI → XhoI 
Nottrott et al., 2002 
pGex–15.5K pGex–4–T–2 vector expressing the human 
15.5K protein with a GST–tag at the N–
terminus; AmpR; restriction sites BamHI → 
SalI 
Nottrott et al., 1999 
pGex–15.5K–1, –2, –3, 
–4 and –5 
pGex–4–T–2 vector expressing mutant 15.5K 
proteins with a GST–tag at the N–terminus; 
AmpR; restriction sites BamHI → SalI 
This study 
pET–hPrp31 pET–28a vector expressing the human hPrp31 
protein with a His–tag at the C–terminus; T7 
promoter; restriction sites EcoRI → HindII 
Makarova et al., 
2002 
pGEM-3Zf(+)-hU3-55K pGEM-3Zf(+) vector containing the sequence 
of the U3-specific hU3-55K protein, subcloned 
in the EcoRI site of the vector; T7 promoter  
Pluk et al., 1998 
phU4 pUC13 vector containing the sequence of the 
human U4 snRNA; SP6 promoter; AmpR; 
linearized with DraI 
Wersig und 
Bindereif, 1990 
phU5 pEMBL 8(+) vector containing the sequence of 
the human U5 snRNA; T7 promoter; AmpR; 
linearized with HindIII 
Wersig und 
Bindereif, 1990 
phU6 pUC13 vector containing the sequence of the 
human U6 snRNA; SP6 promoter; AmpR; 
linearized with BamHI 
Wersig und 
Bindereif, 1990 
pEYFP–15.5K Mammalian expression vector pEYFP-C1 
expressing the human 15.5K protein with a 





3, –4 and –5 
Mammalian expression vector pEYFP 
expressing mutant 15.5K proteins with a YFP–
This study 
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Plasmid Description Source, Reference 
tag; CMV promoter; KanR/NeoR 
pcDNA–Flag15.5K Mammalian expression vector pcDNA3.1 
expressing the human 15.5K protein with a 




–2, –3, –4 and –5 
pcDNA3.1 vector expressing the human 15.5K 
protein with a Flag–tag at the N–terminus; 
CMV promoter; AmpR/NeoR 
This study 
pETM–hPrp31 Mammalian expression vector pETM–41 
expressing the hPrp31 with an MBP–tag at the 
N–terminus; T7 promoter; KanR 




Mammalian expression vector pETM–41 
expressing the hPrp31 deletion mutant with an 
MBP–tag at the N–terminus; T7 promoter; 
KanR 
This study 
pETM–hPrp31 Nop∆C Mammalian expression vector pETM–41 
expressing the hPrp31 deletion mutant with an 
MBP–tag at the N–terminus; T7 promoter; 
KanR 
This study 
pTA2–hPrp31 Mammalian expression vector pTA2 
expressing the human hPrp31 wild–type with 
an HA–tag at the N–terminus; T7 and CMV 
promoter; AmpR/NeoR 
Sunbin Liu, AG 
Lührmann 
pTA2–hPrp31–A194E Mammalian expression vector pTA2 
expressing the human hPrp31 retinitis 
pigmentosa mutant A194E with an HA–tag at 
the N–terminus; T7 and CMV promoter; 
AmpR/NeoR 
This study 
pTA2–hPrp31–A216P Mammalian expression vector pTA2 
expressing the human hPrp31 retinitis 
pigmentosa mutant A216P with an HA–tag at 
the N–terminus; T7 and CMV promoter; 
AmpR/NeoR 
This study 
pCS2-Lamin A pCS2+ vector containing a Flag-tag coding 
sequence, expresses 2.1 TOPO cloning vector
Bechert et al., 2003; 
AG Weber (MPI, 
Göttingen) 
3.1.7. Antibodies 
Antibody Source, Reference 
α–Fibrillarin antibody AG Lührmann (Watkins et al. 2002) 
α–NOP56 antibody AG Lührmann (Watkins et al. 2002) 
α–NOP58 antibody AG Lührmann (Watkins et al. 2002) 
α–TIP48 antibody AG Lührmann (Watkins et al. 2002) 
α–TIP49 antibody AG Lührmann (Watkins et al. 2002) 
α–15.5K antibody rabbit serum AG Lührmann (Nottrott et al. 1999) 
α–hU3-55K Granneman et al., 2002 
α–GST antibody Roche, USA 
α–H20 antibody AG Lührmann (Bochnig et al., 1987) 
Monoclonal α–coilin–antibody (5P10π) M. Carmo–Fonseca, Portugal 
3 Materials and Methods 
 35
Antibody Source, Reference 
Monoclonal α–SC35–antibody Sigma, Taufkirchen 
α–hPrp4 (60K) rabbit serum („Roy”) AG Lührmann (Lauber et al., 1997) 
α–hPrp31 (61K) rabbit serum („4825”) AG Lührmann (Makarova et al. 2002) 
α–40K rabbit serum („Paul”) AG Lührmann (Achsel et al. 1998) 
α–HA antibody Roche, USA 
α–GFP–Antibody Roche, USA 
Goat–α–rabbit antibody, coupled Texas Red  Molecular Probes, USA 
Goat–α–mouse antibody, coupled Alexa 488  Molecular Probes, USA 
Goat–α–rabbit antibody, coupled Alexa 647 Molecular Probes, USA 
3.1.8. Reaction Sets (Kits) 
Kit Manufacturer 
ABI PRISM™ Dye Deoxy Cycle Sequencing Kit  Applied Biosystems, Weiterstadt 
Cell Line Nucleofector Kit R Amaxa, Cologne 
ECL Western Blot Detection Kit  Amersham Biosciences, Freiburg
Lipofectamine 2000 Invitrogen, Netherlands 
QIAquick PCR Purification Kit Qiagen, Hilden 
QIAprep Spin Miniprep Kit Qiagen, Hilden 
QIAquick Gel Extraction Kit Qiagen, Hilden 
QIAquick nucleotide removal kit Qiagen, Hilden 
HiSpeed Plasmid Midi Kit Qiagen, Hilden 
Rabbit Reticulocyte Lysate System Promega, USA 
pCR T7/CT TOPOTM TA Cloning Kit Invitrogen, Netherlands 
Quick Change™ Site–Directed Mutagenesis Kit Stratagene, Heidelberg 
BigDye Terminator Sequencing Kit Perkin Elmer, USA 
Prime it II Random Prime Labelling Kit Stratagene, USA 
TNT T7 Coupled Reticulocyte Lysate System  Promega, USA 
3.1.9. Chromatography Columns und Column Materials 
Product Manufacturer 
Amylose Resin  New England Biolabs, France 
Glutathion–Sepharose 4B Amersham Pharmacia Biotech, 
Freiburg 
Talon resin Clontech, USA 
Protein–A–Sepharose CL – 4B Amersham Pharmacia Biotech, 
Freiburg 
p–Aminobenzamidine Agarose Sigma, Steinheim 
ProbeQuant G-50 and G-20 columns Amersham Pharmacia Biotech, 
Freiburg 
SulfoLink coupling gel Pierce, USA 




Ampicillin Sigma, Deisenhofen 
Kanamycin Sigma, Deisenhofen 
Chloramphenicol Sigma, Deisenhofen 
Penicillin/Streptomycin Biochrom, Berlin 
Gentamycin (G418) Invitrogen, Netherlands 
3.1.11. Miscellaneous Material 
Product Manufacturer 
Ultrafilter (0.2 and 0.45 µm) Millipore, USA 
Microcon Millipore, USA 
Centriplus Millipore,USA 
Cryo freezing container Nalgene, USA 
Slide–A–Lyser dialysis cassette (MWCO, 0.5 – 3 ml) Pierce, USA 
Glassware Merck, Darmstadt 
Reaction Tubes (0.5 ml, 1.5 ml, 2.0 ml) Eppendorf, Hamburg 
Reaction Tubes (15 ml, 50 ml) Falcon, Germany 
Electroporation Cuvettes Bio–Rad, Munich 
Cassetes for exposing X–ray films  Kodak, Augsburg 
X–ray film BioMax MR Kodak, Augsburg 
Parafilm American National Can, USA 
Pipettes (adjustable) Eppendorf, Hamburg 
Whatman 3MM paper Whatmen, England 
Centrifuge Tubes, different sizes Sorvall, USA 
Centrifuge cups ( 1l, 450 ml) Sorvall, USA 
Nylon membrane Hybond XL Amersham Pharmacia Biotech, 
Freiburg 
PVDF (Polyvinylidene difluoride) membrane Bio-Rad, Munich 
Sterican needles Braun, Melsungen 
Spinocan Luer Lock needles Braun, Melsungen 
Syringes, different sizes Braun, Melsungen 
Cell culture flasks, different sizes Sarstedt, Nürnbrecht 
Cell culture dishes, different sizes Greiner, Frickenhausen 
Cell scraper (Rubber policeman) Sarstedt, Nürnbrecht 
3.1.12. Devices 
Device Manufacturer 
Amaxa nucleofector Amaxa, Cologne 
Autoclave, Varioklav  H+P, Oberschleißheim 
CASY Counter TT Schärfe System, Reutlingen 
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Device Manufacturer 
Electroporator, Gene Pulser Xcell Bio–Rad, Munich 
Roll Incubator Karl Hecht, Staufen 
Chambers for gelelectrophoresis  Manufactured in the institute,  
Bio–Rad Munich 
Gel documentation system (Geldoc) Bio–Rad, Munich 
Geldryer Modell 583 Bio–Rad, Munich 
„head–over–tail”–Rotor  Fröbel, Lindau 
Heatblock Unitek HB–30 Grand Instruments, UK 
High–voltage transformer Amersham Pharmacia Biotech, 
Freiburg 
Hybridization oven Hybaid Biometra, UK 
Inverse microscope Axiovert 25 Zeiss, Jena 
Inverse Zeiss LSM 510 META Laser Scanning microscope Zeiss, Jena 
CO2 Incubator BBD 6220 Kendro, USA 
Incubator with and without shaker New Brunswick Science, Nürtingen
Magnetic stirrer KMO 213 KiKA Labortechnik, Staufen 
Megafuge 1.0R Kendro, USA 
Pipette Aid Akkujet Hirschmann 
pH Meter MI 229 Mettler Toledo, Switzerland 
Phosphoimager screens, different sizes Molecular Dynamics 
Phosphoimager Typhoon 8600 Molecular Dynamics 
Rotation Shaker Karl Hecht, Staufen 
X–ray film processor X–Omat Kodak, USA 
Sequencer ABI Prism 310 Perkin Elmer, USA 
Sonifier Bransdon, USA 
Thermocycler Hybaid, Netherlands 
Centrifuges (Sorvall, Heraeus) Kendro, Osterode 
Sorvall SA–600 rotor Kendro, Osterode 
Sorvall SLA–1500 rotor Kendro, Osterode 
Sorvall SS–34 rotor Kendro, Osterode 
Sorvall SLA–6000 rotor Kendro, Osterode 
SpeedVac concentrator Eppendorf, Hamburg 
Spectrophotometer Ultrospec 3000pro Amersham Pharmacia Biotech, 
Freiburg 
Scintillationcounter Tro–Carb 2100TR Packard, Dreieich 
Table centrifuge with and without cooling unit Kendro, Osterode 
Trans–Blot cell Bio–Rad, Munich 
UV lamp, 254 nm Herolab, Wiesloch 
Vortex Scientific Industries, USA 
Waterbath 1012 Gesellschaft für Labortechnik, 
Burgwedel 
Waterbath HBR4 digital Janke & Kunkel, Staufen i. Br. 
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3.1.13. DNA Oligonucleotides 
Listed DNA oligonucleotides were produced by MWG–Biotech AG. Nucleotides 
changed with respect to the wild–type sequence were indicated by bold capitals. 
Oligonucleotide  Sequence 
 




   AC–3' 
15.5K-1B 
 3'–GTTCTTCGATGACCTGGAGCAAGCGTTTAGTTTTCTTTCGCCGGTCGAAGCCTTTCCTCGGTT 
   AC–5' 
15.5K-2A  5'–CTGCACCTGCCGCTGCTGTGTCGCAAAATGAATGTGCCCTACGTGTTTGTG–3' 
15.5K-2B  3'–GACGTGGACGGCGACGACACAGCGTTTTACTTACACGGGATGCACAAACAC–5' 
15.5K-3A  5'–GTGTTTGTGCGCTCCAAGCAGGATCTGGGGGAAGCCTGTGGGGTCTCCAGG–3' 
15.5K-3B  3'–CACAAACACGCGAGGTTCGTCCTAGACCCCCTTCGGACACCCCAGAGGTCC–5' 
15.5K-4A  5'–GAAGGCTCGCAGCTGAAACAGAAAATCAAATCCATTCAGAGCTCCATTGAAAGGCTCTTAG–3' 
15.5K-4B  3'–CTTCCGAGCGTCGACTTTGTCAAATAGTTTAGGTAAGTCTCGAGGTAACTTTCCGAGAATC–5' 
15.5K-5A  5'–TCCAATCCATTCAGCAGTCCATTAGCAGCCTCTTAGTCTAAACCTGTGGC–3' 
15.5K-5B  3'–AGGTTAGGTAAGTCGTCAGGTAATCGTCGGAGAATCAGATTTGGACACCG–5' 
15.5K-6A 
 5'–GGATCCATGACTGAGGCTGATAAAGCGAGCTATGTGAAATTTGAAGTGCCGGCCCACCTCACC 
   AAGAAGCTA–3' 
15.5K-6B 
 3'–CCTAGGTACTGACTCCGACTATTTCGCTCGATACACTTTAAACTTCACGGCCGGGTGGAGTGG 
   TTCTTCGAT–5' 
15.5K-7A  5'–GAGCCACTGGAGATCATTCTGGCGCTGCCGCTGCTGTGTGAAGAC–3' 
15.5K-7B  3'–CTCGGTGACCTCTAGTAAGACCGCGACGGCGACGACACACTTCTG–5' 
15.5K-8A  5'–GACAAGAATGTGCCCTACGTGATTGTGCGCTCCAAGCAGGCCC–3' 
15.5K-8B  3'–CTGTTCTTACACGGGATGCACTAACACGCGAGGTTCGTCCGGG–5' 
15.5K-9A  5'–GCCTGTTCTGTCACCATCAAAAGCGAAGATAAAGGTGCGCAGCAGATCCAATCCATTCAG–3' 
15.5K-9B  3'–CGGACAAGACAGTGGTAGTTTTCGCTTCTATTTCCACGCGTCGTCTAGGTTAGGTAAGTC–5' 
15.5K-10A  5'–TCCAATCCATTCAGCAGTCCGCGGAAAGGGCGTTAGTCTAAACCTGTGGCCTC–3' 
15.5K-10B  3'–AGGTTAGGTAAGTCGTCAGGCGCCTTTCCCGCAATCAGATTTGGACACCGGAG–5' 
15.5K-11A  5'–TCCAATCCATTCAGCAGTCCATTAACGAACTCAAAGGTTAAACCTGTGGCCTCTGCC–3' 
15.5K-11B  3'–AGGTTAGGTAAGTCGTCAGGTAATTGCTTGAGTTTCCAATTTGGACACCGGAGACGG–5' 
15.5K-12A 
 5'–CCATGACTGAGGCTGATGTGTGCCCAGAAGCCAGCCCCCTTGCCCGCGCCCACCTCACCAAGA 
   AGCTA–3' 
15.5K-12B 
 3'–GGTACTGACTCCGACTACACACGGGTATACGGTCGGGGGAACGGGCGCGGGTGGAGTGGTTCT 
   TCGAT–5' 
15.5K-13A  5'–CCATGACTGAGGCTGATGTGTGCCCAGAAGCCTATCCCCTTGCCGATGCCC–3' 
15.5K-13B  3'–GGTACTGACTCCGACTACACACGGGTATACGGATAGGGGAACGGCTACGGG–5' 
15.5K-14A  5'–GGCTGATGTGAATCCAAAGGCCAGCCCCCTTGCCCGCGCCCACCTCACCAAGAAGCTA–3' 
15.5K-14B  3'–CCGACTACACTTAGGTTTCCGGTCGGGGGAACGGGCGCGGGTGGAGTGGTTCTTCGAT–5' 
15.5K-15A  5'–CAAGAAGCTACTGGACCTCGTTCGCAAATCATGTGAATATAAGCAGCTTCGGAAAGG–3' 
15.5K-15B  3'–GTTCTTCGATGACCTGGAGCAAGCGTTTAGTACACTTATATTCGTCGAAGCCTTTCC–5' 
15.5K-16A  5'–GCCTGTTCTGTCACCATCAAAAGCGGCTCGAAACTGGCGCAGCAGATCCAATCCATTCAG–3' 
15.5K-16B  3'–CGGACAAGACAGTGGTAGTTTTCGCCGAGCTTTGACCGCGTCGTCTAGGTTAGGTAAGTC–5' 
15.5K-CYS1A  5'–CTGGACCTCGTTCAGCAGTCAGCGAACTATAAGCAGCTTCGGAAAG–3' 
15.5K-CYS1B  3'–GACCTGGAGCAAGTCGTCAGTCGCTTGATATTCGTCGAAGCCTTTC–5' 
15.5K-CYS2A  5'–TTCTGCACCTGCCGCTGCTGGCGGAAGACAAGAATGTGCCCTAC–3' 
15.5K-CYS2B  3'–AAGACGTGGACGGCGACGACCGCCTTCTGTTCTTACACGGGATG–5' 
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Oligonucleotide  Sequence 
15.5K-CYS3A  5'–CAAGCAGGCCCTGGGGAGAGCCGCGGGGGTCTCCAGGCCTGTCATC–3' 
15.5K-CYS3B  3'–GTTCGTCCGGGACCCCTCTCGGCGCCCCCAGAGGTCCGGACAGTAG–5' 
15.5K-CYS4A  5'–GTCTCCAGGCCTGTCATCGCCGCGTCTGTCACCATCAAAGAAGG–3' 
15.5K-CYS4B  3'–CAGAGGTCCGGACAGTAGCGGCGCAGACAGTGGTAGTTTCTTCC–5' 
15.5K-CYS5A  5'–CTGGACCTCGTTCAGCAGTCAAGCAACTATAAGCAGCTTCGGAAAG–3' 
15.5K-CYS5B  3'–GACCTGGAGCAAGTCGTCAGTTCGTTGATATTCGTCGAAGCCTTTC–5' 
pEYFP-15.5K-4A 
 5'-CCATCAAAGAAGGCTCGCAGCTGAAACAGAAAATCAAATCCATTCAGAGCTCCATTGAAAGGC 
   TCTTAGTCTGAATTCTGC-3' 
pEYFP-15.5K-4B 
 5'-GCAGAATTCAGACTAAGAGCCTTTCAATGGAGCTCTGAATGGATTTGATTTTCTGTTTCAGCT 
   GCGAGCCTTCTTTGATGG-3' 
pEYFP-15.5-4B 
 5'-GCAGAATTCAGACTAAGAGCCTTTCAATGGAGCTCTGAATGGATTTGATTTTCTGTTTCAGCT 
   GCGAGCCTTCTTTGATGG-3' 
pEYFP-15.5K-5A  5'-CCAATCCATTCAGCAGTCCATTAGCAGCCTCTTAGTCTGAATTCTGCAGTCG-3' 
pEYFP-15.5K-5B  5'-CGACTGCAGAATTCAGACTAAGAGGCTGCTAATGGACTGCTGAATGGATTGG-3' 
pEYFP-15.5-5B  5'-CGACTGCAGAATTCAGACTAAGAGGCTGCTAATGGACTGCTGAATGGATTGG-3' 
   
 
 Primers used for introducing point mutations into the hPrp31 
sequence 
hPrp31 RP-A194Ea  5'-GGCCTGCGACATGGAGCTGGAGCTGAACGC-3' 
hPrp31 RP-A194Eb  5'-GCGTTCAGCTCCAGCTCCATGTCGCAGGCC-3' 
hPrp31 RP-A216Pa  5'-CGGATGTCCTTCATCCCACCCAACCTGTCC-3' 









   
  Primers used for the generation of hPrp31 deletion mutants 
hPrp31-aa59  5'-ATGTTTGCTGAGATTATG-3' 
hPrp31-aa92  5'-GTCATCGTGGATGCCAAC-3' 
hPrp31-aa215  5'-ATCGCACCCAACCTGTC-3' 
hPrp31-aa310  5'-CTCGTGGAAACTGTCCAC-3' 
hPrp31-aa335  5'-CGGCGGCTCCTGCCACTT-3' 
  Miscellaneous primers used for cloning and sequencing 
15.5NFlagpcDNA3a  5'-CACCATGGACTACAAGGACGATGATGACAAGCCCGGGATGACTGAGGCTGATGTGAATCC-3' 
15.5NFlagpcDNA3b  5'-GCCACAGGTTTAGACTAAGAGCCTTTCAATGG-3' 
15.5CFlagpcDNA3a  5'-CACCATGACTGAGGCTGATGTGAATCC-3' 
15.5CFlagpcDNA3b  5'-TTACTTGTCATCATCGTCCTTGTAGTCCATCCCGGGGACTAAGAGCCTTTCAATGGACTGC-3' 
61K-TOPO_rev  5'–TCAGGTGGACATAAGGCCACTCTT–3' 
5'-YFP  5'-GCCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTG-3' 
3'-YFP  5'-GCTGCTTCATGTGGTCGGGGTAGCGGGCGAAGCACTGCAGGC-3' 
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3.1.14. RNA Oligonucleotides 
All listed RNA oligonucleotides were obtained from Dharmacon Research Inc., USA. 




U4–1 U4 5' end, nucleotides A1–
U52 
5'–AGCUUUGCGCAGUGGCAGUAUCGUAGCCAAUGAGG 
   UUUAUCCGAGGCGCGAU–3' 
U4–2 
U4 5' stem–loop, nucleotides 
A20–U52 5'–AUCGUAGCCAAUGAGGUUUAUCCGAGGCGCGAU–3' 
U4–3 
U4 5' stem–loop with 
terminal GAAAC penta–loop 5'–AUCGUAGCCAAUGAGGGAAACUCCGAGGCGCGAU–3' 
U4–4 
U4–5' stem–loop with 
terminal ribosomal GNRA 
tetra–loop 5'–AUCGUAGCCAAUGAGGGCAACCGAGGCGCGAU–3' 
U4–5 
U4–5' stem–loop with 
terminal AAGU tetra–loop 5'–AUCGUAGCCAAUGAGGAAGUCCGAGGCGCGAU–3' 
U4–7 
U4 5' stem–loop with an 
elongated stem II by one 
additional base pair 5'–AUCGUAGCCAAUGAGGCUUUAUGCCGAGGCGCGAU–3' 
U4–8 
U4 5' stem–loop with an 
elongated stem II by three 
additional base pairs 
5'–AUCGUAGCCAAUGAGGUCGUUUAUCGACCGAGGCGCG 
   AU–3' 
U4–9 
U4 5' stem–loop with an 
elongated stem II by five 
additional base pairs 
5'–AUCGUAGCCAAUGAGGUCGACUUUAUGUCGACCGAGGC 
   GCGAU–3' 
U4–10 
U4 5' stem–loop deletion 
mutant, nucleotides A20–U52 5'–GGCCAAUGAGGUUUAUCCGAGGCC–3' 
U4–11 
U4–5' stem–loop with 
terminal ribosomal UNCG 
tetra–loop 5'–AUCGUAGCCAAUGAGGUUCGCCGAGGCGCGAU–3' 
U4–12 
U4–5' stem–loop with 
terminal UUU tri–loop 5'–AUCGUAGCCAAUGAGGUUUCCGAGGCGCGAU–3' 
U4–13 
U4–5' stem–loop with an 
elongated stem II by an 
additional A–U base pair 5'–AUCGUAGCCAAUGAGGUUUUAUACCGAGGCGCGAU–3' 
U4–15A 
U4–5' stem–loop containing a 
methylation at position U38 5'–AUCGUAGCCAAUGAGGUmUUAUCCGAGGCGCGAU–3' 
U4–15B 
U4–5' stem–loop containing a 
methylation at position A39 5'–AUCGUAGCCAAUGAGGUUUmAUCCGAGGCGCGAU–3' 
U4–15C 
U4–5' stem–loop containing a 
methylation at position U40 5'–AUCGUAGCCAAUGAGGUUUAmUCCGAGGCGCGAU–3' 
U4–15D 
U4–5' stem–loop containing a 
methylation at position C41 5'–AUCGUAGCCAAUGAGGUUUAUmCCGAGGCGCGAU–3' 
U4–16 
U4–5' stem–loop containing a 
deoxy– Uridine at position 
38 5'–AUCGUAGCCAAUGAGGUdUUAUCCGAGGCGCGAU–3' 
U4–16B 
U4–5' stem–loop containing a 
deoxy–Adenosin at position 
39 5'–AUCGUAGCCAAUGAGGUUUdAUCCGAGGCGCGAU–3' 
U4–16C 
U4–5' stem–loop containing a 
deoxy– Uridine at position 
40 5'–AUCGUAGCCAAUGAGGUUUAdUCCGAGGCGCGAU–3' 
U4–16D 
U4–5' stem–loop containing a 
deoxy–Cytosin at position 41 5'–AUCGUAGCCAAUGAGGUUUAUdCCGAGGCGCGAU–3' 
U4–ol–a 
U4–2, open loop, 5' 
fragment, hybridizes with 
U4–ol–a 5'–AUCGUAGCCAAUGAGGUU–3' 
U4–ol–b 
U4–2, open loop, 3' 
fragment, hybridizes with 5'–UAUCCGAGGCGCGAU–3' 







U4–2, open loop with point 
mutation, hybridizes with 
U4–A2, 5' fragment 5'–AUCGUAGCCAAUGAGGGU–3' 
U4–A2 
hybridizes with U4–A1, 3' 
fragment 5'–UAACCGAGGCGCGAU–3' 
U4–A3 
hybridizes with U4–13, 3' 
fragment 5'–UAGCCGAGGCGCGAU–3' 
U4–A4 
U4–2 without A–bulge, same 
number of bases 5'–GCCGCGCCAAUGAGGUUUAUCCGAGGCGCGGC–3' 
U4–A5 
U4–2 with A–bulge and 
elongated stem I 
5'–GCAUCGUAGCCAAUGAGGUUUAUCCGAGGCGCGAU 
   GC–3' 
U4–A6 
U4–7 open loop with point 
mutations, 5' fragment, 
hybridizes with U4–A7 5'–AUCGUAGCCAAUGAGGCUU–3' 
U4–A7 
oligo 7 open loop, 3' 
fragment, hybridizes with 
U4–A6 5'–UAUGCCGAGGCGCGAU–3' 
U4–A8 
U4–2 without loop, 5' 
fragment, hybridizes with 
U4–A9 5'–AUCGUAGCCAAUGAGG –3' 
U4–A9 
U4–2 without loop, 3' 
fragment, hybridizes with 
U4–A8 5'–CCGAGGCGCGAU–3' 
U4–tetra–loop 
U4–5' stem–loop with 
terminal tetra–loop; 
(Cojocaru et al., 2005) 5'–AUCGUAGCCAAUGAGGUGAACCGAGGCGCGAU–3' 
U4–A10 
U4–2 without loop, 5' 
fragment, hybridizes with 
U4–A11 5'–AUCGUAGCCAAUGAGGU–3' 
U4–A11 
U4–2 without loop, 3' 
fragment, hybridizes with 
U4–A10 5'–ACCGAGGCGCGAU–3' 
U4–A12 
U4–2 without loop, 5' 
fragment, hybridizes with 
U4–A13 5'–AUCGUAGCCAAUGAGGC–3' 
U4–A13 
U4–2 without loop, 3' 
fragment, hybridizes with 
U4–A12 5'–GCCGAGGCGCGAU–3' 
3.1.15. siRNAs 
siRNA Description Sequence 
BB1/Firefly 
luciferase 
siRNA against the mRNA of the firefly 
luciferase (Photinus pyralis); position 




siRNA against the mRNA of protein 
hPrp31; 
position 1648-1706 within the 3' UTR 
(Schaffert et al., 2004) 5'-CAGUAUGGGCUAGAGCAGGUCUU-3' 
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3.1.17. Common Buffers 
10× PBS (pH 7.4)  CE-Buffer 
10 mM Cacodylsäure/KOH pH 7.0 
0.2 mM EDTA pH 8.0 
1.37 M NaCl 
20.7 mM KCl 
80 mM Na2HPO4*7H2O 
20 mM KH2PO4 
 
 
   
10× PBS (pH 8.0)  TE–Buffer 
1.3 M NaCl 
20 mM K2PO4 pH 8.0 
 10 mM Tris/HCL pH 7.5 
1 mM EDTA–(Na)2 
   
10× TBE   
0.89 M Tris 
0.89 M Boric Acid 
25 mM EDTA pH 8.0 
  
All buffers have been filter sterilized before usage. 
3 Materials and Methods 
 43
3.2. Methods 
3.2.1. Standard Molecular Biological Methods 
3.2.1.1. Concentration determination of nucleic acids  
Concentration of DNA and RNA in solution was determined with a spectral 
photometer by measuring the extinction at 260 nm against a reference value (Sambrook et al., 
1989).  
Conversion is done by using the following parameters: 
1 OD260  = 50 µg/ml double-stranded DNA 
1 OD260 = 33 µg/ml single-stranded DNA 
1 OD260 = 40 µg/ml single-stranded RNA 
Measuring the absorption spectra between 210 nm and 310 nm allows determining the 
purity of the DNA. The absorption maximum should be at 260 nm and the ratio of the 
absorption at 260 nm and 280 nm should be between 1.8 and 2.0. 
3.2.1.2. Phenol–Chloroform–Isoamylalcohol extraction (PCA) 
To remove proteins from nucleic acid containing solutions samples have to be 
extracted with phenol–chloroform–isoamylalcohol. After adding phenol-chloroform-
isoamylalcohol and mixing, proteins will enter the organic phase, while nucleic acid will stay 
in the aqueous phase.  
Phenol-chloroform-isoamylalcohol is added to the nucleic acid containing solution at 
the ratio of 1:1 and the mixture is then vortexed for 10 seconds. Subsequently a 2 minutes 
centrifugation step is performed. The upper water-layer is transferred into a new tube and 
ethanol-precipitated (see 3.2.1.3). 
PCA–Solution  
50% (v/v) Phenol 
2% (v/v) Isoamylalcohol,  
48% (v/v) Chloroform 
saturated with TE buffer 
(3.2.1.2) 
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3.2.1.3.  Ethanol precipitation 
Usually, 2.5 - 3 volumes of an 100% ethanol/0.12 M acetate solution is added to the 
DNA or RNA sample in a microcentrifuge tube, which is then placed at –80°C for 
30 minutes. Frequently, this precipitation is performed by incubation at -20°C overnight. To 
recover the precipitated DNA/RNA, the tube is centrifuged at 12.000 × g for 15 minutes at 
4°C in a microcentrifuge, the supernatant is discarded. The DNA/RNA pellet is rinsed with 
70% ethanol (v/v) solution and centrifuged again for 5 minutes, the supernatant is decanted 
and the tube is drained. After a second centrifugation, the residual supernatant is again 
discarded, and the DNA/RNA pellet is dried using a Speed-Vac concentrator. The dried DNA 
is dissolved in ddH20 or TE buffer (3.2.1.2), and dried RNA in ddH20 or CE buffer (3.2.1.17). 
3.2.1.4. Isopropanol precipitation 
For desalting of samples, DNA is precipitated with isopropanol. Subsequently to the 
PCA extraction (3.2.1.2), 0.7 volumes isopropanol is added and mixed.  
To recover the precipitated DNA, the tube is centrifuged at 12.000 × g for 15 minutes 
at 4°C in a microcentrifuge. The supernatant is discarded and the DNA pellet is rinsed with 
70% (v/v) ethanol solution. After a 5 minutes centrifugation the supernatant is decanted. The 
pellet is dried as described above and dissolved in ddH20 or TE buffer (3.2.1.2). 
3.2.1.5. Agarose gel electrophoresis of nucleic acids 
Agarose gel electrophoresis is employed to check the progression of a restriction 
enzyme digestion, to determine the yield and purity of a DNA isolation or PCR reaction, and 
to fractionate DNA molecules by size, which can then be eluted from the gel. Prior to gel 
casting, dried agarose is dissolved in buffer by heating in a microwave oven and the warm gel 
solution then is poured into a mould, which is fitted with a well-forming comb. The 
percentage of agarose in the gel varied. Although 0.7% agarose gels typically are used, in 
cases where accurate size fractionation of DNA molecules smaller than 1 kb is required, a 1, 
1.5, or 2% agarose gel is prepared, depending on the expected size(s) of the fragment(s). 
Ethidium bromide is included in the gel matrix to enable fluorescent visualization of the DNA 
fragments under UV light. Agarose gels are submerged in electrophoresis buffer in a 
horizontal electrophoresis apparatus. DNA samples are mixed with agarose gel loading dye 
and loaded into the sample wells. Electrophoresis usually is at 150-200 mA for 0.5 to 1 hour 
at room temperature, depending on the desired separation. Size markers are co-
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electrophoresed with DNA samples, when appropriate for fragment size determination. After 
electrophoresis, the gel is placed on a UV light box and a picture of the fluorescent ethidium 
bromide-stained DNA separation pattern is taken with a camera (Bio-Rad Gel documentation 
system). 
Agarose gel loading dye (5×) 
0.25% (w/v) Bromophenol blue 
0.25% (w/v) Xylencyanol FF 
30% (v/v) Glycerine 
3.2.1.6. Denaturing Gel electrophoresis of nucleic acids 
The denaturing gel electrophoresis of nucleic acids according to (Maxam and Gilbert, 
1986) provides a method for the separation RNA molecules. Secondary structures within the 
RNA molecules are dissolved before separation by the use of polyacrylamide gels containing 
Urea, which has denaturing characteristics.  
According to the size of the fragments to be separated, polyacrylamide concentrations 
of 8 to 20% were used (Sambrook et al., 1989). The RNA sample was dissolved in RNA 
loading dye solution and was denatured at 95°C for 5 minutes before loading on the gel. Gel 
electrophoretic separation of the RNA was performed in 1× TBE at 20 mA. 
If denaturing gel electrophoresis was performed with the aim to purify in vitro 
translated RNAs or RNA oligonucleotides separated RNAs were visualized by UV shadowing 
(see section 3.2.1.7). 
Urea polyacrylamide gel  RNA loading dye solution 
8M Urea 
8%-20% Polyacrylamide/Bisacrylamide (40%) 
1× TBE 
ad 100 ml H2O 
80% Formamide TBE 
1 mM EDTA pH 8.0 
0.025% (w/v) Bromophenol Blue 
0.025% (w/v) Xylencyanol FF 
500 µl APS (10%) 
50 µl TEMED 
 
 
3.2.1.7. UV shadowing 
UV shadowing is a technique for visualizing nucleic acids separated on 
acrylamide/urea gels. The technique utilizes shortwave UV light (254 nm) and a fluor-coated 
TLC plate. The detection limit of UV shadowing is approximately 0.3 µg of nucleic acid. 
RNA oligonucleotides and RNA transcripts prepared for in vitro binding assays were purified 
by electrophoretic separation and elution from gel fragments. 
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After electrophoresis, the glass plates and cover of the gel with plastic wrap are 
removed. The gel is wrapped with a plastic sheet. In a darkened room, the plastic-wrapped gel 
is placed on top of the fluor-coated TLC plate. The nucleic acid bands are visualized by 
shining a hand-held UV light source (254 nm) on the surface of the gel. Nucleic acid appears 
as dark purple shadow while the TLC plate will appear green. Care must be taken since the 
xylencyanol and bromophenol blue dyes present in most gel loading buffers also appear as 
dark shadows during UV shadowing and maybe mistaken for nucleic acid. The band of 
interest is marked, and cut out with a clean scalpel, and the gel piece is further cut into tiny 
pieces which are then transferred into a tube. The RNA is eluted from the gel in elution buffer 
at 4°C over night. Additionally the eluted sample is PCA extracted (see 3.2.1.2) and ethanol 
precipitated (see 3.2.1.3). 
Elution Buffer 
0.5 M NH4OAc  
1 mM EDTA 
0.1% SDS 
3.2.1.8. „Polymerase Chain Reaction“ (PCR) 
The Polymerase chain reaction (PCR) was mainly used for cDNA cloning and plasmid 
construction in the presented work (e.g. YFP-15.5K-5, Flag-15.5K-1 to 15.5K-5, and hPrp31 
deletion mutants). To specifically amplify DNA sequences, to introduce compatible 
restriction enzyme sites and to introduce sequence elements (e.g. Flag-tag), 20 to 30 base 
pairs long nucleotides forward and reverse primers were designed. These were 
complementary to the beginning and end of the DNA fragment to be amplified. To allow the 
efficient digestion by restriction enzymes at the 5' and 3' end of the PCR product several 
additional nucleotides (3 to 6) were added at the 5' ends of the primers (3.1.13) adjacent to the 
restriction site.  
The PCR process usually consists of a series of twenty to thirty-five cycles. Each cycle 
consists of three steps. In the first step, the double-stranded DNA is heated to 95°C in order to 
separate the strands. This step is called denaturing; it breaks apart the hydrogen bonds that 
connect the two DNA strands. After separating the DNA strands, the temperature is lowered 
so the primers can attach themselves to the single DNA strands. Prior to the first cycle, the 
DNA is normally denatured for an extended time to ensure that the template DNA is single-
strand. The second step is called annealing. The temperature of this stage depends on the 
primers and is usually 5°C below their melting temperature (45-60°C). The third step is called 
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elongation and the DNA-Polymerase has to copy the DNA strands. This step is called. The 
elongation temperature depends on the DNA polymerase. The optimal temperature for the 
Taq- or Pfu DNA polymerase enzyme to work is 72°C.  
The main difference between Pfu and the Taq DNA polymerase is that Pfu possesses a 
superior thermostability and 'proofreading' properties. This means that Pfu DNA polymerase-
generated PCR fragments will have fewer errors than Taq-generated PCR fragments. As a 
result, Pfu is more commonly used for molecular cloning of PCR fragments than the 
historically popular Taq. 
The time for this step depends both on the DNA polymerase itself and on the length of 
the DNA fragment to be amplified (about 1 minute per 1 kbp). A final elongation step is used 
after the last cycle to ensure that any remaining single stranded DNA is completely copied.  
PCR–reaction  Stock 
10 µl Pfu Polymerase buffer 
10 µl DMSO 
2.5 µl dNTP–Mix 
2.5 µl 5' primer 
2.5 µl 3' primer 
0.5 µg DNA 
1 µl Taq or Pfu DNA Polymerase 







Typical parameters for a PCR-reaction used in this work: 
Step Temperature Time 
Denaturing 




2.   
1. Denaturing 
2. Annealing 
3. Elongation  








3.   
3. Elongation  





3.2.1.9. Restriction digest using restriction Endonucleases 
The restriction digest was used to prepare DNA for analysis or other processing like 
molecular cloning. Restriction enzymes cut DNA segments within a specific nucleotide 
sequence, and always make its incisions in the same way. These recognition sequences are 
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typically only four to twelve nucleotides long. For the ligation of the vector DNA and the 
insert DNA both have to be prepared by digesting with suitable restriction enzymes and 
purified after digest (QIAquick PCR Purification Kit (Qiagen)). 
All restriction digest was performed according to the manufacturer's manual (New 
England Biolabs). 
3.2.1.10. Elution of DNA-fragments from agarose gels 
This method is used to quickly extract and purify DNA fragments of 70 bp to 10 kb 
length from standard or low-melt agarose gels for use in subsequent reactions like e.g. 
restriction digests, ligations or PCR reactions. For this procedure, a gel extraction kit was 
used and the purification was performed according to the manufacturer instructions 
(QIAquick gel extraction kit, Qiagen).  
3.2.1.11. Ligation of vector and insert DNA 
For ligation, vector and insert DNA are first prepared by digesting with appropriate 
restriction enzymes. Then they are purified with the QIAquick PCR Purification Kit (Qiagen) 
according to the manufactures instructions.  
The ligation reaction was as follows. For the optimal ligation efficiency, two DNA 
molecules in the range of 3:1 to 5:1 molar ratio of insert to vector were prepared for the 
ligation reaction (see below). This reaction mixture was incubated at 16°C for 3 to 16 hours. 
Next, the reaction was incubated at 65°C for 15 minutes to inactivate the enzyme. Then, 2 µl 
of the ligation reaction were used for transformation of E.coli (see 3.2.4.6). 
Ligation reaction  Stock 
2 µl T4 DNA–Ligase buffer 
50 ng linearized vector 
150 ng dephosphorylated 
insert 
1 µl T4 DNA–Ligase 






3.2.1.12. Preparation of endotoxin-free plasmid DNA 
Isolation and preparation of endotoxin-free plasmid DNA from E. coli was performed 
using the QIAGEN Hi Speed Plasmid Midi Kit and the QIAprep Spin Miniprep Kit (see 
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3.1.8). The extraction and purification procedure was performed according to the 
manufacturer instructions. 
3.2.1.13. Sequencing of recombinant DNA by Dye Deoxy 
Sequencing 
Sequencing of recombinant DNA was performed using the ABI PRISM Dye Deoxy 
Cycle Sequencing Kit (Applied Biosystems). This sequencing method, also called Taq–
Cycle–sequencing was developed by Manoni et al. (1992) according to Sanger et al. (1977). 
Copies of the DNA-template are synthesized in a sequencing PCR by the Taq DNA–
Polymerase in the presence of an oligonucleotide primer, dNTPs and dideoxynucleotides 
(ddNTPs), terminator bases, which are labeled with high-sensitivity dyes (see below). The 
incorporation of the labeled ddNTPs causes termination of the chain. The essence of the 
technique is the creation of a set of DNA fragments that match the chain to be sequenced. 
Each fragment is one nucleotide longer than the last. By determining the identity of the final 
nucleotide in each fragment, the sequence of the whole chain can be determined. The 
generated DNA fragments are separated by capillary electrophoresis. As the fragments 
electrophoresed, the beam of the laser focused at the bottom of the gel made the dye-labeled 
fragments glow as they passed. The colour of each dye-labeled fragment was then interpreted 
by the computer as a specific base. 
The ABI PRISM Model 377 Sequencer is equipped with an argon laser for exciting 
the dyes and is able to read at maximum capacity, over 400.000 bases in a day. The purity and 
quality of the DNA template are of most importance for a successful sequencing reaction.  




100 to 300 ng DNA 
1 pmol 3' or 5'primer 
4 µl BigDye Terminator Mix 
0.5 µl DMSO 
ad 10 µl ddH2O 
Cycling Parameters used for sequencing: 
Step Temperature Time Cycles 













Following the PCR reaction, synthesized DNA is purified by Ethanol-precipitation 
(3.2.1.3) or using the Qiagen DyeEx and dried using a SpeedVac concentrator. Before loading 
the samples onto the sequencer, dried DNA is resuspended in 20 µl ABI PRISM buffer and 
incubated 3 minutes at 90°C. 
3.2.1.14. Northern-Blot 
For the analysis of RNAs associated in vivo with YFP-tagged protein 15.5K (4.2) and 
HA-tagged protein hPrp31 (4.4) immunoprecipitation experiments were performed (3.2.3.2). 
After separating co-precipitated RNA molecules on a denaturing gel (see 3.2.1.6), RNA 
molecules in the gel were transferred to a nylon membrane. The RNAs of interest can then be 
identified by hybridisation to radioactive probes and visualised by autoradiography. The 
described protocol is adapted from Sambrook et al. (1989). 
RNA molecules in the gel were transferred to the nylon membrane by wet transfer at 
17V over night at 4°C in transfer buffer (see below). RNAs were covalently bound to the 
nylon membrane by UV cross-linking (120 mJ/cm2). The blot could be stored for several 
days at 4°C or -20°C wrapped in plastic wrap. Before hybridization with the radioactive 
probes, unspecific binding is saturated with salmon sperm DNA by the incubation with 
prehybridization buffer for 2 hours at 42°C. Membranes are then incubated for 48-72 hours at 
42°C with a radioactive DNA probe (3.2.1.15) specific for the RNA of interest.  
After that, the membrane is washed 2 times for 5 minutes with 2× SSC/0.5% SDS 
(w/v), 2 times for 5 minutes with 2× SSC/0.1% SDS (w/v) at room temperature and finally 
with 2× SSC/0.1% SDS (w/v) at 50°C. Next the radioactive signals are visualized by 
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autoradiography. The membrane can be re-blotted with another probe after removal of the 
bound probe by cooking the membrane in a solution consisting of 1× SSC and 0.1% SDS 
(w/v). 
Prehybridization Buffer  Hybridization Buffer 
Same buffer as 
prehybridization buffer, plus 2 
– 3× 107 cpm of each 
radioactive probe 
20× SSC 
25 mM Sodium phosphate, pH 6.5 
6× SSC  
5× Denhardt´s 
0.5% SDS  
50% Formamide 




100 x Denhardt´s  Transfer Buffer 
2% (w/v) Polyvinylpyrrolidon 
2% (w/v) BSA 
2% (w/v) Ficoll 400 
25 mM Sodium phosphate, pH 
6.5 
 
20 x SSC 
3 M NaCl 
0.3 M Sodium citrate 
pH 7.0 
3.2.1.15. Preparation of the radioactive DNA probe 
For detection of the U snRNAs and snoRNAs by northern blotting a radioactive probe 
was prepared using the Prime It II Random Primer Labelling Kit (Stratagene) according to the 
supplier's protocol. In this procedure, DNA is radioactively labelled using a Klenow fragment 
which exhibits 5’ → 3’ polymerase activity and the 3’ → 5’ exonuclease activity.  
As a template 25-50 ng of plasmid DNA or PCR fragment containing the coding 
region for the according U snRNA and snoRNAs were used. 
At the beginning the DNA template is denatured. Next, normally 6 nucleotides long 
random prime oligonucleotides are added and anneal to the DNA template. The Klenow 
fragment uses these primers for synthesising the DNA probe incorporating [α-³²P]-dATP 
(3000Ci/mmol). Then, unbound nucleotides were removed by gel-filtration (ProbeQuant G-50 
column). Before hybridisation, the radioactive probe was denatured for 10 minutes at 70°C. 
For one northern analysis 2-3× 107 cpm were used. 
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3.2.1.16. In vitro Transcription  
The radio-labeled U4 snRNA, U14 box C/D and U3 box B/C snoRNA used in this 
work were generated by run-off transcription (Melton et al., 1984). This method is based on 
the observation that the transcription complex will fall off from a DNA template if complex 
reaches the end of the template. A restriction enzyme site within the gene can therefore be 
chosen to generate run-off transcripts of the desired length.  
First, plasmids containing the sequence coding for the designated RNA is linearized 
using the appropriate restriction enzyme (see below). Complete digest was checked by 
agarose gel electrophoresis (see 3.2.1.5). Linearized DNA was purified by phenol-
chloroform-isoamylalcohol extraction and ethanol precipitation. The dried pellet was 
resuspended to a final concentration of 0.5-1 µg/µl. 
RNA Restriction enzyme Promoter 
U4 snRNA DraI SP6 
U14 box C/D snoRNA BamHI T7 
U3 box B/C RNA BamHI T7 
Transcription reaction is set as described below using either SP6 or T7 RNA 
polymerases with respect to the promoter sequence of the DNA template (see table above). 
The set reaction is incubated for 4 hours at 37°C. Subsequently, the DNA template is digested 
by the addition of RQ DNase (1U/µg DNA–template) incubating for another 15 minutes at 
37°C. 
The RNA transcript is then purified by phenol-chloroform-isoamylalcohol and ethanol 
precipitation. After drying the pelleted RNA transcript, RNA is resuspended in 10-30 µl 
ddH2O. When there was too much background from aberrant premature stops, the RNA 
transcript was additionally purified by UV-shadowing and elution from gel-fragments (see 
3.2.1.7). 
1. SP6-controlled in vitro transcription reaction 
Transcription Buffer (5×) 5 µg linearized DNA 
20 µl 5× Transcription Buffer 
20 µl rNTPs (each 25mM ATP, 
CTP, GTP) 
1 µl Enzyme Mix Sp 6 
ad 100 µl with ddH2O 
400 mM HEPES–KOH, pH 7,5 
160 mM MgCl2 
10 mM Spermidine 
200 mM DTT 
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2. T7-controlled in vitro transcription reaction 
Transcription Buffer (5×) 5 µg linearized DNA 
20 µl 5× Transcription Buffer 
30 µl rNTPs (each 25mM ATP, 
CTP, GTP) 
1 µl Enzyme Mix T7 
ad 100 µl with ddH2O 
400 mM HEPES –KOH, pH 7,5 
120 mM MgCl2 
10 mM Spermidine 
200 mM DTT 
3.2.1.17. In vitro Transcription of radio-labeled RNA 
For the preparation of radio-labeled U4 snRNA, U14 snoRNA and U3 box B/C RNA 
transcripts, the in vitro transcription reaction described above was performed in the presence 
of [α-³²P]-UTP. 
In vitro transcription reaction 
Transcription Buffer (5×) 1 µg linearized DNA 
2 µl 5× Transcription Buffer 
1 µl rNTP mix 
2 µl [α-³²P]-UTP (3000 Ci/mmol) 
0.5 µl RNasin (40 U/µl) 
1 µl Enzyme Mix T7 or SP6 
ad 10 µl with ddH2O 
400 mM HEPES –KOH, pH 7,5 
120 mM MgCl2 
10 mM Spermidine 
200 mM DTT 
 
10× rNTP mix 
5 mM ATP, GTP and CTP 
1 mM UTP 
Transcription reaction is incubated for 2 hours at 37°C. Subsequently, the DNA 
template is digested by the addition of RQ DNase (1U/µg DNA–template) incubating for 
another 15 minutes at 37°C. 
The RNA transcript is then purified by phenol-chloroform-isoamylalcohol and ethanol 
precipitation. After drying the pelleted RNA transcript, RNA is resuspended in 10-30 µl 
ddH2O. The RNA transcript can be additionally purified by denaturing gel electrophoresis 
(3.2.1.6) and subsequent elution from gel-fragments (see 3.2.1.7). 
3.2.1.18. 5'-end-labeling of RNA 
RNA oligonucleotides were labeled with [³²P] γATP (6000 Ci/mmol) by 
phosphorylation of the 5'-end using the T4 polynucleotide kinase (New England Biolabs, 
Schwalbach) according to the instructions by the manufacturer.  
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Kinase labelling reaction 
PNK Buffer (10×) 1 µl RNA oligonucleotide 
1 µl 10× PNK buffer 
5 µl [³²P] γATP (6000 Ci/mmol) 
1 µl T4 polynucleotide kinase 
ad 10 µl with ddH2O 
0.7 M Tris-HCl 
0.1 M MgCl2 
50 mM Dithiothreitol 
pH 7.6 
The reaction was incubated for 1 hour at 37°C. Next, 40 µl of buffer CE were added 
and the reaction was transferred to a G-20 or G-50 spin column (Probe Quant G-20/G-50 
micro columns) for removal of remaining radionucleotides. Labeled RNAs were then purified 
by PCA extraction (3.2.1.2) and ethanol precipitation (3.2.1.3) and the dried pellet was 
resuspended in ddH2O or CE buffer.  
Labeled RNA oligonucleotides can be additionally purified by denaturing gel 
electrophoresis (3.2.1.6) and subsequent elution from gel-fragments (see 3.2.1.7). 
3.2.1.19. Coupled in vitro Transcription and Translation 
For analysing protein-protein interaction of GST-15.5K and the U3 box B/C RNA-
specific protein hU3-55K, protein hU3-55K was radio-labeled with 35S-Methionine using the 
TNT Coupled Reticulocyte Lysate Systems from Promega according to instructions by the 
manufacturer.  
In vitro transcription and translation was performed with T7 RNA polymerase and 
full-length hU3-55k cDNA cloned in vector pGEM-3Zf(+) essentially as described by Pluk et 
al. (1998).  
The reaction components were assembled following the example below. After addition 
of all the components, the lysate was gently mixed by pipetting the reaction up and down. All 
handling of the lysate components has been performed on ice. 
Example of TNT Lysate Reactions 
TNT® Rabbit Reticulocyte Lysate  
TNT® Reaction Buffer  
TNT® RNA Polymerase (SP6, T3 or T7) 
Amino Acid Mixture, Minus Methionine 
[35S]Methionine (1,000 Ci/mmol) 
RNasin® Ribonuclease Inhibitor (40u/µl) 
DNA template(s) (0.5 µg/µl) 









The reaction was incubated for 2 hours at 30°C. Subsequently 2 µl are analysed via 
SDS-PAGE and autoradiography. Translates can be stored at -80°C and were used in GST-
pull-down assays (see 3.2.7.2). 
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3.2.2. Protein Biochemical Methods 
3.2.2.1. Bradford Assay 
The Bradford assay is a convenient and very fast method to determine protein 
concentrations in aqueous solutions. The procedure is performed according to the 
manufacturer’s instructions (Bio-Rad).  
The assay is based on the fact that the absorbance maximum of the Coomassie 
Brilliant Blue G-250 shifts from 465 nm to 595 nm when binding to protein occurs. Both, the 
hydrophobic and ionic interactions stabilize the anionic form of the dye, are causing the 
visible colour change.  
To 20 µl of a protein solution are added 980 µl dilute Bio–Rad protein assay solution 
(diluted 1:5, v/v; 1 mg/ml Coomassie Brilliant Blue G 250 in 85% H3PO4). After 5 minutes 
incubation time the absorbance is measured at 595 nm and calibrated against a blank value, 
set up with ddH2O. The protein concentration is then determined by calibration against BSA 
standards. In parallel protein standards (1, 2, 3, 4, 5 and 6 mg/ml) are measured, which are 
then used to determine the concentration of the protein solution.  
3.2.2.2. SDS-PAGE (SDS-Poly Acrylamide Gel Electrophoresis) 
The SDS-Poly Acrylamide Gel Electrophoresis was used to separate proteins by size 
and was performed according to (Laemmli, 1970). The purpose of this method is to separate 
proteins according to their size, independent of other physical feature. The solution of proteins 
to be analyzed is first mixed with SDS (Sodium dodecyl sulfate), an anionic detergent, which 
denatures secondary and non–disulfide–linked tertiary structures, and applies a negative 
charge to each protein in proportion to its mass.  
The denatured proteins are then applied to one end of a layer of polyacrylamide gel. 
An electric current is applied across the gel, causing the negatively-charged proteins to 
migrate across the gel. Depending on their size, each protein will move in a different way 
through the gel matrix. 
Two glass plates were cleaned once with ddH2O and once with absolute ethanol, 
before the plates are used to assemble a gel chamber with the help of 1.2 mm spacers. The 
separating gel was cast using either 8 or 12% polyacrylamide gel solutions (see table below) 
to separate proteins in the molecular-weight range of interest. Polymerization was started by 
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addition of TEMED and 10% ammonium-persulfate. The gel was poured immediately up to 
¾ of the height of the glass plates and the acrylamide- solution was overlaid with a few ml of 
H2O in order to prevent air-exposure and allow the acrylamide solution polymerize evenly. 
The gel was allowed to polymerize for 1 hour at room temperature. After polymerization, the 
H2O covering the gel was removed and the stacking gel was prepared and poured 
immediately, a comb was inserted, and the gel was allowed to polymerize for 1 hour at room 
temperature. After complete polymerization of the polyacrylamide, the gel was associated 
with a gel chamber submerged with electrophoresis buffer. Protein samples are mixed with 
100 µl SDS sample buffer and heated to 95°C for 10 minutes and 40 µl of each were loaded 
into a sample well of the gel. Proteins are focused while moving through the stacking gel at 
15-25 mA and separated in the separating gel at 35 mA.  
12% Separating 
gel solution 
  8 % Separating gel 
solution 






12 ml  Acrylamide 30% (0.8% 
Bis–Acrylamide) 






7.5 ml  Separating gel buffer 
(4×) 
7.5 ml  Stacking gel 
buffer (4×) 
2.5 ml 
H2O 10,5 ml  H2O 14.5  H2O 5.89 
        
APS 10% 100 µl  APS 10% 100 µl  APS 10% 50 µl 
TEMED 100 µl  TEMED 100 µl  TEMED 50 µl 
 
Separating Gel Buffer (4×)  Stacking Gel Buffer (4×) 
1.6 M Tris/HCl pH 8,8 
0.4% (w/v) SDS 
 500 mM Tris/HCl pH 6.8 
0.4% (w/v) SDS 
   
Electrophoresis Buffer  SDS Sample Buffer 
192 mM Glycine 
25 mM Tris/HCl pH 8.8 
0.1% (w/v) SDS 
 60 mM Tris/HCl pH 6.8 
1 mM EDTA 
2% (w/v) SDS 
16% (v/v) Glycine 
0.1% (w/v) Bromphenol blue 
0.05% (v/v) β–Mercaptoethanol 
3.2.2.3. Staining of proteins with Coomassie Brilliant Blue 
Coomassie Blue staining is based on the non-specific binding of the dye Coomassie 
Brilliant Blue R 250 and G250 to basic and aromatic amino acid side chains.  
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The gel is soaked in a solution of the dye for about 1 hour. During the subsequent 
destaining procedure, only the dye bound to the protein is retained in the gel. The gel is then 
fixed in the fixing solution for about 1 hour and dried. Coomassie Blue binds to proteins 
approximately stoichiometrical, so this staining method is useful when relative amounts of 
protein need to be determined by densitometry. The detection is limited to 0.1–0.5 µg of 
protein. 
Staining solution  Destaining solution 
0.25% (w/v) Coomassie Brilliant Blue R 250  40% (v/v) Methanol 
0.1% (w/v) Coomassie Brilliant Blue G 250  10% (v/v) Acetic acid 
40% (v/v) Methanol   
10% (v/v) Acetic acid  Fixing solution 
  3% Glycerol (v/v) 
  30% Methanol 
3.2.2.4. Affinity purification of MBP-fusion proteins 
The hPrp31 cDNA was subcloned into pETM–41 (EMBL, Heidelberg) to produce 
MBP-fusion proteins. E. coli strain HMS174 was transformed with pETM–41–hPrp31 and 
grown at 20°C with shaking (200 rpm) to an OD600 of 0.8 in LB media in the presence of 
Kanamycin (see table below). IPTG was added to a concentration of 1 mM to induce protein 
expression. After further incubation for 3 hours at 20°C with shaking, cells were pelleted. 
Cells were resuspended in 25 ml buffer B and incubated for 1 hour at 4°C in the presence of 
1 mg/ml lysozyme (Sigma Aldrich) and one tablet of complete protease inhibitor (Roche, 
Mannheim). Cells were then subjected to sonication with a microtip (Branson) with three 20 
second bursts at an amplitude of 40%. Insoluble material was pelleted by centrifugation at 
10.000 g for 30 min, and the MBP–hPrp31–containing lysate was loaded directly onto 2 ml of 
Amylose Sepharose slurry (Amersham Pharmacia Biotech). Bound MBP–hPrp31 was washed 
once with 20 ml buffer C and twice with buffer B. Bound MBP–hPrp31 was eluted then with 
buffer B containing 10 mM maltose and finally fractions of 500 µl each (usually 3-4 
fractions) were collected. Protein content of the fractions was detected by Bradford (see 
3.2.2.1). The peak fractions were pooled and dialysed against buffer B. 
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Buffer B  Buffer C  Elution Buffer  
50 mM Tris pH 8.0 
150 mM NaCl 
1 mM EDTA 
1 mM DTT 
50 mM Tris/HCl pH 8.0 
300 mM NaCl 
1 mM EDTA 
1 mM DTT 
 
50 mM Tris pH 8.0 
150 mM NaCl 
1 mM EDTA 
1 mM DTT 
10 mM maltose 
Expressed proteins and transformed E.coli strains are listed: 
Recombinant protein vector Resistance Strain for expression  
MBP-hPrp31 wt and 
deletion mutants 
pETM-41 Kanamycin E.coli HMS174 
3.2.2.5. Affinity purification of GST–fusion proteins 
The glutathione S-transferase (GST) affinity tag allows for rapid, near homogeneous 
purification of proteins expressed from GST expression systems. GST-15.5K and GST–
hPrp31 are expressed in E.coli and isolated from bacteria in a similar procedure as described 
above in section 3.2.2.4.  
2 ml of GST resin are washed with 20 ml of buffer 2 in a 50 ml Falcon tube and the 
protein-rich supernatant from a 1 litre E.coli culture is added. GST resin and supernatant are 
incubated for 1 hour at room temperature shaking gently. Supernatant is removed after 
spinning down the beads at 2000 rmp and GST-sepharose washed two times with 20 ml 
buffer 2. During the last washing step, the slurry of beads is poured into an empty column 
(Bio-Rad) and the wash buffer is released by gravity flow. GST-fusion proteins can be 
released from the GST resin keeping the GST-tag. In this case, 6 ml of elution buffer are 
added to the GST resin and the eluate collected in 500 µl fractions by gravity flow. 
Another possibility is to cleave the GST-tag while the protein is still bound to the 
GST-sepharose. The GST-tag remains on the beads while the protein is released to the 
supernatant. To perform this cleavage reaction, 6 ml of buffer 2 and 75U Thrombin or 
PreScission protease are added to the slurry and incubated over night shaking gently at room 
temperature. The supernatant is released by gravity flow from the empty column and collected 
in 500 µl fractions. The beads are washed two times with 2 ml buffer 2 and the wash is 
collected. Protein concentration is determined by Bradford (see 3.2.2.1). 
To remove the Thrombin protease from the eluate after cleavage, 50 µl P-
Aminobenzamidine Agarose (binding capacity 10-20 mg/ml), which binds the Thrombin 
protease are added, and incubated for 30 minutes at 30°C shaking gently. P-
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Aminobenzamidine Agarose is removed from the eluate by centrifugation and filtration. 
Without loss of activity, eluates can be stored at -80°C for prolonged periods of time.  
Buffer 2  Elution Buffer 
50 mM Tris pH 7.9 
100 mM NaCl 
2.5 mM MgCl2 
2 mM DTT 
0.1% Triton X-100 
50 mM Tris/HCl pH 7.9 
100 mM NaCl  
2.5 mM MgCl2 
2 mM DTT 
15 mM reduced Glutathion 
 
Recombinant protein vector Resistance Strain for expression  
GST-15.5K pGex–4–T–2 Ampicillin E.coli BL21 pLysS 
GST-hPrp31 pGex-6-P-1 Ampicillin E.coli BL21 RP 
3.2.3. Immunological Methods 
3.2.3.1. Western–Blot 
For Western–Blot analysis proteins were first separated by SDS-PAGE (3.2.2.2). 
Next, separated proteins were transferred from the SDS-gel to a PVDF (Polyvinylidene 
difluoride) membrane (Bio-Rad) using a wet transfer apparatus (Bio-Rad). A pre-stained 
molecular weight marker, which was applied before SDS-gel electrophoresis, was used as an 
indication for a successful transfer. The gel, membrane and sheets of Whatman paper 3MM 
were soaked in transfer buffer (see table below), and the sandwich containing the gel and 
membrane was placed between sheets of 3MM Whatman paper. The transfer was performed 
for 1 hour at 350 mA in the presence of an ice cooling unit in the transfer chamber. Upon 
completion of the transfer, the blotting sandwich was disassembled and the membrane then 
used for Western-blotting. 
To decrease non-specific binding of antibodies, non-specific binding sites on the 
membrane were blocked in TBS-Triton X-100 buffer (see table below) containing 5% non-fat 
dry milk (w/v) for two hours at room temperature or at 4°C overnight on a rocking platform. 
All further steps were carried out in TBS-Triton X-100 buffer containing 1% non-fat dry milk 
(w/v). After blocking, the membrane was washed 3 times, and then incubated with primary 
antibody against the protein of interest for one hour at room temperature on a rocking 
platform. The optimum dilution of primary antibodies used in this work, were determined by 
titration and are listed in the table below.  
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The membrane was washed three times for 15 minutes each and then incubated with a 
secondary antibody. Depending on the origin of the first antibody, this was either anti-mouse 
or anti-rabbit, both of the IgG class with a coupled peroxidase. They were used at a dilution of 
1:50000 (anti-rabbit) or 1:30000 (anti-mouse) respectively. 
The membrane was washed three times and developed with enhanced 
chemiluminescence (ECL) detection reagents (Amersham Biosciences) as follows. An 
appropriate amount of equal volumes of Amersham detection reagents 1 and 2 were first 
mixed and the applied to the membrane. After incubation for 60-90 seconds at room 
temperature, the membrane was drained, wrapped in plastic film and exposed to X-ray film 
for 10 seconds to 5 minutes depending on the intensity of the signal. The membrane could be 
re-probed with a different antibody after stripping it of the previous antibody. For this 
purpose, the membrane was incubated in stripping buffer (see table below) at 50°C for 
30 minutes on a rocking platform.  
Transfer Buffer  SLAB 4 
1.5 l SLAB 4 
0.6 l Methanol 
0.9 l ddH2O 
 50 mM Tris/HCl pH 8.5 
380 mM Glycine 
0.1% (w/v) SDS 
   
TBS-Triton X-100  Stripping Buffer 
20 mM Tris/HCl pH 7.5 
150 mM NaCl 2% (w/v) 
0.05% (v/v) Triton X-100 
 100 mM 2-Mercaptoethanol 
2% (w/v) SDS 
62.5 mM Tris/HCl pH 6.7 
 
Dilution of used 
antibodies 
Origin Dilution 
α-hPrp4 (“Roy”) Rabbit serum 1: 500 
α-hPrp31 „4825”  Rabbit serum 1: 100 
α-GFP Mouse monoclonal 
antibody 
1:2000 
α–40K (“Paul”) Rabbit serum 1:500 
α–HA antibody Mouse monoclonal 
antibody 
1:2000 
3.2.3.2. Radio-immunoprecipitation (RIPA) 
For the analysis of protein-protein interactions within the U4/U6 snRNP or the box 
C/D snoRNP complexes described in this work, radio-immunoprecipitation was a used 
through out. In this procedure 
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In this procedure, the antibody against the bait protein was immobilized on protein-A-
sepharose beads. For this purpose, 20 µl protein-A-sepharose beads per reaction were first 
washed three times with. Subsequently, 5-20 µl affinity purified antibodies or antiserum were 
added per 20 µl beads aliquot, and after an addition of five volumes PBS (pH 8.0), incubation 
was performed for 1h at 4°C. Unbound antibodies were then removed from the beads by 
washing three times with PBS. Next, beads were used in the assay by adding the different 
samples to be analysed (see below).  
After adjusting the volume to 300 µl with reconstitution buffer (see table below), 
CypH/hPrp4/hPrp3 binding to U4/U6 snRNA was performed according to Nottrott et al, 
(2002) by incubating ~60 fmoles U4/U6 duplex, containing ³²P-labeled minimal U6 snRNA 
with 40 pmoles purified CypH/hPrp4/hPrp3 complex in the presence or absence of 30 pmoles 
recombinant, purified 15.5K or mutant 15.5K (see below). Immunoprecipitation was with 
anti-hPRP4. Protein-A-sepharose beads were washed four times with 500 µl of reconstitution 
buffer and the associated U4/U6 snRNA was extracted by PCA extraction (3.2.1.2) and 
ethanol precipitation (3.2.1.3), and then analysed by PAGE and autoradiography.  
In vitro box C/D snoRNP assembly using nuclear extracts was performed as described 
by Watkins et al, (2002). Briefly, 800 pmoles of SL1 oligonucleotide was added to 10 µl 
HeLa nuclear extract to block the endogenous 15.5K. In vitro transcribed ³²P-labeled 
U14 snRNA, pre-incubated in the absence or presence of recombinant 15.5K (or mutant 
protein), was added to the nuclear extract and incubated for 30 minutes at 30°C in 300 µl 
reconstitution buffer (see below). Immunoprecipitation was with antibodies specific for the 
core box C/D snoRNP proteins and the two assembly factors TIP48 and TIP49. RNA was 
recovered as described above. 
In vitro assembly of the U3 box using nuclear extracts was performed essentially 
similar except that ³²P-labeled U3 box B/C RNA was used and the precipitation was with anti-
hU3-55K antibodies.  
Radio-immunoprecipitation using α-GFP, α–40K and α–HA was performed similarly 
as described for the box C/D snoRNP. However, nuclear extracts used here derived from a 
small scale extract preparation as described in section 3.2.5.4. Following the final washing 
procedure, RNAs were extracted by phenol-chloroform-isoamylalcohol extraction and ethanol 
precipitation. Proteins were directly eluted from a separate bead aliquot by adding one volume 
of protein loading dye to the protein-A-sepharose.  
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RNA was analysed by denaturing PAGE followed by northern blotting and proteins by 
PAGE and western blot analysis.  
Antibodies Complex type Reconstitution Buffer 
α-hPrp4 (“Roy”)  U4/U6 snRNP 20 mM Tris/HCl pH 7.4, 150 mM NaCl, 




Box C/D snoRNP 20 mM Hepes/KOH pH 7.9, 150 mM NaCl, 
3 mM MgCl2, 0.1% Triton X-100, 0.5 mM 
DTT, 10% Glycerol (v/v) 
α-hU3-55K U3 Box B/C RNP 20 mM Hepes KOH pH 7.9, 150 mM NaCl, 
3 mM MgCl2, 0.1% Triton X-100, 0.5 mM 
DTT, 10% Glycerol (v/v) 
α-GFP U4/U6 snRNP 
and Box C/D 
snoRNP  
20 mM Tris/HCl pH 7.4, 150 mM NaCl, 
0.1% Triton X-100 
α–40K (“Paul”) U4/U6 snRNP 20 mM Tris/HCl pH 7.4, 150 mM NaCl, 
0.1% Triton X-100 
α–HA antibody U4/U6 snRNP  20 mM Tris/HCl pH 7.4, 150 mM NaCl, 
0.1% Triton X-100 
3.2.3.3. Affinity purification of antibodies 
Peptides (2 mg; 3.1.16) were coupled to SulfoLink coupling gel as described by the 
manufacturer. 1/10 volume of PBS (pH 8.0) was added to 5 ml of crude serum. Next, the 
serum was filtered (0.45 µm aseptic filter), loaded on the peptide column and the column was 
rotated for 2 hours at room temperature. The column was washed with 30 volumes of PBS 
and the antibodies were eluted with 100 mM Glycine (pH 2.9). The collected 500 µl fractions 
were immediately neutralized by adding 100 µl of 1M Tris. The amount of purified antibody 
was determined by the Bradford assay (3.2.2.1). Fractions with an OD595 > 0.25 were pooled, 
BSA was added to a final concentration of 50 µg/ml and the antibodies were dialysed over 
night against PBS. The affinity purified antibodies were stored in aliquots at –80°C. 
3.2.4. Microbiological Methods 
3.2.4.1. Cultivation of E.coli 
Bacterial strains carrying plasmids or genes with antibiotic selection marker were 
cultured in liquid or on solid medium containing the selective agent. Stock solutions of 
antibiotics were sterilised by filtration and aliquots stored at -20°C. Antibiotics were added to 
freshly autoclaved medium (cooled to below 50°C); concentrations of stocks and working 
solutions of the antibiotics are listed below. 
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LB Medium (capsules, BIO 101) 
10 g Tryptone 
5 g Yeast extract 
0.5 g NaCl 
 
Antibiotic Stock solution Working solution 
Ampicillin 50 mg/ml in water, -20°C 100 µg/ml, 1/500 
Tetracycline 5 mg/ml in ethanol, -20°C 50 µg/ml, 1/100 
Streptomycin 10 mg/ml in water, -20°C 50 µg/ml, 1/200 
Chloramphenicol 34 mg/ml in ethanol, -20°C 170 µg/ml, 1/200 
3.2.4.2. Plates 
E.coli strains can be streaked and stored on LB plates containing 1.5% agar and the 
appropriate antibiotic. With a flamed and cooled wire loop an inoculum of bacteria from a 
glycerol stock was streaked on top of a fresh agar plate, and incubated upside down at 37°C 
for 12-14 hours until colonies developed.  
LB Agar Medium (capsules, BIO 101) 
10g Tryptone 
5g Yeast extract 
0.5g NaCl 
15g Agar 
3.2.4.3. Liquid cultures 
Bacterial liquid cultures for small scale plasmid preparations were grown as follows. 
A culture of 1–5 ml LB medium containing the appropriate selective antibiotic is inoculated 
by a single colony from a freshly streaked selective plate. The solution is incubated for 12–16 
h at 37°C with vigorous shaking (240 rpm). Bacterial cells are harvested by centrifugation at 
> 8000 rpm (6800 x g) in a conventional, table-top microcentrifuge for 3 min at room 
temperature (15–25°C). Plasmid preparation is performed as described in 3.2.1.12. 
Bacterial liquid cultures for big scale plasmid preparations were grown as described 
below. A starter culture was prepared by inoculating 10 ml LB medium containing the 
appropriate antibiotic with a single colony from a freshly streaked selective plate. The culture 
was grown for 4–6 h hours at 37°C with vigorous shaking (~240 rpm) until OD600 = 0.8–1.2. 
The starter culture was diluted 1/500 to 1/1000 into a larger volume of selective LB medium 
and grown overnight (12-16 h) at 37°C with shaking (~250 rpm). Cells were harvested by 
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centrifugation at 6.000 × g for 15 min. The cell pellet was then ready for the plasmid 
purification protocol (see 3.2.1.12). Plasmid preparation is performed as described in 3.2.1.12. 
3.2.4.4. Preparation of competent E. coli cells  
Competent E. coli cells are prepared according to the procedure described by Dagert 
and Ehrlich (1979). For the preparation 5 ml of the E. coli strain BL21 codon plus RIL/RP 
cells or XL1 cells were grown in LB medium in an Erlenmeyer flask at 37°C over night. The 
flask is chosen at least five times the volume of the culture (>25 ml) to allow good aeration of 
the cells. E. coli codon plus RIL cells contain extra copies of the E. coli argU, ileY, and leuW 
tRNA genes while the BL21-CodonPlus RP strains contain the argU and proL tRNA genes 
which are selected by Chloramphenicol. To keep the extra plasmids BL21-CodonPlus cells 
have to be grown in the presence of Chloramphenicol whereas E. coli XL1 cells are grown 
without antibiotic. 2.5 ml of the over night culture are transferred into 50 ml LB media. Cells 
are grown to the early log phase at a density of OD600 = 0.5–0.7 and are collected by 
centrifugation at 5.000 × g at 4°C for 5 minutes. Cells have to be kept ice cold in all further 
steps. Cells are resuspended in 1/2 culture volume of 0.1M ice-cold CaCl2. Cells are collected 
again by centrifugation (see above) and then are gently resuspended in 1/10 culture volume 
0.1M ice-cold CaCl2. Ice-cold sterile glycerol (87%, v/v) is added to a final concentration of 
10% (v/v). After gently mixing, the cells are left on ice for 30 minutes. Aliquots of 50 µl of 
the cell suspension are flash frozen and then stored at –80°C 
3.2.4.5. Glycerol E.coli stocks 
E.coli strains can be stored for many years at -80°C in 15% glycerol (v/v). For this 
purpose, 0.15 ml glycerol were first placed into a 2 ml screw-cap vial and sterilised by 
autoclaving. 0.85 ml of the E.coli culture were then added and mixed to ensure even 
distribution of the bacterial culture and the glycerol. Cultures were flash frozen in liquid 
nitrogen and stored at -80°C. 
3.2.4.6. Transformation of E.coli 
Competent cells were removed from the -80°C freezer and allowed to thaw on ice. 100 
µl cells aliquots were placed into pre-chilled 12 ml polypropylene tubes. Then, 1 µl from the 
ligation reaction or plasmid preparation (1-10 ng DNA) were added to the cells, moving the 
pipette through the cells while dispensing. Cells were incubated for 30 minutes on ice and 
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heat-shocked for 45 seconds to 2 minutes at 42°C. Then, cells were placed on ice for 2 
minutes, and 0.9 ml of room temperature LB medium was added. The culture was incubated 
for 1 hour at 37°C with shaking (225 rpm). Following, cells were centrifuged at 10.000 × g 
for 2 minutes and resuspended the in 100 µl LB medium. Of this suspension, 90 and 10 µl 
were plated on separate LB plates containing the required antibiotic and incubated overnight 
upside-down at 37°C. Bacterial colonies can then be used for plasmid preparation (see 3.2.4.3 
and 3.2.1.12). 
3.2.5. Cell Culture 
3.2.5.1. Cultivation of HeLa cells 
HeLa SS6 were grown in an CO2 Incubator at 37°C and 5% CO2 with saturating 
humidity (95%) in cell culture growth medium (see below). 
Cell Culture Growth Medium 
Dulbecco’s modified eagle medium (DMEM) 
10% (v/v) Fetal Calf Serum (FCS) 
100 U/ml Penicillin/Streptomycin 
3.2.5.2. Passaging HeLa cells 
Cells were split routinely three times a week and for this they were harvested by 
trypsinisation. For trypsinisation, the medium was removed from the flask and cells were 
washed carefully with PBS (pH 7.4) to remove residual medium. 1-2 ml of pre-warmed 
Trypsin-EDTA solution was added to the flask (75 cm2) and incubated at 37°C until cells 
were detached (1-2 minutes). Trypsinisation was stopped by adding a 2 ml of growth medium. 
Following, cells were resuspended in an appropriate volume of pre-warmed growth medium. 
Appropriate dilutions of HeLa SS6 cells were transferred to a fresh cell culture flask (75 cm2) 
containing 10 ml medium. Typically, confluent HeLa SS6 cells were split in a 1:10 ratio, 
confluency was then reached again after 2-3 days. 
3.2.5.3. Freezing and thawing of HeLa cells 
The cells were trypsinized, resuspended in medium containing serum, centrifuged at 
1.000 × g for 5 minutes, and then resuspended in freezing medium (see below). 1 ml of the 
cell suspension (approximately 3-5 x 106 cells) was transferred into each freezing vial. 
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Freezing vials were placed into a Cryo freezing container (Nalgene) and stored in a -80°C 
freezer overnight. This allowed freezing of the cells at a rate of 1°C/minute. The following 
day vials were transferred to a liquid nitrogen chamber. For thawing, a vial of frozen cells was 
removed from liquid nitrogen and placed in a 37°C water bath until thawed. To remove 
DMSO from the freezing medium, the cell suspension was pipetted into a centrifuge tube 
containing pre-warmed medium, and centrifuged at 1.000 × g for 5 minutes. The supernatant 
was discarded; cells were resuspended in fresh growth medium and transferred to the cell 
culture flask. Cells were incubated overnight under their usual growth conditions, and the 
medium was replaced the next day.  
Freezing Medium 
Dulbecco’s modified eagle medium (DMEM) 
10% (v/v) Fetal Calf Serum (FCS) 
7.5% DMSO 
3.2.5.4. Small-scale procedure for preparation of nuclear and 
nucleolar extracts 
For the biochemical analysis of HeLa cells either expressing YFP-15.5K (see section 
4.2) or HA-hPrp31 Retinitis Pigmentosa mutants after hPrp31 knock-down (see section 4.4) 
nuclear extract was prepared using a small scale procedure modified from (Lee and Green, 
1990). 
Cells of four cell culture plates (Ø 14.5 cm; ~0.5-1× 108 cells) were washed once with 
cold PBS (pH 7.4) and were harvested by scraping carefully using a cell scraper. Cells were 
resuspended in 10 ml of cold PBS and were transferred to a 50 ml Falcon tube. Tubes were 
filled up to 50 ml with PBS. Next, cells were pelleted by centrifugation for 5 minutes at 1.000 
× g without brake at 4°C. Then, cells were resuspended in about 1 ml of PBS, transferred to 
an Eppendorf tube and the packed cell volume was determined after pelleting cells for 5 
minutes at 1.000 × g by either using the calibration on the Eppendorf tube or comparing 
against known volumes. The packed cells were resuspended in one packed cell volume of 
buffer A (see below) and allowed to swell on ice for 15 minutes. Next, cells were lysed by 
rapidly pushing them through a narrow-gauge needle (25g 5/8; 15.9 mm) as follows. A 1 ml 
hypodermic syringe with needle attached is filled with buffer A and the syringe plunger was 
used to displace the buffer as fully as possible to remove air bubbles. The cell suspension was 
drawn slowly into the syringe from a 1.5-ml Eppendorf tube and then ejected with a single 
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rapid stroke. Seven rapid strokes are usually sufficient to break more than 95% of the cells. 
The homogenate was centrifuged for 60 seconds at 12.000 × g and 4°C. The nuclear pellet is 
resuspended in two thirds of one packed cell volume (determined above) of buffer C. Next, a 
30 minutes incubation step on ice at 4°C with stirring using a mini-magnet followed. The 
suspension was then centrifuged for 5 minutes at 12.000 × g to pellet cell debris and nucleoli. 
The supernatant (nuclear extract) is dialyzed against buffer D for 2 hours at 4°C. For 
preparation of nucleolar extract, the pelleted nucleoli were then resuspended in five packed 
cell volumes of buffer D' and then sonicated by 3× 5 pulses (Output control: 4; Duty cycle: 
30%) using a microtip (Branson). To recover the snoRNPs from the nucleoli the suspension 
was centrifuged for 30 minutes at 16.000 × g. 
The nuclear and nucleolar extracts can be used directly or quick-frozen in liquid 
nitrogen and stored at –80°C. Frozen extracts should be centrifuged 1 minute at 12.000 × g 
before use to remove precipitates. To an approximation, two 75 cm2 cell culture flasks of cells 
at 80% confluence yield about 150 µl of nuclear extract with a protein concentration of 
~5mg/ml. 
Buffer A  Buffer D 
10 mM HEPES-NaOH [pH 7.9] 
1.5 mM MgCl2 
10 mM KCl 
1.0 mM DTT 
 20 mM HEPES-NaOH [pH 7.9] 
10% Glycerol (v/v) 
100 mM KCl 
0.2 mM EDTA 
0.5 mM PMSF 
1.0 mM DTT 
 
Buffer C  Buffer D' 
20mM HEPES-NaOH [pH 7.9] 
25% Glycerol (v/v) 
420 mM NaCl 
1.5 mM MgCl2 
0.2 mM EDTA 
0.5 mM Phenylmethylsulfonyl fluoride (PMSF) 
1.0 mM DTT 
 20 mM HEPES-NaOH [pH 7.9] 
150 mM NaCl 
0.2 mM EDTA 
0.5 mM DTT 
10% Glycerol (v/v) 
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Stocks 
100 mM PMSF 
1M DTT in H2O 
3.2.5.5. Generation of a stable EYFP-15.5K expressing HeLa cell 
line 
To set up the selection for the stable EYFP-15.5K expressing cell line (HeLaEYFP-15.5K; 
4.2), freshly split cells were transfected (see 3.2.6.3) with the pEYFP-C1-15.5K. The 
following day, the standard media was replaced with media containing Gentamycin (G418; 
400 µg/ml). This will select for cells that have stably incorporated the GFP plasmid into their 
genomic DNA. Selection for colonies expressing EYFP-15.5K was carried out for three 
weeks. The Gentamycin containing media in the dish was changed every day, taking care to 
wash dead cells off the bottom of the dish, and leaving only colonies of stable cells behind. 
Colonies were picked and transferred to a 24-well dish with 1 ml media containing 
Gentamycin in each well. The colonies were picked blind as there was no inverted light 
microscope available under sterile conditions. Cells were rinsed with PBS (pH 7.4) and then 
colonies were dispersed by incubating with PBS containing 5% Trypsin. Using a Gilson 
pipette with a sterile yellow tip, colonies of interest were scraped and sucked gently into the 
tip. The colonies were then transferred to a well in the 24-well plate.  
Always when grown to confluency level, cells were split and transferred to a 6-well 
plate with a coverslip on the bottom of each well that would allow screening the colonies. 
Colonies were selected according to their expression level of EYFP-15.5K. Colonies of 
interest were passaged from the 6-well plate into the next bigger dish. Cells were grown under 
selection conditions until a sufficient number of cells for the maintenance of the cell line was 
reached (about 20% confluency). Half of the cells were frozen and stored in a liquid nitrogen 
container (see 3.2.5.3), the other half was cultivated for small scale nuclear extract preparation 
(see 3.2.5.4) and biochemical analysis (4.2). 
3.2.6. Microscopic Methods 
3.2.6.1. Fluorescence microscopy 
After performing indirect immuno-fluorescence staining (3.2.6.2), images were 
acquired with a Zeiss LSM 510 META confocal microscope. Proteins to be detected and the 
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used fluorophores are listed below. YFP and Alexa 488 were excited with Argon laser lines at 
488 nm and by using a dichroic beam splitter (HFT 488). Texas Red was excited with Helium 
Neon laser lines at 543 nm and by using a dichroic beam splitter (HFT 488/532). Alexa 647 
was excited with Helium Neon laser lines at 633 nm by using a dichroic beam splitter (HFT 
514/633). The pinhole diameter was set to 106 µm - 1.12 Airy units according to a layer 
thickness of 0.8 µm. Fluorescence was recorded with a Plan Apochromat 63x/1.4 oil 
immersion objective.  
Background levels were obtained by measuring the mean intensity of each stain 
outside the cells. Bleedthrough was checked by taking images of cells with a single 
transfection (e.g. YFP-15.5K) or no transfection and acquiring dual channel images with the 





Wavelength Complex or Foci 
15.5K α−15.5K Goat–α–rabbit antibody, 
coupled Texas Red 
532 nm U4/U6 snRNP, Box C/D and 
B/C snoRNPs 
SC35 α−SC35 Goat–α–rabbit antibody, 
coupled Texas Red 
532 nm Splicing speckle marker 
SC35 α−SC35 Goat–α–mouse antibody, 
coupled Alexa 488 
488 nm Splicing speckle marker 
15.5K  EYFP 488 nm U4/U6 snRNP, Box C/D and 
B/C snoRNPs 
Coilin α−Coilin Goat–α–rabbit antibody, 
coupled Alexa 647 
633 nm Cajal Body marker 
hPrp31 α−hPrp31 Goat–α–mouse antibody, 
coupled Alexa 488 
488 nm U4/U6 snRNP 
hPrp4 α−hPrp4 Goat–α–rabbit antibody, 
coupled Alexa 647 
633 nm U4/U6 snRNP 
3.2.6.2. Indirect immuno-fluorescence staining 
For immuno-fluorescence studies, HeLa cells were grown on multi-well slides. For 
analysing the localisation of the 15.5K protein (section 4.2), HeLa cells were grown 
overnight, fixed and stained as described below. For studying the influence of hPrp31 
Retinitis Pigmentosa mutations on the localisation of protein hPrp31 and protein hPrp4 
(section 4.4), HeLa cells were fixed and stained 48 hours after transfection of HA-hPrp31 and 
siRNAs against either protein hPrp31 (EA2) or the firefly luciferase (control, GL2) as 
described in the following procedure. 
HeLa cells were washed once PBS (pH 7.4) and then fixed by incubating for 20 
minutes in PBS containing 4% (w/v) paraformaldehyde (PFA) at room temperature. 
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Subsequently, cells were again washed once PBS. The cells can be stored like this until 
needed. For long term storage, cells can be covered with PBS containing 0.05% (v/v) sodium 
azide and 0.2% (w/v) PFA.  
Following the paraformaldehyde fixation, cells were permeabilized by incubating 
them in PBS containing 0.2% Triton X-100 for 15 minutes at room temperature. To remove 
the detergent, cells were washed four times with PBS and unspecific binding sites were 
saturated by incubating with PBS containing 10% FCS (v/v) for 1 hour at room temperature 
or overnight at 4°C. The solution was removed and the slides were dried carefully in air; the 
usage of a Kleenex which sucks the liquid of the slide is very useful and careful. Next, 50µl of 
the first antibody in PBS containing 10% FCS were pipetted onto the cells and incubation was 
for 1 to 2 hours at room temperature. The first antibody was then removed by quickly 
washing three times and then three times for 10 minutes with PBS. The liquid was removed 
from the slides as described above and then, 50 µl of second antibody in PBS containing 10% 
FCS were pipetted onto the cells and incubated 1 to 2 hours at room temperature. Following 
further extensive washings exactly as described above, cells were finally mounted on glass 
slides with Mowiol 4-88 (Calbiochem, USA) and were dried for at least one hour before the 
confocal microscopy examination.  
First Antibody Type/Species Dilution Comment 
α–15.5K Polyclonal rabbit 1:200 Stains 15.5K 
α–NOP56 antibody Polyclonal rabbit 1:500 Stains NOP56 
P80 (coilin) Polyclonal rabbit 1:1000 Stains Cajal bodies 
α–HA antibody Mouse monoclonal 
antibody 
1:2000 Stains HA-tagged proteins 
α–hPrp4 (“Roy”) Rabbit serum 1: 500 Stains hPrp4 
α–SC35 Mouse monoclonal 
antibody 
1:1000 Stains splicing factor SC35 
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3.2.6.3. Transient transfection of mammalian cells 
For analysing the localisation of the EYFP-15.5K protein (4.2), HeLa cells were 
grown over night, fixed and stained as described above. For transfection, HeLa (SS6) cells 
were cultured in 24-well plates and grown on coverslips overnight until 40-80% confluency 
and the transfection was performed using the Lipofectamine 2000 reagent (Invitrogen, 
Netherlands) according to the supplier’s protocol.  
The day before transfection, cells were trypsinized, counted, and plated the in 24-well 
plates at 2× 105 cells per well so that they would be 80-90% confluent on the following day 
for the transfection. Cells were plated in their normal growth medium containing serum and 
antibiotics (Penicillin/Streptomycin). For each well of cells to be transfected, 1-5 µg of 
plasmid DNA were diluted into 50 µl of OptiMEM 1 medium. In addition, for each well of 
cells, 1.5 µl of Lipofectamine 2000 reagent were diluted into 50 µl OptiMEM 1 medium and 
the mixture was incubated for 5 minutes at room temperature. Once the Lipofectamine 2000 
reagent was diluted, it had to be combined with the plasmid DNA within 30 minutes. This 
dilution was prepared as a master mix for multiple wells.  
The diluted DNA was combined with the diluted Lipofectamine 2000, and the mixture 
was incubated at room temperature for 20 minutes to allow DNA- Lipofectamine complexes 
to form. Growth medium was then removed from cells and 0.5 ml of serum-free medium were 
added to each well. Next, the DNA- Lipofectamine complexes (100 µl) were added directly to 
each well and mixed gently by rocking the plate back and forth. 
Transfected cells were incubated at 37°C in a CO2 incubator for 4-5 hours. Then, 0.5 
ml of growth medium containing 10% FCS, were added. Cells were incubated ~16 hours 
post-transfection and the expression and co-localisation of the product of the transfected gene 
analysed by immuno-fluorescence microscopy (3.2.6.1). For the preparation of small-scale 
nuclear extracts (3.2.5.4) the protocol was scaled up. The scale-up requirements were 
determined by estimating the expression efficiency and the needed amount of extract. 
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3.2.7. Special Methods 
3.2.7.1. Electrophoretic Mobility Shift Assay (EMSA) 
Binding specificity of the 15.5K protein mutants with the U4 snRNA and the U14 
snoRNA (see 4.1.1), and the interaction of the U4/U6 snRNP-specific protein hPrp31 with the 
U4 snRNA were investigated by Electrophoretic Mobility Shift Assay (EMSA) (see 4.3.2).  
The Electrophoretic Mobility Shift Assay, variously also called Gel Shift, or Band 
Shift Assay, is a technique for studying protein:RNA interactions. The assay is based on the 
fact that complexes of protein and RNA migrate through a non-denaturing polyacrylamide gel 
more slowly than free RNA fragments or oligonucleotides.  
Approximately 0.03 pmol ³²P–labeled U14 or U4 snRNA transcribed RNA or RNA 
oligonucleotides were incubated with 25 pmol recombinant protein 15.5K and/or 50 pmol 
MBP–hPrp31 or 250 pmol MBP-hPrp31 deletion mutants in the presence of 10 µg of E. coli 
tRNA (Boehringer, Mannheim) for 1 hour at 4°C in a final volume of 20 µl buffer B. 
Subsequently, RNA and RNA–protein complexes were resolved on a 6% (80:1) native 
polyacrylamide gel containing 0.5× TBE and visualised by autoradiography as described 
(Reuter et al., 1999). Additionally, quantification was performed on a Phosphoimager. 
6% Gel solution   5× Heparin loading dye 
12 ml Gel A (30% Acrylamide)  0.5 x TBE 
2,25 ml Gel B (2% Bisacrylamide)  5 µg/µl Heparin 
3 ml 10× TBE   50% Glycerine 
ad 60 ml with dH2O  0.25% Bromphenol blue 
750 µl APS (10% stock)   
37,5 µl TEMED   
 
Buffer B 
50 mM Tris/HCl pH 8.0 
150 mM NaCl 
1 mM EDTA 
1 mM dithiothreitol (DTT) 
2% Triton X-100 
3.2.7.2. GST pull-down assay 
Protein-protein interactions within the U4/U6 snRNP (see 4.1.2) and the box C/D 
snoRNP (see 4.1.6) were investigated by GST pull-down. The pull-down assay is a simple 
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technique to test the interaction between a tagged protein and another interaction partner 
which can be a protein or an RNA molecule. The GST-tagged bait protein, purified from an 
appropriate expression system (see 3.2.2.4), is immobilized on a glutathione affinity gel. The 
bait serves as the secondary affinity support for identifying new protein partners or for 
confirming a previously suspected protein partner of the bait. Prey protein can be obtained 
from multiple sources including recombinant purified proteins, nuclear extract or in vitro 
transcription/translation reactions (see 3.2.1.17). Protein-RNA and protein-protein interactions 
can be visualized by SDS-PAGE and associated detection methods depending on the 
sensitivity requirements of the interacting proteins. These methods include Western blotting, 
35S-radioisotopic detection or the co-precipitation of a ³²P-labeled in vitro transcribed RNA 
which is dependent on the interaction of the bait and prey protein or RNA. 
For instance, the binding of hPrp31 to the U4 snRNA was assayed by GST pull-down 
by incubating purified recombinant GST-hPrp31 with ³²P-labeled in vitro transcribed 
U4 snRNA in the presence or absence of recombinant, purified 15.5K or mutant 15.5K. 
Complexes were purified using glutathione sepharose and U4 snRNA association analysed by 
PAGE and autoradiography. 
To assay hU3-55K binding to 15.5K, in vitro translated 35S-labeled hU3-55K (see 
3.2.1.17) was incubated with either GST or GST-15.5K. Complexes were isolated using 
glutathione sepharose and the co-purifying hU3-55K analysed by SDS-PAGE and 
autoradiography. 
The procedure includes the following steps. Per reaction 20 µl of glutathione 
sepharose beads were washed three times with 500 µl PBS (pH 8.0) and next incubated for 1 
hour at 4°C with blocking buffer (see below). Beads were washed again three times and are 
equilibrated with reaction buffer (see below). 
For assaying the interaction of the GST-tagged U4/U6-specific hPrp31 with the 15.5K 
protein, protein GST-hPrp31 is pre-bound to the glutathione sepharose by incubating 
30 pmoles of GST-hPrp31 with 20 µl glutathione sepharose beads for 1 hour at 4°C in 200 µl 
of reaction buffer on a head-over-tail rotor. Non-bound protein is removed by washing the 
beads three times with 500 µl reaction buffer. Next, bound hPrp31 protein is incubated with ³²
P-labeled in vitro-transcribed U4 snRNA (see 3.2.1.16) in the presence or absence of 15 pmol 
of recombinant, purified 15.5K or 15.5K mutant. Complexes were purified using glutathione 
sepharose, and U4 snRNA association was analyzed by polyacrylamide gel electrophoresis 
(PAGE) and autoradiography. 
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To assay hU3-55K binding to 15.5K, in vitro-translated 35S-labeled hU3-55K (see 
3.2.1.17) was incubated with either GST or GST-15.5K according to Granneman et al. 
(2002). Complexes were isolated using glutathione sepharose, and the co-purifying hU3-55K 
was analyzed by sodium dodecyl sulfate SDS-PAGE and autoradiography. All data from pull-
down experiments were quantified using either a phosphorimager or scanned autoradiographs. 
Where necessary, the signals were normalized relative to either the input or supernatant for 
that particular sample. 
Blocking Buffer  Reaction Buffer 
20 mM Tris/HCl, pH 7.5 
100 mM NaCl 
0.1% Triton X-100 
20 mM Hepes/HCl, pH 7.9 
300 mM KCl 
0.01% Triton X-100 
10 mg/ml tRNA 
0.5 mg/ml BSA 
20 mg/ml Glycogen 
 
 
3.2.7.3. Site-directed mutagenesis of proteins 
Site-directed mutagenesis was performed using the QuikChange Site–Directed 
Mutagenesis Kit (Stratagene) according to the manufacturer’s instructions. The PCR-based 
site-directed mutagenesis allows site-specific mutations to be incorporated in double-stranded 
plasmid DNA.  
Synthetic oligonucleotides, or primers, complementary to opposite strands of the 
vector containing the desired mutation(s) are annealed to the target region. During the PCR 
reaction the mutant oligonucleotides are extended using a plasmid DNA strand as the template 
by the PfuTurbo DNA polymerase introducing the desired point mutations. First, 
oligonucleotides containing the desired point-mutation were designed. Oligonucleotides are 
favourable between 25 and 45 bases in length and with a melting temperature (Tm) of ≥ 75°C. 
Sense and anti-sense primers should have a similar melting temperature, should have a 
minimum GC content of 40% and should terminate in one or more C or G bases. The primers 
designed for introducing point-mutations for studying protein-protein interactions in this work 
are listed in 3.1.13. 
Following, the product is treated with the DpnI endonuclease, which is specific for 
methylated and hemi-methylated DNA and is used to digest the parental DNA template and to 
select for the mutation-containing synthesized DNA. The DNA isolated from more or less all 
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E. coli strains is dam methylated and therefore susceptible to DpnI digestion. Next, the vector 
DNA containing the desired mutations is transformed into XL1-Blue supercompetent cells.  
Mutant strand synthesis reaction: 
Reaction Stock 
5 µl reaction buffer 10× 
5–50 ng dsDNA template  
125 ng primer 1  
125 ng primer 2  
1 µl dNTP mix  
ad 50 µl ddH2O  
1 µl PfuTurbo® DNA polymerase 2.5 U/µl
Cycling Parameters used in this work: 
Step Temperature Time 
Denaturing  95°C 30 seconds 
Annealing 55°C 1 minute 
Elongation 68°C 13 minutes 
Cycles:  18  
3.2.7.4. UV cross-linking 
For UV cross–linking of in vitro reconstituted hPrp31-15.5K-U4 snRNA complexes 
(4.3.3), complexes containing 0.3 pmol labelled RNA were prepared in a final volume of 
20 µl as described in section 3.2.7.1. UV cross-linking of in vitro reconstituted hPrp31-15.5K-
U4 snRNA complexes was carried out in 96 well microtiter plates using a UV-B light source 
at 254 nm (4x8W, G8T5, Herolab) at a distance of ~3 cm. Samples were cooled during 
illumination by putting the 96 well microtiter plates on an ice. To check whether a formed 
product derived only by the covalent bonding of the protein to the RNA after cross-linking, 
control samples were either digested by RNase T1/A or Proteinase K using 3 µg RNase A and 
T1 for 1 hour at 37°C. Then, samples were directly analysed by SDS-PAGE on 10% gels. 
Proteins cross–linked to the RNA were visualised by autoradiography.  
3.2.7.5. Preparation of RNA Duplexes 
The U4/U6 snRNA duplexes used for investigating the effect of mutant 15.5K protein 
on the association of the hCypH/hPrp3/hPrp4 with the U4/U6 snRNP (4.1.3) were formed by 
annealing 20 nM ³²P-labeled U6 snRNA oligonucleotide (nucleotides 58-87 of the U6 
snRNA; see 3.2.1.17) with 200 nM un-labeled U4 snRNA in buffer A (see below) as 
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described in Nottrott et al. (2002). Samples were incubated at 80°C for 1 min, cooled slowly 
to 30°C and placed on ice.  
Buffer A 
50 mM Tris-HCl pH 7.5 
150 mM NaCl 
5 mM MgCl2 
1 mM EDTA 
1 mM DTT 
3.2.7.6. Transient transfection of plasmid DNA and/or double-
stranded siRNAs into HeLa cells via nucleofection 
The effect of hPrp31 Retinitis Pigmentosa mutations on localisation of protein hPrp31 
and protein hPrp4 was analysed by transfecting HeLa cells simultaneously with HA-tagged 
hPrp31 protein wild type and mutants, and siRNA duplexes against the 3' UTR of protein 
hPrp31. Attempts to transfect cells only with HA-hPrp31 wild type and mutants lead to a low 
expression of the protein. The Nucleofector technology offered the possibility of gently 
transfecting cells with plasmids and siRNAs simultaneously, whereas transfection using the 
Bio-Rad Electroporator caused high cell mortality and low transfection/expression efficiency.  
For the transfection of HeLa cells the Cell Line Nucleofector Kit R was used. Cells for 
transfection were in the logarithmic phase (~50-60% confluency). Two cell culture flasks (75 
cm2 growth area) were taken, corresponding to 5-6× 106 cells. Cells were washed with PBS 
(pH 7.4) and trypsinized with 3 ml of Trypsin-EDTA. Cells from the two cell culture flasks 
were combined (2× 106 cells/ml in 6 ml Trypsin-EDTA) in a Falcon tube and the volume was 
filled up to 10 ml by the addition of DMEM/10% FCS/Penicillin/Streptomycin to obtain 1.2× 
106 cells/ml. Next, 1× 106 - 5× 106 cells were taken for each cuvette to be used and 
centrifuged at 200 × g for 10 minutes. The supernatant was removed and cells were 
resuspended in 100 µl Nucleofector solution. 1-5 µg of plasmid DNA (1-5 µl in ddH2O or TE 
buffer (3.2.1.2)) and/or 0.5-3 µg siRNA duplexes were added to the 100 µl cell suspension 
and transferred to the cuvettes supplied. For transfection of HeLa cells with both plasmid 
DNA and siRNAs, Nucleofector program I-13 was chosen, since it was useful for a high 
transfection efficiency. Following transfection, 500 µl pre-warmed culture medium were 
added to the cuvette, and the cell suspension transferred to a 12-well plate (1.5 ml/well). Cells 
were grown at 37°C under standard conditions for 48 hours till the knock down of hPrp31 and 
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expression of the HA-hPrp31 were efficient. The knock-down/add-back effect was analysed 




4.1. Protein-protein and protein-RNA contacts both 
contribute to the 15.5K protein-mediated assembly of 
the U4/U6 snRNP and the box C/D snoRNPs 
4.1.1. Mutation of conserved amino acids on the surface of 
protein 15.5K not involved in RNA binding 
The high sequence conservation of protein 15.5K suggests that this protein may play 
additional roles in the function and/or assembly of one or more of the 15.5K-containing RNP 
complexes. Indeed, conserved amino acids may be important for protein-protein interactions 
essential for the formation of the RNP complexes. 
 α1 β1 α2 β2 α3 
 
  10 20 30 40 50 60 70 
  | | | | | | | 
H. sapiens (1) ---MTEADVNPKAYPLADAHLTKKLLDLVQQSCNYKQLRKGANEATKTLNRGISEFIVMAADAEPLEIILHLPL 
S. cerevisiae (1) -----MSAPNPKAFPLADAALTQQILDVVQQAANLRQLKKGANEATKTLNRGISEFIIMAADCEPIEILLHLPL 
C. elegans (1) ---MADDGVNPKAFPLADTNLSQKLMDLVQQAMNYKQLKKGANEATKTLNRGISEIIVMAADAEPLEILLHLPL 
D. melanogaster (1) ----MTEEVNPKAFPLADAQLTAKIMNLLQQALNYNQLRKGANEATKTLNRGLADIVVLAGDAEPIEILLHLPL 
A. thaliana (1) ---MTGEVVNPKAYPLADSQLSITIMDLVQQATNYKQLKKGANEATKTLNRGISEFVVMAADAEPLEILLHLPL 
X. leavis (1) ---MAEPEVNPKAYPLADAQLTKTLLDLVQQAANYKQLRKGANEATKTLNRGISEFIVMAADAEPLEIILHLPL 
L7a H. sapiens (100) HKYRPETKQEKKQRLLARAEKKAAGKGDVPTK-RPPVLRAGVNTVTTLVENKKAQLVVIAHDVDPIELVVFLPA 
  
 β3 α4 β4 α5 
 
 
 80 90 100 110 120 
  | | | | | 
H. sapiens (72) LCEDKNVPYVFVRSKQALGRACGVSRPVIACSVTIKEGSQLKQQIQSIQQSIERLLV------ 
S. cerevisiae (70) LCEDKNVPYVFVPSRVALGRACGVSRPVIAASITTNDASAIKTQIYAVKDKIETLLI------ 
C. elegans (72) LCEDKNVPYVFVRSKAALGRACGVTRPVIAASITQNEGSQLKSQIQKIKEDVEKLLI------ 
D. melanogaster (71) LCEDKNVPYVFVRSKQALGRACGVSRPIVACSVTTNEGSQLKSQITSIQQEIERLLV------ 
A. thaliana (72) LAEDKNVPYVFVPSKQALGRACGVTRPVIACSVTSNEASQLKSQIQHLKDAIEKLLI------ 
X. leavis (71) LCEDKNVPYVFVRSKQALGRACGVSRPVISCSVTIKEGSQLKPQIQSVQQAIERLLV------ 
L7a H. sapiens (173) LCRKMGVPYCIIKGKARLGRLVHRKTCTTVAFTQVNSEDKGALAKLVEAIRTNYNDRYDEIRR 
  
Figure 4-1 Sequence alignment of the human 15.5K protein with highly homologous proteins.  
Amino-acid alignment of protein 15.5K from human (H. sapiens), Saccharomyces cerevisiae (Snu13p), 
Caenorhabdidis elegans (Accession no. Q21568), Drosophila melanogaster (Accession no. GH03082), 
Arabidopsis thaliana (Accession no. A71421), and Xenopus laevis (Accession no. AAH46579) with the human 
ribosomal protein L7a sequence using the ClustalV program. Conserved residues are indicated by grey boxes 
and are grouped as described in (Schulz and Schirmer, 1979). Identical and conserved residues are indicated in 
white on black boxes and in black on grey boxes, respectively. Residues specifically conserved in protein 15.5K 
are depicted in white on blue boxes. Amino-acid positions are indicated on the left. The secondary structure of 
the human 15.5K protein (Vidovic et al., 2000) is indicated above the alignment, and amino acids involved in 
RNA-binding are indicated by blue circles. 
In order to test this possibility, conserved amino acids at the surface of protein 15.5K 
were identified that could be mutated in order to test their function in the assembly of the 
various RNPs. Conserved amino acids were identified from a sequence alignment using 
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sequences of homologous, but not functionally related, human L7a ribosomal protein in order 
to indicate the amino acids that are highly conserved in this family of RNA-binding proteins 
(Figure 4-1; indicated in black and grey).  
The remaining conserved amino acids are therefore specific to protein 15.5K (Figure 
4-1; indicated in blue). By using the crystal structure of protein 15.5K bound to the 5' stem-
loop of the U4 snRNA (Vidovic et al., 2000) clusters of conserved amino acids present at the 
surface of the protein were identified and mutated (see Materials and Methods and Figure 
4-2). 
 α1 β1 α2 β2 α3 
 
  10 20 30 40 50 60 70 
  | | | | | | | 
15.5K-1 (1) ---MTEADVNPKAYPLADAHLTKKLLDLVRKSKESGQLRKGANEATKTLNRGISEFIVMAADAEPLEIILHLPL 
15.5K-2 (1) ---MTEADVNPKAYPLADAHLTKKLLDLVQQSCNYKQLRKGANEATKTLNRGISEFIVMAADAEPLEIILHLPL 
15.5K-3 (1) ---MTEADVNPKAYPLADAHLTKKLLDLVQQSCNYKQLRKGANEATKTLNRGISEFIVMAADAEPLEIILHLPL 
15.5K-4 (1) ---MTEADVNPKAYPLADAHLTKKLLDLVQQSCNYKQLRKGANEATKTLNRGISEFIVMAADAEPLEIILHLPL 
15.5K-5 (1) ---MTEADVNPKAYPLADAHLTKKLLDLVQQSCNYKQLRKGANEATKTLNRGISEFIVMAADAEPLEIILHLPL 
15.5K-6 (1) ---MTEADKASYVKFEVPAHLTKKLLDLVQQSCNYKQLRKGANEATKTLNRGISEFIVMAADAEPLEIILHLPL 
15.5K-7 (1) ---MTEADVNPKAYPLADAHLTKKLLDLVQQSCNYKQLRKGANEATKTLNRGISEFIVMAADAEPLEIILALPL 
15.5K-8 (1) ---MTEADVNPKAYPLADAHLTKKLLDLVQQSCNYKQLRKGANEATKTLNRGISEFIVMAADAEPLEIILHLPL 
15.5K-9 (1) ---MTEADVNPKAYPLADAHLTKKLLDLVQQSCNYKQLRKGANEATKTLNRGISEFIVMAADAEPLEIILHLPL 
15.5K-10 (1) ---MTEADVNPKAYPLADAHLTKKLLDLVQQSCNYKQLRKGANEATKTLNRGISEFIVMAADAEPLEIILHLPL 
15.5K-11 (1) ---MTEADVNPKAYPLADAHLTKKLLDLVQQSCNYKQLRKGANEATKTLNRGISEFIVMAADAEPLEIILHLPL 
15.5K-12 (1) ---MTEADVCPEASPLADAHLTKKLLDLVQQSCNYKQLRKGANEATKTLNRGISEFIVMAADAEPLEIILHLPL 
15.5K-13 (1) ---MTEADVAPEASPLARAHLTKKLLDLVQQSCNYKQLRKGANEATKTLNRGISEFIVMAADAEPLEIILHLPL 
15.5K-14 (1) ---MTEADVAPEAYPLADAHLTKKLLDLVQQSCNYKQLRKGANEATKTLNRGISEFIVMAADAEPLEIILHLPL 
15.5K-15 (1) ---MTEADVNPKASPLARAHLTKKLLDLVQQSCNYKQLRKGANEATKTLNRGISEFIVMAADAEPLEIILHLPL 
15.5K-16 (1) ---MTEADVNPKAYPLADAHLTKKLLDLVQQSCNYKQLRKGANEATKTLNRGISEFIVMAADAEPLEIILHLPL 
15.5K-Cys1 (1) ---MTEADVNPKAYPLADAHLTKKLLDLVQQSCNYKQLRKGANEATKTLNRGISEFIVMAADAEPLEIILHLPL 
15.5K-Cys2 (1) ---MTEADVNPKAYPLADAHLTKKLLDLVQQSCNYKQLRKGANEATKTLNRGISEFIVMAADAEPLEIILHLPL 
15.5K-Cys3 (1) ---MTEADVNPKAYPLADAHLTKKLLDLVQQSCNYKQLRKGANEATKTLNRGISEFIVMAADAEPLEIILHLPL 
15.5K-Cys4 (1) ---MTEADVNPKAYPLADAHLTKKLLDLVQQSCNYKQLRKGANEATKTLNRGISEFIVMAADAEPLEIILHLPL 
15.5K-Cys5 (1) ---MTEADVNPKAYPLADAHLTKKLLDLVQQSSNYKQLRKGANEATKTLNRGISEFIVMAADAEPLEIILHLPL 
  
 β3 α4 β4 α5 
 
 
 80 90 100 110 120 
  | | | | | 
15.5K-1 (72) LCEDKNVPYVFVRSKQALGRACGVSRPVIACSVTIKEGSQLKQQIQSIQQSIERLLV------ 
15.5K-2 (72) LCRKMNVPYVFVRSKQALGRACGVSRPVIACSVTIKEGSQLKQQIQSIQQSIERLLV------ 
15.5K-3 (72) LCEDKNVPYVFVRSKQDLGEACGVSRPVIACSVTIKEGSQLKQQIQSIQQSIERLLV------ 
15.5K-4 (72) LCEDKNVPYVFVRSKQALGRACGVSRPVIACSVTIKEGSQLKQAIASIQASIERLLV------ 
15.5K-5 (72) LCEDKNVPYVFVRSKQALGRACGVSRPVIACSVTIKEGSQLKQQIQSIQQSISSLLV------ 
15.5K-6 (72) LCEDKNVPYVFVRSKQALGRACGVSRPVIACSVTIKEGSQLKQQIQSIQQSIERLLV------ 
15.5K-7 (72) LCEDKNVPYVFVRSKQALGRACGVSRPVIACSVTIKEGSQLKQQIQSIQQSIERLLV------ 
15.5K-8 (72) LCEDKNVPYVTVRSKQALGRACGVSRPVIACSVTIKEGSQLKQQIQSIQQSIERLLV------ 
15.5K-9 (72) LCEDKNVPYVFVRSKQALGRACGVSRPVIACSVTIKSEDKGAQQIQSIQQSIERLLV------ 
15.5K-10 (72) LCEDKNVPYVFVRSKQALGRACGVSRPVIACSVTIKEGSQLKQQIQSIQQSTERTLV------ 
15.5K-11 (72) LCEDKNVPYVFVRSKQALGRACGVSRPVIACSVTIKEGSQLKQQIQSIQQSNELKGV------ 
15.5K-12 (72) LCEDKNVPYVFVRSKQALGRACGVSRPVIACSVTIKEGSQLKQQIQSIQQSIERLLV------ 
15.5K-13 (72) LCEDKNVPYVFVRSKQALGRACGVSRPVIACSVTIKEGSQLKQQIQSIQQSIERLLV------ 
15.5K-14 (72) LCEDKNVPYVFVRSKQALGRACGVSRPVIACSVTIKEGSQLKQQIQSIQQSIERLLV------ 
15.5K-15 (72) LCEDKNVPYVFVRSKQALGRACGVSRPVIACSVTIKEGSQLKQQIQSIQQSIERLLV------ 
15.5K-16 (72) LCEDKNVPYVFVRSKQALGRACGVSRPVIACSVTIKSGSKLAQQIQSIQQSIERLLV------ 
15.5K-Cys1 (72) LCEDKNVPYVFVRSKQALGRACGVSRPVIACSVTIKEGSQLKQQIQSIQQSIERLLV------ 
15.5K-Cys2 (72) LAEDKNVPYVFVRSKQALGRACGVSRPVIACSVTIKEGSQLKQQIQSIQQSIERLLV------ 
15.5K-Cys3 (72) LCEDKNVPYVFVRSKQALGRAAGVSRPVIACSVTIKEGSQLKQQIQSIQQSIERLLV------ 
15.5K-Cys4 (72) LCEDKNVPYVFVRSKQALGRACGVSRPVIAASVTIKEGSQLKQQIQSIQQSIERLLV------ 
15.5K-Cys5 (72) LCEDKNVPYVFVRSKQALGRACGVSRPVIAASVTIKEGSQLKQQIQSIQQSIERLLV------ 
  
Figure 4-2 Conserved amino acids present at the surface of the protein were identified and mutated.  
Mutated amino acids were highlighted in red in the sequence alignment. Amino acids are shaded as described in 




Note that mutations were not made in the conserved amino acids known to be involved 
in RNA binding or to be in close proximity to the RNA-binding pocket (Figure 4-3) (Vidovic 
et al., 2000). In addition, by replacing the conserved residues with amino acids present at the 
corresponding positions of structurally similar proteins, such as the human L7a protein, it was 
hoped that the changes would not disrupt the overall structure of the protein. However, only 5 
of the 21 mutants originally constructed (Figure 4-2) were soluble after overexpression in 
E. coli. (Soluble mutants are shown in Figure 4-3 in the 15.5K crystal structure). The 
insoluble mutants included both single amino-acid changes and larger mutations, and there 
was no obvious explanation regarding which mutants were soluble and which were not. 
However, it should be emphasised that the soluble mutants cover the main conserved regions 
of the protein surface not involved in RNA-binding (see Figure 4-3). The only conserved 
region not covered in this series of mutations was the N terminus. Unfortunately, proteins 
containing either point mutations or larger multi-amino-acid changes in this region were 
completely insoluble. 
 
Figure 4-3 Mutations indicated in the 15.5K-U4 crystal structure.  
The positions of the residues targeted for mutagenesis on the surface of protein 15.5K are depicted using the 
crystal structure of protein 15.5K bound to the 5' stem-loop of the U4 snRNA (Vidovic et al., 2000). The surface 
plot of protein 15.5K is shown in white and the U4 snRNA is shaded grey. The positions of the amino acids 
targeted for mutagenesis are indicated in red (mutant 15.5K-1), green (15.5K-2), turquoise (15.5K-3), blue 
(15.5K-4), or yellow (15.5K-5). 
One important aspect of this approach is that the mutant proteins should not affect 
RNA-binding. Even though care was taken to avoid selecting regions close to the RNA-
binding domain, it was important for the various snRNP and snoRNP assembly assays that the 
mutants bind the RNA with an affinity and specificity similar to that of the wild-type protein. 
In order to test this, purified recombinant proteins were incubated with ³²P-labelled U4 
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(Figure 2-4), U3 box B/C snoRNA (Figure 2-13), U14 box C/D snoRNA (Figure 2-13), or 
mutant U14 RNAs box C/D snoRNA (Watkins et al., 2000), and the resulting complexes 
were then resolved on a native polyacrylamide gel. This demonstrated that each of the mutant 
proteins bound the U4 and U14 RNAs with specificity similar to that seen for the wild-type 
protein (Figure 4-4 C, and data not shown). Importantly, titration experiments to measure the 
affinity of U4, U14, and U3-box B/C RNA (Watkins et al., 2000) binding showed that all of 
the mutant proteins bind these RNAs with a Kd value that is basically the same as that of the 
wild-type protein (< 2-fold variation; data not shown). Interestingly, the migration behaviour 
of the 15.5K-RNA complex in the native gel was slightly different for each mutation. It 
appears likely that this is due to changes to the surface properties of the protein, which in turn 
affect the migration behaviour in native gels.  
 
Figure 4-4 RNA-binding by soluble mutants of protein 15.5K.  
A. Table of soluble mutants. B. SDS PAGE of 15.5K mutants. C. Gel mobility-shift analysis of the interaction of 
recombinant protein 15.5K and its mutants with U4, U14 and U14 mutants. The mutant proteins were incubated 
with ³²P-labelled snRNA prepared by transcription in vitro or snoRNA transcripts and the resulting RNA-protein 
complexes were resolved on a 6% native polyacrylamide gel and visualised by autoradiography. The identity of 
the protein used is indicated above each lane. The position of the protein-RNA complex (RNP) and the free RNA 
are indicated on the right. The RNA used is indicated on the left. 
Importantly, none of the proteins bound the U14 mutD (GA to GC in the box D) and 
U14 stII RNAs (stem II: U-U, G-C, A-U changed to U-U, C-C, G-U), in which the conserved 
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GA nucleotides and stem II of the U14 snoRNA box C/D motif have been mutated, 
respectively (Watkins et al., 2002). Therefore, in creating the mutants neither the affinity nor 
specificity of RNA-binding was changed; this is consistent with the fact that the changed 
amino acids are not part of the RNA-binding domain.  
4.1.2. Conserved amino acids on the surface of protein 15.5K 
are required for hPrp31 association with the U4 snRNA  
Next, it was of interest to determine whether any of these mutations block the 
formation of 15.5K-dependent RNP complexes. As a first approach, the ability of these 
mutants to support hPrp31 binding to the U4 snRNA was investigated. Recombinant 15.5K 
protein (either wild-type or mutant) was incubated with GST-hPrp31 (Figure 4-5 B) and ³²P-
labelled U4 snRNA (Figure 4-5 A). Importantly, for both, wild-type and mutant 15.5K 
proteins, the amount of protein used, was shown to be in excess of that required to bind fully 
the RNA in the experiment. After incubation, GST-hPrp31 was isolated using glutathione 
Sepharose, and bound RNAs were analysed by polyacrylamide gel electrophoresis. Consistent 
with earlier work (Nottrott et al., 2002), protein 15.5K is required for the co-precipitation of 
the U4 snRNA with GST-hPrp31 (Figure 4-5 C; cf. lanes 1 and 2). Quantitative measurement 
revealed that mutants 15.5K-1, 15.5K-3, 15.5K-4 and 15.5K-5 also supported hPrp31 
association with the U4 snRNA, and with similar efficiency: only 15.5K-1 showed a slight 
reduction (85%) compared with the wild-type protein (taken as 100%, Figure 4-5 C; cf. lane 2 
with lanes 3, 5, 6, and 7). In contrast, a fourfold reduction of U4 snRNA association with 
hPrp31 was observed with 15.5K-2 (Figure 4-5 C, lane 4). Importantly, electrophoretic 
mobility-shift analysis (EMSA) of the binding reactions showed that all mutant proteins 
bound the U4 snRNA demonstrating (i) that the lack of 15.5K-2-recruitment of hPrp31 is not 
due to a lack of RNA-binding under these conditions and that (ii) each of the proteins is stable 




Figure 4-5 Binding of hPrp31 to the U4 snRNA requires residues in alpha helix 3 of 15.5K.  
A. Postulated secondary structure of the single U4 snRNA (modified from (Myslinski and Branlant, 1991; 
Achsel et al., 1999). The Sm protein-binding site is depicted by grey shading. B. SDS PAGE of GST-hPrp31. 
GST-hPrp31 was stained with Coomassie blue. C. GST-hPrp31 was incubated with ³²P-labelled U4 snRNA in 
the presence (lanes 2, 3, 4, 5, 6 and 7) or absence (lane 1) of either wild-type or mutant 15.5K. GST-hPrp31 was 
isolated by using glutathione resin, and the bound RNA was extracted and ethanol-precipitated. The bound RNA 
(upper panel; GST-hPrp31) and unbound RNA (lower panel; 10% Sup.) was analysed on a denaturing 8% 
polyacrylamide/7 M urea gel and visualised by autoradiography. The identity of the 15.5K protein used is 
indicated above each lane. 
Since 15.5K-2 bound to the U4 snRNA on its own (see Figure 4-4 C, lane 4) the lack 
of hPrp31 recruitment must be due to the mutation of surface amino acids in α helix 3 and the 
adjacent loop α3–β3 (see Figure 4-3). The fact that this region of the protein is important for 
the recruitment of hPrp31 in this simple three-component system supports the hypothesis that 
protein 15.5K mediates the assembly of RNP complexes, in part, through protein-protein 
contacts. 
4.1.3. Numerous mutations on the surface of protein 15.5K 
disrupt the binding of the CYPH/hPrp4/hPrp3 complex to 
U4/U6 snRNA 
After the demonstration that changes in the surface amino acids can affect the binding 
of hPrp31 to U4 snRNA, the question of whether the mutations would support the binding of 
the CypH/hPrp4/hPrp3 heteromeric complex to U4/U6 snRNA was investigated. To answer 
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the question, the reconstitution assay developed by Nottrott et al. (2002) was used. Briefly, 
recombinant 15.5K protein was incubated together with (i) radiolabelled U4/U6 snRNA 
duplex, in which the minimal fragment of U6 snRNA required for CypH/hPrp4/hPrp3 binding 
was radiolabelled (Figure 4-6 A), and (ii) biochemically purified CypH/hPrp4/hPrp3 protein 
complex (Figure 4-6 B). The assembled complexes were then immunoprecipitated using 
anti-hPrp4 antibodies, and the co-precipitated RNAs were analysed by polyacrylamide gel 
electrophoresis. 
Consistent with previous findings (Nottrott et al., 2002), the U4/U6 snRNA duplex 
was co-precipitated by anti-hPrp4 antibodies when incubated with CypH/hPrp4/hPrp3 and 
15.5K, but not when it was incubated with CypH/hPrp4/hPrp3 alone (Figure 4-6; lanes 1 and 
2). Analysis of the mutants in this assay revealed that 15.5K-1 supported the U4/U6 snRNA-
CypH/hPrp4/hPrp3 interaction to 80% of the level seen with the wild-type protein (Figure 
4-6; lane 4). In contrast, a greater than five-fold reduction in complex formation, relative to 
the wild-type protein, was observed using 15.5K-3 and 15.5K-4 (Figure 4-6; lanes 4 and 7) 
and the interaction was effectively abolished in the presence of 15.5K-2 and 15.5K-5 (lanes 5 
and 8). Therefore, four of the five regions – including α helix 3 and the adjacent loop α3-β3, 
α helix 4 and α helix 5 – are required for the interaction between U4/U6 snRNA and the 
CypH/hPrp4/hPrp3 complex. This suggests that significant contacts are made between one or 
more of the proteins in the CypH/hPrp4/hPrp3 complex and protein 15.5K that are important 




Figure 4-6 Association of CypH/hPrp4/hPrp3 to the U4/U6 snRNA requires several regions on the surface 
of 15.5K.  
A. The secondary structure of the U4 snRNA in complex with the U6 snRNA nucleotides 58-87. The Sm 
protein-binding site is depicted by grey shaded capitals. (modified from Myslinski and Branlant (1991) and 
Achsel et al. (1999)). B. SDS PAGE of the purified, native CypH/hPrp4/hPrp3 protein complex. 
CypH/hPrp4/hPrp3 complex was visualized by silver staining. C. Purified CypH/hPrp4/hPrp3 complex was 
incubated with U4/U6 snRNA duplex (U4 snRNA base-paired with ³²P-labelled U6 nucleotides 58-87) in the 
presence (lanes 2-7) or absence (lane 1) of wild-type or mutant 15.5K. The CypH/hPrp4/hPrp3 complex was 
then immunoprecipitated using anti-hPRP4 antibody; the co-precipitated RNA (upper panel; α-hPRP4) and the 
RNA present in the supernatant (lower panel; 5% Sup.) were analysed on a denaturing 8% polyacrylamide/7 M 
urea gel and visualized by autoradiography. The identity of the 15.5K protein used is indicated above each lane. 
4.1.4. Box C/D snoRNP assembly requires multiple regions on 
the surface of protein 15.5K 
Next, attention was turned to the assembly of the box C/D snoRNP. For this, a system 
was used that was established earlier to investigate the assembly of the U14 snoRNP (Watkins 
et al., 2002). Briefly ³²P-labelled U14 snoRNA (Figure 4-7 A), prepared by transcription in 
vitro, was incubated with HeLa nuclear extract and snoRNP assembly determined by 
immunoprecipitation using antibodies specific to the core box C/D proteins and the assembly 
factors TIP48 and TIP49. In this system, the binding of the endogenous protein 15.5K in the 
extract could be selectively blocked by introducing an excess of the 5' stem-loop of the U4 
snRNA (SL1, Figure 4-7 B) (Watkins et al., 2002). Box C/D snoRNP assembly in the blocked 
extract was restored by the addition of recombinant protein 15.5K. Therefore, this approach 
was used to determine the ability of the mutant proteins to support box C/D snoRNP 
assembly. Protein-binding was subsequently investigated by using anti-fibrillarin, NOP56, 
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NOP58, TIP48, and TIP49 antibodies; the co-precipitated RNAs were analysed by 
polyacrylamide gel electrophoresis. 
 
Figure 4-7 Several regions on the surface of protein 15.5K are required for box C/D snoRNP assembly.  
A. Secondary-structure model for the U14 box C/D snoRNA base-paired with the 18S pre-rRNA (according to 
Kiss (2001)). The consensus sequences for boxes C, C', D, and D' are indicated by the grey shading. B. U4 
snRNA 5' stem-loop RNA oligonucleotide (SL1) used to block the endogenous 15.5K. C. HeLa nuclear extract 
was pre-incubated either with 800 pmol of U4-SL1 RNA oligonucleotide (+) or with buffer (-). Radiolabelled 
U14 snoRNA was subsequently added in the presence (lanes 2-8) or absence (lane 1) of wild-type or mutant 
15.5K. The binding of individual snoRNP proteins was then assayed by immunoprecipitation. Bound RNAs 
were recovered and then separated on an 8% polyacrylamide/7M urea gel. Antibodies used for 
immunoprecipitation are indicated on the left. Input: 10% of the RNA after incubation in nuclear extract. The 
15.5K protein used is indicated above each lane. 
Consistent with previous observations (Watkins et al., 2002), the addition of U4 SL1 
RNA inhibited the assembly of box C/D snoRNP, while the binding of all proteins was 
restored by the addition of recombinant protein 15.5K (Figure 4-7 C, lanes 1-3). Similar 
levels of association of NOP56, NOP58, fibrillarin, TIP48, and TIP49 with the U14 snoRNA 
were also observed when the wild-type protein was replaced by either mutant 15.5K-3 or 
15.5K-4 (Figure 4-7; lanes 6 and 7). In most cases, the level of precipitation was slightly 
higher than that seen for the wild-type protein, however, slightly reduced for fibrillarin and 
NOP58 (90% of wild-type levels) when mutant 15.5K-3 was used. In contrast, the binding of 
all proteins was either reduced by a factor greater than 20 or effectively abolished when 
mutants 15.5K-1 and 15.5K-2 were used in this assay (lanes 4 and 5). Interestingly, 15.5K-5 
supported the binding of only a subset of the box C/D-associated proteins (lane 8). In the 
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presence of 15.5K-5, NOP58, TIP48, and fibrillarin, the association observed was equivalent 
to that seen with the wild-type protein, whereas the binding of TIP49 and NOP56 was either 
reduced (80% of wild-type levels) or effectively abolished (~2% of wild-type), respectively. 
These results imply that several regions of the 15.5K protein surface are important for 
box C/D snoRNP assembly, including amino acids in α helix 1 (15.5K-1), in α helix 3 and in 
the adjacent loop between α3 and β3 (see Figure 4-3) for complete box C/D snoRNP 
formation, and including amino acids in α helix 5 for the specific association of NOP56 and 
TIP49. 
4.1.5. Alpha helix 4 of protein 15.5K is required for hU3–55K 
binding to the U3 snoRNA 
Following the investigation of the effect of the mutations on the formation of U4 
snRNP, U4/U6 snRNP and box C/D snoRNP, the assembly of the U3-specific box B/C RNP 
complex was addressed. It has already been shown, by using the U4 5' stem-loop as a 
competitor, that the binding of hU3–55K to the U3 B/C motif in nuclear extract is dependent 
on exogenous protein 15.5K (Granneman et al., 2002). Therefore, this approach was used to 
investigate the ability of the 15.5K mutants to support hU3–55K binding. Briefly, ³²P-labelled 
U3 box B/C RNA (Figure 4-8 A) was incubated with nuclear extract that had been pre-treated 
with the U4 5' stem-loop RNA SL1 (see Figure 4-7 B), and then the extent of protein binding 
was determined by immunoprecipitation using anti-hU3–55K antibodies. Co-precipitated 
RNAs were then analysed by polyacrylamide gel electrophoresis. Consistent with earlier 
observations (Granneman et al., 2002), addition of SL1 RNA inhibited the co-precipitation of 
the U3 box B/C snoRNA with anti-hU3–55K antibodies (Granneman et al., 2002).  
This interaction was restored by the addition of recombinant protein 15.5K. The ability 
of the mutant proteins to restore protein binding was then determined. The mutants 15.5K-1, 
15.5K-2, 15.5K-4 and 15.5K-5 all effectively restored the association of the hU3–55K with 
the U3 box B/C RNA, i.e., to 90-100% of the wild-type level (Figure 4-8 B, lane 4, 5, 7, and 
8, respectively). In contrast, protein 15.5K-3 resulted in a reduction in the association of the 
hU3–55K protein by a factor greater than 10 (lane 6). These results show that the conserved 
region of α helix 4, found on the protein surface, is important for interaction of hU3–55K 




Figure 4-8. hU3–55K binding to the U3 box B/C motif requires a distinct region on the surface of protein 
15.5K.  
A. Schematic depiction of the U3 B/C RNA. B. HeLa nuclear extract was pre-incubated either with 800 pmol 
U4-SL1 RNA oligonucleotide (+) or with buffer (-). Radiolabelled U3 box B/C motif RNA was subsequently 
added in the presence (lanes 3-8) or absence (lanes 1 and 2) of recombinant protein 15.5K or mutant 15.5K. The 
binding of hU3–55K was then assayed by immunoprecipitation. Bound RNAs were recovered and then separated 
on an 8% polyacrylamide/7M urea gel. Input: 5% of the RNA after incubation in nuclear extract. The 15.5K 
protein used is indicated above each lane. 
4.1.6. A direct interaction between proteins hU3–55K and 
15.5K 
In earlier work, an in vitro assembly system, using recombinant 15.5K and hU3–55K 
prepared by translation in vitro, was developed to analyse the assembly of the box B/C RNP 
complex (Granneman et al., 2002). This system was used to investigate further the relative 
importance of the RNA and protein 15.5K in the recruitment of hU3–55K. GST-tagged 15.5K 
was incubated with 35S-labelled hU3–55K (prepared by translation in vitro) in the presence or 
absence of box B/C RNA. GST-15.5K was isolated by using glutathione Sepharose, and its 
association with hU3–55K was determined by SDS polyacrylamide gel electrophoresis 
followed by autoradiography. As described previously (Granneman et al., 2002), when 0.25 
pmol GST-15.5K was used, co-purification of the hU3–55K was dependent on the presence 
of the box B/C RNA (Figure 4-9 A, lane 3 and 5). This amount of protein was also previously 
shown still to be capable of binding the U3 box B/C snoRNA in the absence of hU3–55K 
(Granneman et al., 2002), indicating that the protein is stable in the absence of the U3-specific 
protein. However, increasing the amount of GST-15.5 (25 pmol) resulted in a significant co-
precipitation of 15.5K in the absence of the B/C RNA (Figure 4-9 A, lane 6). Interestingly, 
under these conditions the binding of hU3–55K was stimulated more than 3-fold by the 
presence of the B/C RNA (Figure 4-9 A, lanes 4 and 6), suggesting that the full interaction is 
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mediated by both the RNA and 15.5K. The use of 25 pmol of GST alone failed to precipitate 
hU3–55K, showing that this interaction is specific (lane 2).  
The observed interaction between protein 15.5K and protein hU3–55K was not 
susceptible to RNase A treatment of the translate (data not shown), suggesting that the result 
was not due to endogenous RNA present in the reticulocyte lysate.  
 
Figure 4-9 Mutant 15.5K-3 inhibits the binding of hU3–55K to the U3 box B/C in the absence of the 
corresponding RNA.  
A. 35S-labelled hU3–55K was incubated either with GST-15.5K (0.25 or 25 pmol) in the absence (-) or presence 
(+) of U3 box B/C RNA (lanes 3-6), or with 25 pmol GST (lane 2). Bound, radiolabelled proteins were purified 
using glutathione resin, resolved on a 12% polyacrylamide SDS gel and revealed by autoradiography. The 
amount of recombinant protein 15.5K used is indicated above each lane. Input; 10% of the input material. B. 
35S-labelled hU3–55K was incubated with 25 pmol of either wild-type or mutant GST-15.5K (lanes 3-8) or GST 
(lane 2). Bound, radiolabelled proteins were purified using glutathione resin and resolved on a 12% 
polyacrylamide SDS gel. Input; 10% of the input material. The identity of the GST-protein used is indicated 
above each lane. 
If the interaction observed with the in vitro hU3-55K translate is the same as the 
proposed interaction, required for hU3–55K recruitment as observed in experiments using 
nuclear extract (see 4.1.5), then one would predict that 15.5K-3 (mutation in Alpha helix 4) 
should not bind this protein. Therefore, the ability of the 15.5K mutants to interact with hU3–
55K was investigated. Protein hU3–55K (prepared by translation in vitro) was allowed to 
react with 25 pmol of the GST-tagged protein. The experiment showed that GST-15.5K-1, -2, 
and -4 associated with hU3–55K either to a level equivalent to that of the wild-type protein, or 
even more efficiently (~2-fold higher for GST-15.5K-2; Figure 4-9 B, cf. lane 2 and lanes 4, 
5, and 7). GST-15.5K-5 bound hU3–55K to about 60% of the levels seen for the wild-type 
protein (Figure 4-9 B, lane 8). This suggests that, although this mutant does not function as 
efficiently as the wild-type protein, the mutation does not suppress significantly the 
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association between hU3–55K and the 15.5K-box B/C RNA complex. However, GST-15.5K-
3 showed a reduction in hU3–55K co-precipitation levels by a factor of ~20 (lane 6). These 
data therefore provide compelling evidence that a protein-protein interaction with 15.5K is 
important for the binding of hU3–55K to the U3 snoRNA. 
4.2. Protein 15.5K is located in nucleoplasmic foci and is 
associated with the U4/U6 di–snRNP and the 
U3 snoRNA in vivo 
4.2.1. The U4/U6 di–snRNP and box C/D snoRNP-associated 
protein 15.5K localises to nucleoplasmic foci 
The next question was whether the 15.5K mutants show a localisation pattern different 
from that of the 15.5K protein wild-type and the 15.5K protein mutants affect RNP complex 
assembly in vivo.  
To address this question, initially the location of 15.5K protein wild-type was 
determined. This protein was made visible both by immuno-fluorescence and by expression 
of protein 15.5K fused to enhanced yellow fluorescent protein (EYFP; Cormack et al., 1996). 
The distribution of the labelled 15.5K protein was observed by fluorescence microscopy. As 
the epitope for α-15.5K antibody is likely not accessible in the tri-snRNP as it is probably 
covered by complex-specific proteins (Nottrott et al., 1999), detection of protein 15.5K 
without SDS treatment was not possible. It has been shown that pre-treatment with 1% SDS 
produces a dramatic increase in staining intensity by indirect immuno-fluorescence (Brown et 
al., 1996). Thus, to allow detection of 15.5K, HeLa cells were treated with SDS after fixation 




Figure 4-10 The 15.5K protein is localised in nucleoli, Cajal bodies and splicing speckles.  
A–F. HeLa cells were fixed and stained with α-15.5K and counterstained with α-SC35 antibodies. In addition, 
HeLa cells were transiently transfected with pEYFP–15.5K for 16 h, fixed and counterstained with α-SC35 
antibody. Cells shown in A-C were treated with SDS before staining. G–J. Cells were transiently transfected 
with pEYFP–15.5K and treated as described above. Fixed cells were counterstained with α-NOP56 and α-Coilin 
antibodies. Splicing speckles are indicated by solid arrows. The arrowheads indicate Cajal bodies and dashed 
arrows indicate nucleoli. 
Antibody-labelled protein 15.5K was seen to be confined to the nucleus; it 
accumulated in large areas (Figure 4-10 A and Figure 4-10 B, dashed arrows) and also in a 
number of smaller clusters (Figure 4-10 A, solid arrows). The distribution of 15.5K protein 
fused to EYFP was similar to that of antibody-labelled 15.5K; thus, EYFP–15.5K was also 
seen to accumulate in large areas. However, in contrast to antibody-labelled 15.5K, the 
nucleoplasmic distribution of EYFP–15.5K was more homogeneous. The smaller clusters 
were less obvious (Figure 4-10 D). However, a nucleus expressing EYFP–15.5K showed 
small foci, adjacent to the nucleoli, where the EYFP-protein 15.5K accumulated (Figure 4-10 
G, arrowheads). 
As 15.5K protein is a component of splicing active snRNPs and snoRNPs, which 
specifically localise to splicing speckles, Cajal bodies and/or nucleoli, the distribution of 
15.5K was compared with the distributions of (i) antibody-labelled SC35 protein, as a marker 
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for splicing speckles, (ii) NOP56 as a marker for nucleoli, and (iii) coilin as a marker for Cajal 
bodies (Figure 4-10). 
Endogenous 15.5K protein and transiently expressed EYFP–15.5K both co-localised 
with SC35 in the splicing speckles (Figure 4-10 A–F, indicated by solid arrows), suggesting 
that 15.5K is a component of the splicing speckles. The small differences in the appearance of 
the splicing speckle patterns are likely to be due to the SDS treatment of HeLa cells before 
antibody incubation during the immuno-fluorescence procedure (Figure 4-10 B).  
As the reactivity of NOP56, NOP58 and fibrillarin with antibody is impaired in SDS-
treated cells, it was not possible to observe the immuno-fluorescence of the box C/D snoRNP-
specific proteins or fibrillarin together with antibody-labelled 15.5K protein. Therefore, 
experiments to show co-localisation of 15.5K with nucleolar proteins and Cajal bodies were 
performed using EYFP–15.5K fusion protein. Transiently expressed EYFP–15.5K 
co-localised with NOP56 in the nucleoli (Figure 4-10 G, H, and J) and also in Cajal bodies 
(Figure 4-10 G, I, and J).  
The localisation of 15.5K in nucleoli and Cajal bodies is consistent with earlier results 
(Leung and Lamond, 2002). However, a permanent localisation of 15.5K in the splicing 
speckles has not been reported before. Leung and Lamond (2002) demonstrated that newly 
imported 15.5K transiently co-localises with splicing factors in splicing speckles. At later 
time points, the signal in speckles was no longer detected and EYFP–15.5K accumulates 
specifically in nucleoli and Cajal bodies.  
The localisation of the 15.5K mutants was determined by using the YFP-tagged 
mutants 15.5K-1 to 15.5K-5. The 15.5K mutants 15.5K-1, 15.5K-3, 15.5K-4, and 15.5K-5 
localised to splicing speckles, nucleoli, and to Cajal bodies similar to the wild-type protein 
15.5K (see Figure 4-11, Figure 4-12, and Figure 4-13). However, mutant 15.5K-2, which was 
only expressed to a very low level (see Figure 4-14, lane 4), was prevented from translocating 




Figure 4-11 Cellular localisation of YFP-tagged 15.5K mutants analysed by co-staining of splicing factor 
SC35. 
HeLa cells were transiently transfected with pEYFP–15.5K and fixed and stained with α-SC35 antibodies 16 h 




Figure 4-12 Cellular localisation of YFP-tagged 15.5K mutants analysed by co-staining of protein NOP56. 
HeLa cells were transiently transfected with pEYFP–15.5K and fixed and stained with α-NOP56 antibodies 16 h 




Figure 4-13 Cellular localisation of YFP-tagged 15.5K mutants analysed by co-staining Cajal body marker 
protein coilin. 
HeLa cells were transiently transfected with pEYFP–15.5K and fixed and stained with α-coilin antibodies 16 h 




Figure 4-14 Western blot analysing the expression level of YFP-15.5K-1 to 15.5K-5 in HeLa cells.  
HeLa cells were transiently transfected with pEYFP–15.5K wild type, mutants and Flag-Lamin A (Bechert et al., 
2003; AG Weber), which was used as a transfection, expression and loading control. 16 h post transfection 
nuclear extracts were prepared and the expression level of EYFP–15.5K wild type and mutants were analysed by 
western blot using anti-GFP. Loaded amount of extract was normalized by cell number before extract 
preparation. The level of Flag-Lamin A detected by anti-Flag antibodies demonstrates that equal amounts of 
extract were loaded. 
4.2.2. EYFP–15.5K fusion protein in vivo is complexed 
specifically with the same RNA targets that protein 
15.5K was shown to bind directly in vitro 
As the expression level of the YFP-15.5K wild type and mutants in HeLa cells was 
very unequal (see Figure 4-14) a biochemical analysis using transiently transfected HeLa cells 
turned out to be difficult due to problems in normalizing pull down experiments and due to a 
low yield of nuclear extract. To facilitate investigating the role of protein 15.5K on U4/U6 
snRNP and box C/D snoRNP complex assembly in vivo, it was tried to generate HeLa cell 
line stably expressing EYFP–15.5K wild type and mutants (see 3.2.5.5).  
Unfortunately, the generation of stable cell lines expressing the 15.5K mutants failed 
as there could be no YFP-15.5K mutant expressing colonies selected likely due to a cytotxic 
effect of the mutants to the cells. Therefore, the biochemical analysis of 15.5K mutants 
expressed in HeLa cells was not possible. However, experiments were carried out using the 
stable cell line expressing EYFP-15.5K wild type (HeLaEYFP-15.5K; see 3.2.5.5) identifying 
RNPs 15.5K is associated with in vivo. 
The expression level of the exogenous YFP-15.5K protein is about three times lower 
compared to that of the endogenous 15.5K protein (see Figure 4-15). However, as it was of 
only of interest to find out which RNAs bind to the 15.5K protein in vivo, this fact was of 




Figure 4-15 HeLa cell line stably expressing EYFP–15.5K.  
A western blot was performed using anti-GFP and anti-15.5K antibodies showing expression levels of 
endogenous 15.5K and EYFP–15.5K in the nuclear extract prepared from a HeLa cell line stably expressing 
EYFP-15.5K (HeLaEYFP-15.5K). Membrane was blotted twice using first anti-GFP and then anti-15.5K antibodies. 
The first antibody was removed from the membrane by membrane stripping. 
To confirm that the EYFP–15.5K fusion protein expressed in the stable HeLaEYFP-15.5K 
cell line behaves biochemically in a manner similar to recombinant 15.5K protein and 15.5K 
protein from HeLa cells, observed in previous in vitro binding studies (Nottrott et al., 1999; 
Watkins et al., 2000), its specificity of RNA-binding in vivo was investigated. An extract 
from HeLaEYFP-15.5K cells was immunoprecipitated with an α-GFP antibody. RNAs in the 
immunoprecipitate were separated by urea-polyacrylamide gel electrophoresis, transferred to 
nylon membrane, and hybridised with probes for U2, U4, U5, and U6 snRNAs and 
U3 snoRNA (Figure 4-16). This showed that U3 snoRNA, U4, U5 and U6 snRNA – but not 
U2 snRNAs – had been co-precipitated with the α-GFP antibody (Figure 4-16, lane 8). 
Control experiments, i.e., bead control (Figure 4-16, lanes 2, 4 and 7 respectively) and an 
HeLaEGFP-Fibrillarin nuclear cell extract (Figure 4-16, lane 5; HeLaEGFP-Fibrillarin cell line provided 
by the laboratory of Prof. Angus Lamond), showed that although the α-GFP antibody still 
precipitated the fluorescent fusion protein from these extracts (western blot data not shown), it 
did not precipitate any of the RNAs tested, whereas the same α-GFP antibody precipitated the 
U3 snoRNA, but not the U2, U4, U5, and U6 snRNAs, from a HeLaEGFP-Fibrillarin cell extract 
(Figure 4-16, lane 5). 
It is known that U4 and U6 snRNAs usually exist as a duplex inside the nucleus 
(Bringmann et al., 1984; Hashimoto and Steitz, 1984; Rinke et al., 1985; Brow and Guthrie, 
1988). The co-immunoprecipitation of U4 and the U6 snRNA is therefore not surprising. 
However, the α−GFP antibodies failed to precipitate tri-snRNP particles above the 
background values, as the U5 snRNA signal does not exceed background level compared to 
the level co-precipitated by ECFP-fibrillarin (Figure 4-16 , compare lane 5 and lane 8). The 
fraction of 15.5K bound to the U4/U6.U5 tri-snRNP is probably poorly accessible for the α-
GFP antibodies. This idea is consistent with the observation that the 15.5K epitope is 
inaccessible to 15.5K antibodies in the tri-snRNP as it is probably covered by complex-
specific proteins (Nottrott et al., 1999). Associated complex-specific proteins could also cover 
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even a tag of the scale of a GFP-tag fused to 15.5K making it inaccessible to the α-GFP 
antibody.  
These results show that the EYFP–15.5K fusion protein is specifically complexed in 
vivo with the same RNA species that protein 15.5K was shown to bind directly to in vitro 
(Nottrott et al., 1999; Watkins et al., 2000). 
 
Figure 4-16 In vivo RNA-binding by EYFP–15.5K.  
The in vivo RNA-binding by EYFP–15.5K was assayed by immunoprecipitation, and the binding of snRNAs 
U2, U4, U5, and U6 as well as of snoRNA U3 was tested by northern hybridisation. 
Following the demonstration that EYFP–15.5K is specifically complexed with the 
same RNA molecules that 15.5K was shown to bind directly in vitro, the binding specificity 
of the U4/U6 di–snRNP and the box C/D snoRNP complex-specific proteins hPrp4 and 
NOP56 was investigated. The EYFP–15.5K fusion protein was immunoprecipitated by using 
anti-hPrp4 and anti-NOP56 antibodies, and the co-precipitated EYFP–15.5K fusion protein 
was investigated by western blotting using α-GFP antibodies. 
Briefly, nuclear extract from HeLaEYFP-15.5K cells was incubated with protein-A-
Sepharose beads to which α-hPrp4 or α-NOP56 antibodies had previously been coupled. The 
EYFP–15.5K fusion protein was co-precipitated with anti-hPrp4 and detected with α-GFP 
antibodies. The results, shown in Figure 4-17, revealed that both α-NOP56 (lane 5) and α-
hPrp4 antibodies (lane 5) precipitated the EYFP–15.5K fusion protein. The bead controls 
(lanes 3 and 4) showed that the EYFP–15.5K fusion protein was specifically precipitated by 
beads with coupled α-NOP56 and α-hPrp4 antibodies. This experiment shows that in vivo the 
4 Results 
 99
EYFP–15.5K fusion protein is specifically complexed with U4/U6 snRNP and 
box C/D snoRNP, containing hPrp4 and NOP56 respectively. 
 
Figure 4-17 In vivo RNP-binding of EYFP–15.5K.  
The in vivo RNP-binding of EYFP–15.5K was assayed by immunoprecipitation with α-hPrp4 and α-NOP56 
antibodies and was analysed by western blotting using an α-GFP antibody. NE = nuclear extract, NOE = 
nucleolar extract. 
4.3. Association of the spliceosomal hPrp31 protein with 
the U4 snRNP: Requirement for U4 snRNA's kink-turn 
stem II and the Nop domain 
4.3.1. Hydroxyl-radical footprinting reveals direct contact of 
protein hPrp31 with various regions of the U4 snRNA  
It was shown earlier that protein hPrp31 only makes direct contact with the U4 snRNA 
after protein 15.5K binds to the kink-turn motif of U4 snRNA (Nottrott et al., 2002). In order 
to narrow down the possible locations of this contact in the ternary 15.5K-hPrp31-U4 snRNA 
complex, hydroxyl-radical footprinting experiments performed by Stephanie Nottrott have 
been re-examined (see Schultz et al., 2006b). In this method, hydroxyl radicals are produced; 
these cleave the RNA backbone at the ribose units, and an RNA that is shielded by protein 
will be protected from such cleavage. Analysis was performed by using primer extension with 
reverse transcriptase. Through a comparison with cleavage sites on naked RNA, the absence 
of a transcriptional stop before a particular position is considered as a protection at this 
position in the complex.  
The ternary U4 snRNA–15.5K–hPrp31 complex was assembled by incubating full-
length U4 snRNA (prepared by transcription in vitro) with an excess of recombinant protein 
15.5K and glutathione-S-transferase (GST)-hPrp31 (Nottrott et al., 2002). Under the 
conditions used, more than 95% of the U4 snRNA was converted into the ternary complex, as 
assayed by EMSA (data not shown). In order to distinguish nucleotides protected by protein 
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hPrp31 from those protected by protein 15.5K only, a binary 15.5K-U4 snRNA complex was 
assembled in a parallel sample; naked RNA was used as a reference. These complexes were 
treated with H2O2 in the presence of Fe(II)–EDTA to generate hydroxyl radicals. The RNA 
was subsequently analysed by primer extension (Figure 4-18 A) of the U4 snRNA. 
A comparison of the cleavage pattern of naked RNA (lane 2) with that of a control 
omitting the reagent Fe(II)–EDTA (lane 1) shows distinct cleavages at all nucleotides 
(compare lanes 1 and 2). Lane 3 shows the hydroxyl-radical cleavage pattern observed in the 
binary 15.5K–U4 snRNA complex. Strong protection is found in the kink-turn and in the 
adjacent stems I (A29–G34) and II (G43–C47) (lanes 2 and 3; compare (Figure 4-18, FP 2 
and FP 1, red bars). This is in agreement with the results of earlier studies (Vidovic et al., 
2000; Nottrott et al., 2002) in which these nucleotides were identified as the binding site for 
protein 15.5K.  The cleavage pattern of U4 snRNA in the ternary complex revealed a number 
of additional protection sites arising from the presence of protein hPrp31. One region 
extended from G35 to C42 (lanes 3 and 4; FP A in (Figure 4-18 A) comprising the penta-loop 
and nucleotides of stem II not protected by protein 15.5K. Further, protection was observed in 
stem I next to the kink-turn at positions G26, C27, and C28 (FP B) and at nucleotides C16 and 




Figure 4-18 Protein hPrp31 binds directly to U4 snRNA.  
A. Hydroxyl radical footprints performed by Stephanie Nottrott (see Schultz et al., 2006b) of the U4 snRNA–
15.5K–hPrp31 and the U4/U6–15.5K–hPrp31 protein complexes analysed by primer extension, with a primer 
was complementary to nucleotides 65–82 of the U4 snRNA. Riboses protected from cleavage in the presence of 
protein 15.5K are indicated by red bars on the right (FP 1 and FP 2), and those protected additionally by hPrp31 
by green (FP A, FP B and FP C). The reverse transcriptase stop is one nucleotide before the actual cleavage site. 
Lane 1 contains unmodified U4 snRNA as a control for spontaneous stops by the reverse transcriptase. C, U, A 
and G refer to dideoxy sequencing reactions (0, no ddNTPs added). The footprints were additionally analysed by 
densitometry of the autoradiographs (data not shown). B. Superposition of the cleavage data onto the secondary 
structure models of the human U4 snRNA 5′ stem-loop (Myslinski and Branlant, 1991) and the U4/U6 snRNA 
duplex (Bringmann et al., 1984). The open circles indicate non–Watson-Crick base pair interactions as found in 
the crystal structure of the U4 5′ stem-loop bound by protein 15.5K (Vidovic et al., 2000). Other non–Watson-
Crick base pairs are depicted by solid dots. The positions of the footprints of protein 15.5K are indicated by 
filled circles (FP 1 and FP 2) and those of protein hPrp31 by open squares (FP A, FP B and FP C). 
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In the U4/U6 snRNA duplex, FP C would be located in the U4/U6 helix II, adjacent to 
the three-way junction of the U4/U6 duplex. Therefore it would be of interest to know 
whether protein hPrp31 would similarly protect these nucleotides when binding to the 15.5K–
U4 snRNA complex in the context of the duplex. To investigate this, first the duplex was 
created by annealing U6 snRNA to U4 snRNA before addition of proteins 15.5K and hPrp31. 
Formation of the U4/U6 duplex was quantitative, and the duplex was as efficient as the 
single-stranded U4 snRNA in ternary complex formation, as determined by EMSA (data not 
shown). Hydroxyl radical footprinting was then performed as above, on (i) the protein-free 
U4/U6 duplex (Figure 4-18, lane 6), (ii) the complex formed between the duplex and protein 
15.5K (Figure 4-18, lane 7), and (iii) the complex formed between the pre-formed 15.5K-
U4/U6 snRNA complex and protein hPrp31 (Figure 4-18 A, lane 8). Duplex formation on its 
own did not influence the accessibilities of the riboses in U4 snRNA (Figure 4-18 A, lanes 6 
and 2), except for a reduced reactivity at A39–G43 in the U4/U6 snRNA duplex. Similarly, 
the footprint of protein 15.5K on the U4 in the U4/U6 duplex was essentially identical to the 
one described above (Figure 4-18 A, lanes 7 and 3, FP 1 and FP 2). The addition of protein 
hPrp31 resulted in protection of nucleotides essentially identical to those seen in the absence 
of U6 snRNA Figure 4-18 A, lanes 8 and 4). In particular, the protection of the penta-loop and 
the adjacent stem II was unchanged (FP A). Protection at the bottom of stem I (FP B), 
adjacent to the binding site for protein 15.5K, was more extensive in that A25 also showed 
protection. Somehow more enlarged was FP C, which was found to extend from G14 to G18. 
Figure 4-18 B depicts the footprints on the secondary structures of U4 snRNA (Myslinski and 
Branlant, 1991) and the U4/U6 snRNA duplex (Bringmann et al., 1984) respectively. The 
overall pattern of protection of U4 snRNA by protein hPrp31 was thus comparable in the 
hPrp31-15.5K-U4 snRNA and the hPrp31-15.5K-U4/U6 snRNA complexes, with only 
differences observed on the borders of the protected regions in FP B and C. In summary, these 
data show that in vitro protein hPrp31 protects regions of stems I and II, the complete 
terminal penta-loop, and nucleotides in the helix adjacent to the three-way junction. 
4.3.2. Protein hPrp31 requires stem I and stem II of the 5′ 
stem-loop of U4 for binding 
The next question investigated was that of which of the structural elements of 
U4 snRNA that were found to be protected from hydroxyl radical attack by protein hPrp31 in 
the footprinting experiment were required for stable binding of protein hPrp31 to the 
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15.5K-U4 snRNA binary complex. For this more detailed analysis, a series of mutant RNA 
oligonucleotides was prepared, and these were assayed by EMSA for ternary-complex 
formation. To ease solubilisation of hPrp31, a fusion protein comprising the maltose-binding 
protein (MBP) fused to hPrp31 was used (Figure 4-19 A). This behaves in a manner identical 
to non–tagged hPrp31 (data not shown). In all experiments, the binary 15.5K-U4 snRNA 
complex (B in Figure 4-19 B) was first assembled with recombinant 15.5K protein and 
radiolabelled RNA oligonucleotide. Formation of the ternary complex (T in Figure 4-19 B) 
was then initiated by adding MBP-hPrp31 protein. Complexes were then analysed directly by 
native PAGE at 4 °C.  
Since the single-stranded 5′ region of the U4 snRNA was protected by the protein, this 
segment was deleted first (U4-2, Figure 4-19 B). No reduction in the amount of ternary 
complex formed (Figure 4-19 B; lanes 3 and 7) was observed compared with the longer 
deletion mutant U4 snRNA (U4-1), which binds in a manner identical to that of the wild-type 
U4 snRNA (Nottrott et al., 2002). Hence, the contact between the single-stranded 5′ end of 
the U4 snRNA and protein hPrp31 is not required for stable binding. However, the deletion of 
five base pairs from stem I severely depressed the formation of stable ternary complex (U4-3; 
Figure 4-19 B, lanes 3 and 11). Residual ternary complexes (in yields of approximately 20% 
compared with the U4-2 or U4-1 RNA) were unstable, resulting in an ill-defined smear 
migrating above the binary 15.5K-U4 snRNA complex. Binding activity could not be restored 
by extending the truncated three-base-pair-long stem I of mutant U4-3 by a C-G base pair 
(U4-4, SL1 in reference Nottrott et al. (2002), Figure 4-19 B). Furthermore, changing the 
sequence of the upper part of stem I while leaving the number of base pairs intact, or deleting 
the bulged-out A, did not reduce the yield of ternary complex (oligonucleotides U4-10 and 
U4-11; data not shown). Therefore, it is possible to reach the conclusion that the length of 
stem I is critical for stable binding of protein hPrp31 to the binary 15.5K–U4 snRNA 
complex, and that this double-helical RNA structure, irrespective of sequence, forms part of 




Figure 4-19 Binding of hPrp31 to the U4 snRNP requires the complete stems I and II of the 5' stem-loop of 
the U4 snRNA.  
A. SDS PAGE of MBP-hPrp31. MBP-hPrp31 was stained with Coomassie blue. B. The gels show EMSA of the 
interaction between protein hPrp31 and the 15.5K–U4 snRNA deletion mutant complex. The binary complex 
was first assembled with protein 15.5K and mutant U4 snRNA s (top panels), and ternary-complex formation 
was then initiated by adding protein hPrp31. Complexes were separated on a 6% native polyacrylamide gel. The 
positions of the protein-RNA complexes are indicated on the right: R, free RNA; B, binary complex consisting 
of the RNA and 15.5K; T, ternary complex, consisting of the RNA, 15.5K and protein hPrp31. The sequence and 
structure of the respective U4 snRNA deletion mutant used is indicated above each panel. 
The hydroxyl-radical footprint showed protection of the entire penta-loop in the 
ternary complex (Figure 4-18 A and B). Next, a number of different penta-loop mutants were 
tested, and their effect on stable ternary-complex formation in the experimental system 
outlined above was assayed. The U4-2 mutant (Figure 4-19 B), which has wild-type 
properties while being closest in length to the other mutants, was used as a reference with 
which to compare the mutants. Replacement of the penta-loop by an unrelated sequence did 
not impair complex formation (U4-5, Figure 4-20).  
Its replacement with a tetranucleotide loop (UGAA in U4-6, Figure 4-20; other loops 
tested were UUCG and GCAA) likewise had no effect (Figure 4-20, lanes 3 and 11 and data 
not shown). Therefore, a more dramatic change in the penta-loop's backbone was introduced 
by opening it up. An RNA duplex with dangling ends was created by annealing the 5′ (20–37) 
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and 3′ (38–52) halves of the U4 snRNA 5′ stem-loop (U4-A, Figure 4-20). Unexpectedly, this 
duplex still allowed efficient ternary-complex formation (Figure 4-20, lanes 3 and 15). 
Finally, the penta-loop was simply deleted, by annealing 5′ and 3′ halves lacking the penta-
loop sequence entirely (U4-B, Figure 4-20).  
 
Figure 4-20 Binding of hPrp31 to the U4 snRNP does not depend on sequence and structure of the 
terminal penta-loop.  
EMSA analysis of the interaction between protein hPrp31 and the 15.5K–U4 snRNA complex containing mutant 
RNAs was performed as described in Figure 4-19. U4-A and U4-B duplexes were generated before the assay by 
annealing the radiolabelled 5′ and the unlabelled 3′ half of the 5′ stem-loop. A schematic representation of the 
sequence and the structure of each loop mutation in the U4 5′ stem-loop (corresponding to oligonucleotide U4-2) 
is indicated above the respective panel. Numerous other penta– and tetranucleotide loops were tried out; all with 
the same result (see text). 
This duplex's stability was dramatically impaired (EMSA; data not shown); it no 
longer supported the formation of significant amounts of stable binary 15.5K–U4 snRNA 
complex (Figure 4-20, lane 18), as compared with the reference U4-2 (lane 2) and with all 
other mutants tested (lanes 6, 10, 14). However, this duplex did support the efficient 
formation of stable ternary complex upon addition of protein hPrp31 to the binary complex 
assembly mixture (lane 19). Protein hPrp31 therefore appears to stabilise transient interactions 
of protein 15.5K with U4 snRNA in the ternary complex. Therefore, it may be inferred that 
the penta-loop per se is not essential for protein hPrp31 binding to the 15.5K–U4 snRNA 
binary complex. In addition to the penta-loop, protein hPrp31 had also been found to be in 
contact with the adjacent short stem II (Figure 4-18A and B). Since the penta-loop was not 
4 Results 
 106 
required for stable ternary-complex formation, the function of stem II in ternary-complex 
formation was next investigated. 
 
Figure 4-21 Elongation of stem II is critical for hPrp31 binding to the U4 snRNP.  
EMSA analysis of the interaction between protein hPrp31 and the 15.5K–U4 snRNA complex containing mutant 
RNAs was performed as described in Figure 4-19. A schematic representation of the sequence and the structure 
of each stem II mutation tested is given above the respective panel. 
As a first step, stem II was extended by a single C-G base pair (U4-7, Figure 4-21). 
Strikingly, this mutant no longer supported ternary-complex formation in the assay system 
used (Figure 4-21, lanes 3 and 7; approximately 90% reduction of ternary complex formation 
when quantified by Phosphoimager analysis). Extension by a U-A base pair (U4-8, Figure 
4-21) had a similar effect (Figure 4-21, lane 11). Not surprisingly, identical results were 
obtained by increasing the length of the stem to 5 or 7 base pairs (Figure 4-21, U4-12 and 
U4-9; lane 19 and 15 respectively). Furthermore, deletion of the penta-loop with retention of 
the three-base-pair-long stem II (U4-C, Figure 4-21) was similarly detrimental to ternary-
complex formation (Figure 4-21, lane 23). The inhibitory effect of this additional base pair 
was thus independent of the presence of the penta-loop. A shortening of stem II was not 
deemed feasible because the already weak binding of 15.5K to the penta-loop deletion 
(mutant U4-3) would be further compromised by interfering with the 15.5K binding site 
(Reuter et al., 1999; Vidovic et al., 2000). 
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Taken together, these data show that the length of stem II is important for the 
association of protein hPrp31 with the 15.5K–U4 snRNA binary complex. Since protein 
hPrp31 is known to interact also with the 15.5K-U4atac snRNA binary complex (Nottrott et 
al., 2002), while the U4atac snRNA has a different stem II sequence and the same length, the 
conclusion may be strengthened: the determining factor is apparently the length, and not the 
sequence. 
So far, these results show that both stem I and stem II are required for stable binding 
of protein hPrp31 to the 15.5K–U4 snRNA binary complex, to form the ternary 
hPrp31-15.5K–U4 snRNA complex. While stem I could not be shortened without loss of 
binding activity, stem II – unexpectedly – could not be elongated. 
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4.3.3. The Nop domain is necessary and sufficient for 15.5K-
dependent hPrp31 binding to U4 snRNA  
Having established the elements of the U4 snRNA structure required to bind protein 
hPrp31, it was next investigated whether the so-called Nop domain of protein hPrp31 (see 
2.1.2.2 and 2.3) is sufficient for binding U4 snRNA in the 15.5K–U4 snRNA binary complex. 
Exact demarcation of the Nop domain from sequence alignments is difficult because of 
ambiguities in locating its boundaries (Gautier et al., 1997; Vithana et al., 2001; Makarova et 
al., 2002). However, in the crystal structure of the archaeal homologue Nop5p, which has 
recently become available (Aittaleb et al., 2003), an independent structural domain can be 
identified at the C terminus of Nop5p (B), indicated by red α-helices and grey loops). This 
domain corresponds to the conserved central domain in NOP56, NOP58, and hPrp31 (B). On 
the basis of these structure-based alignments, it may be inferred that the conserved Nop 
domain of hPrp31 corresponds to α helices 6-12 of Nop5p. Delineation of this domain is fully 
consistent with secondary-structure prediction (A and C). Therefore, amino acids 215–335 of 
hPrp31 will hereafter be referred to as the Nop domain. This assignment differs slightly from 
previously published definitions of the Nop domain (Gautier et al., 1997; Vithana et al., 2001; 
Makarova et al., 2002; Kühn-Hölsken et al., 2005). However, the Nop domain sequence as 
identified here is contained in all the published definitions.  
The protein fragment corresponding to the hPrp31 Nop domain (E) was expressed as 
an MBP fusion protein in E. coli (Figure 4-23 A). Its activity in ternary-complex formation, 
with the U4-2 RNA, was compared with that of the full-length protein in the binding assay 
described above (4.3.2 and Figure 4-19). Remarkably, the Nop domain on its own supported 
ternary-complex formation (Figure 4-23 B, lane 5) but with a slightly lower affinity compared 
with that of the full-length protein (lane 3). Deletion of 20 amino acids from the C terminus 
(amino acids 310–335; E) would be predicted to disrupt the Nop domain (α helix 12 of 
Nop5p, E). This truncated Nop domain was prepared in the same way as the full-length Nop 
domain (Figure 4-23 A) and was found to be completely inactive in ternary-complex 








Figure 4-22 Delineation of hPrp31 Nop domain. 
 
A. Fold Index for protein hPrp31. Putatively folded regions are shown in green and disordered regions are shown 
in red. B. Crystal structure of the archaeal Nop5p protein of A. fulgidus according to Aittaleb et al. (2003). The 
position of the homologous central Nop domain is indicated by the red α-helices and grey loops and the 
disordered loop within the Nop domain of Nop5p protein is indicated by the dashed grey line. C. Secondary 
structure prediction using Predict Protein by Burkhard Rost (EMBL, Heidelberg, Germany; Rost and Sander, 
1993). PHD = PHD: Profile network prediction HeiDelberg. PHD predicted secondary structure: H=helix, 
E=extended (sheet), blank=other (loop). Rel_sec: reliability index for PHDsec prediction (0=low to 9=high). 
SUB_sec: subset of the PHDsec prediction, for all residues with an expected average accuracy > 82%. For this 
subset the following symbols are used: L is loop. No prediction is made for this residue, as the reliability is < 5 
in the reliability index. Secondary-structural elements comprising the Nop domain derived from the archaeal 
Nop5p crystal structure are indicated above the sequences. D. Alignment of the human hPrp31 with the 
homologous sequences of human NOP56, NOP58 and the archaeal Nop5p; the respective GenBank accession 
numbers are NP_006383, NP_057018 and NP_070912. Sequence alignments were performed by the Clustal 
method. Identical and conserved amino-acid residues are indicated in white on a black background and white on 
a blue background, respectively. Similar amino-acid residues are boxed in grey. Secondary-structural elements 
comprising the Nop domain derived from the archaeal Nop5p crystal structure are indicated above the 
sequences. E. Schematic representation of the hPrp31 deletion mutants. The light grey box represents the 
putative Nop domain in hPrp31. 
In the absence of protein 15.5K, neither the full-length Nop domain nor the truncated one 
bound the RNA on its own (lanes 6–8); this resembles the situation for the full-length protein 
hPrp31. Furthermore, binding of the Nop domain was dependent on the presence of the 
correct flanking RNA elements, since a U4 mutant with an elongated stem II (U4-9; for 
details, see above and the legend to Figure 4-23 C) did not support ternary-complex formation 
(Figure 4-23 C, lane 3). It thus appears that the Nop domain is both necessary and sufficient 
for binding to the U4 snRNA in the 15.5K–U4 snRNA binary complex. 
The band-shift experiments demonstrate that the Nop domain is sufficient for stable 
ternary-complex formation. However, it was not clear whether this domain is sufficient to 
induce the direct RNA-protein contacts to the penta-loop that were observed earlier (Nottrott 
et al., 2002; Kühn-Hölsken et al., 2005). This issue was of particular interest because the 
penta-loop is not essential for ternary-complex formation (see Figure 4-20). Therefore, 
RNA-protein contacts in the penta-loop by UV cross-linking in the minimal ternary complex 
were investigated. For this purpose, this complex was assembled with radiolabelled U4-2 
RNA oligonucleotide and the Nop domain, UV cross-linking was performed and the reaction 
mixture was analysed by SDS-PAGE (Figure 4-23 D, lane 3). As controls, the reaction was 
performed with the RNA component only (lane 1), with RNA and protein 15.5K but not the 
Nop domain (lane 2) and with omission of protein 15.5K (lane 4). A prominent cross-linking 
product of about 65 kDa was detected clearly in the complete assembly mixture only (lane 3). 
The cross-linked species contained both RNA and protein, since it was sensitive to digestion 
with Proteinase K or with RNase T1 (data not shown). Further, the apparent molecular weight 
4 Results 
 111
is consistent with the sum of the MWs of the hPrp31 Nop domain MBP fusion protein 
(53.9 kDa) and the U4-2 RNA oligonucleotide (10.6 kDa). 
These data demonstrate that the Nop domain is sufficient to induce the RNA-protein 
contacts between itself and the penta-loop of the RNA. 
 
Figure 4-23 The Nop domain is necessary and sufficient for binding of hPrp31 to the U4 snRNP. 
A. SDS PAGE of hPrp31 deletion mutants. B. EMSA to test the interaction between the hPrp31 deletion mutants 
and the U4 snRNA 5′ stem-loop (U4-2; see Figure 4-19, Figure 4-20, and Figure 4-21) was performed as 
described in Figure 4-19. C. To test the binding specificity of the Nop domain, a binding assay was performed 
using a U4 snRNA mutant in which stem II was elongated by five additional base pairs (for sequence see 
Materials and Methods). This mutant did not support binding of wild-type hPrp31 (data not shown). D. 
Recombinant 15.5K and the hPrp31 Nop domain were reconstituted with 5′-end-labelled U4-2 RNA 
oligonucleotide. The protein-RNA complexes were then UV-irradiated and the irradiation products were 
resolved on a 12% polyacrylamide-SDS gel. The cross-linking product of about 65 kDa is indicated by the 
arrow. 
4.4. Mutations associated with retinitis pigmentosa in the 
U4/U6-specific protein hPrp31 
4.4.1. Cellular localisation of wild-type and mutant hPrp31 in 
transfected HeLa cells 
In this section, the effects of hPrp31 adRP point mutations A194E and A216P (see 
section 2.1.4) on the location of protein hPrp31 within human cells and the formation of the 
tri-snRNP are addressed. Experimentally, this was done by combining RNAi depletion with 
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fluorescence microscopy and biochemical methods. (The mutations associated with adRP are 
referred to hereinafter as “adRP mutations”; this is not meant to imply an established causal 
connection.) 
To address the question of the location in the cell of hPrp31 adRP mutations and to 
investigate biochemically the formation of tri-snRNP, wild-type and mutant hPrp31 was 
subcloned into the pTA2 vector (Invitrogen) and tagged at its NH2 terminus with an HA-tag. 
As no antibody against hPrp31 is available, the observation of endogenous hPrp31 was not 
possible. 
To increase the expression level of the ectopically expressed HA-tagged hPrp31 
protein and to investigate the effect of the introduced hPrp31 mutant alone, HeLa SS6 cells 
were depleted of endogenous hPrp31 by RNAi. This depletion raised the expression of the 
HA-hPrp31 wild-type protein from 20% to 80%. This higher expression level was important 
for later biochemical studies with nuclear extracts prepared on a small scale. RNAi 
experiments were performed using 21-nt siRNA duplexes (Elbashir et al., 2001; Elbashir et 
al., 2002). An siRNA duplex targeting the 3'UTR of the mRNA encoding the hPrp31 was 
used to “knock down” the endogenous hPrp31 protein; as a control, a non–human protein 
with no human homologues (firefly luciferase; GL2) was used. The transfection procedure 
was performed on a millilitre scale, with simultaneous transfection of pTA2-HA-hPrp31 and 
the siRNA (EA2) by electroporation (Amaxa nucleofector). In this way, enough cells were 
obtained for a small-scale preparation of nuclear extract that was suitable for subsequent 
biochemical assays (Lee and Green, 1990). 
To demonstrate that the cells had indeed been depleted of the hPrp31 wild-type, 
western blot analyses with antibodies directed against hPrp31 were performed. As shown in 
Figure 4-24 B, the level of protein hPrp31 was reduced by about 95% (lane 2). This knock-
down was specific, as cells treated with an siRNA against luciferase did not show a knock-




Figure 4-24 Knock-down of spliceosomal hPrp31 protein by siRNAs.  
A. HeLa cells transfected with siRNA targeting firefly luciferase (Control, GL2) and the U4/U6 protein hPrp31 
(EA2, ∆hPrp31) were examined 48 h after transfection using indirect immunofluorescence. B. A western blot 
showing levels of hPrp31 protein in the nuclear extract prepared from HeLa cells 48 h after transfection with 
hPrp31-specific siRNA (EA2, ∆hPrp31) and a luciferase siRNA control (GL2). C. Anti-40K was used to 
immunoprecipitate snRNPs from the nuclear extract prepared from HeLa cells 48 h after transfection with 
siRNAs targeting luciferase and the U4/U6 protein hPrp31 (∆hPrp31). PAS: Protein A-Sepharose incubated with 
nuclear extract. RNA was isolated from the immunoprecipitated snRNPs and characterised by northern blotting. 
It has been shown that intact tri-snRNP particles require the presence of the hPrp31 
protein (Schaffert et al., 2004). Consistent with these earlier studies, antibodies against 
protein 40K, a protein that is a part of the U5 snRNP, precipitate intact tri-snRNPs from cell 
extracts transfected with an siRNA against the non–human firefly luciferase (GL2, Figure 
4-24 C, lane 3). In extracts of cells that have been depleted of protein hPrp31, the antibody 
precipitates primarily U5 snRNPs (Figure 4-24 C, lane 6). Therefore, the lack of protein 
hPrp31 prevents interaction between the U5 snRNP and U4/U6 di–snRNP. 
A possible effect of hPrp31 knock-down on the distribution of the U4/U6 di–snRNP-
specific proteins hPrp3, hPrp4 and p110 was investigated by fluorescence microscopy with 
appropriately labelled antibodies. Consistent with the results of Schaffert et al. (2004), 
removal of hPrp31 by RNAi led to a pronounced accumulation of the U4/U6-specific protein 
hPrp4 in discrete nuclear foci (Figure 4-24 A, ∆hPrp31), so called Cajal bodies (compare 
Schaffert et al. 2004). In all cases, the intensity of the fluorescence signals in the Cajal bodies 
increased significantly in comparison with cells that had undergone control transfections 
(Figure 4-24 A, Control). 
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As demonstrated by western blotting with antibodies directed against hPrp31 and the 
HA-tag (Figure 4-25 B), in cells depleted of the endogenous, hPrp31 (lane 2, lower panel) the 
exogenous HA-hPrp31 protein wild-type is expressed at a similar level (lane 3, upper and 
lower panel) as the endogenous hPrp31 wild-type protein in extracts of cells transfected with 
an siRNA against the non–human firefly luciferase (lane 1, lower panel). There was only 
minimal expression of the adRP causing hPrp31 mutant A194E detectable by western blotting 
(Figure 4-25 B, lane 4, upper and lower panel), whereas the expression of hPrp31 mutant 
A216P was reduced about five times compared to the HA-hPrp31 wild-type protein (Figure 
4-25 B, lane 5, upper and lower panel).  
To analyse the effect of the mutations on localisation of protein hPrp31 and the U4/U6 
di-snRNP, the distribution of the hPrp31 mutants and the U4/U6-specific protein hPrp4 was 
checked by immunofluorescence. The distribution of the HA-hPrp31 wild-type and mutant 
fusion protein was investigated by fluorescence microscopy 46 hours after the simultaneous 
transfection of pTA2-HA-hPrp31 and siRNAs in HeLa cells, and it was compared with the 
distribution of the U4/U6 di–snRNP specific protein hPrp4 (60K) as detected by immuno-
fluorescence (Figure 4-25 A). Expression of HA-hPrp31 rescues the hPrp31 knock-down 
phenotype described by Schaffert et al. (2004). Hence, cells expressing HA-hPrp31 do not 
show the pronounced accumulation of protein hPrp4 in Cajal bodies (Figure 4-25 A, a, b, and 
c). Both HA-hPrp31 and hPrp4 are distributed in a speckle-like pattern. In Figure 4-25 A (a, 
b, and c) two cells strongly expressing HA-hPrp31 are shown, next to a third cell expressing 
HA-hPrp31 weakly (a, indicated by the dashed line). These examples show different levels of 
the rescued knock-down phenotype within the same cell population, as hPrp4 is still localised 
in intensely labelled foci in the cell that weakly expresses HA-hPrp31, whereas these hPrp4 
foci do not appear in cells with high levels of HA-hPrp31 expression. (Note that this 
demonstration does not represent the general transfection or expression efficiency of the 




Figure 4-25 Expression of HA-hPrp31 (wild-type and mutants) in HeLa cells depleted of the endogenous 
hPrp31.  
A. HeLa cells transfected with siRNA targeting the U4/U6 protein hPrp31 (EA2, ∆hPrp31) and pTA2-HA-
hPrp31 wild-type (a, b, and c) and mutants A194E (d, e, and f) and A216P (g, h, and i) were examined 48 h after 
transfection as described in Figure 4-24. B. A western blot was performed using anti-HA and anti-hPrp31 
antibodies showing levels of hPrp31 wild-type and mutants in the nuclear extract prepared from HeLa cells 48 h 
after transfection with hPrp31-specific siRNA (EA2, ∆hPrp31), a luciferase siRNA control (GL2) and pTA2-
HA-hPrp31 wild-type and mutants A194E and A216P. Analyses of the U4/U6.U5 tri-snRNP incorporation of 
hPrp31 mutant A216P. Membrane was blotted twice using first anti-HA and then anti-hPrp31 antibodies. The 
first antibody was removed from the membrane by membrane stripping. 
As detected previously by western blotting, adRP mutant hPrp31 A194E is expressed 
very poorly in HeLa cells (Figure 4-25 B, lane 4). The same observation is made by 
immunofluorescence: in the experiment shown, only every tenth cell expressed the mutant 
hPrp31 A194E protein (Figure 4-25 A, d). Interestingly, mutant hPrp31 A194E arises in the 
cytoplasm and only a small fraction is transported to the nucleus. The nucleoli, in which there 
is no HA-hPrp31 A194E, are visible as black holes in the staining pattern of the cell nucleus 
(d, indicated by the dashed line). Counterstaining of hPrp4 reveals that hPrp31 A194E does 
not accumulate in Cajal bodies as hPrp4 and that hPrp4 is still present in these foci. Thus, 
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mutant hPrp31 A194E is not able to reverse the accumulation of hPrp4 in Cajal bodies in 
hPrp31 knock-down cells (Figure 4-25 A, e, indicated by solid arrows). 
In contrast to HA-hPrp31 A194E, mutant HA-hPrp31 A216P is localised in the cell 
nucleus (Figure 4-25 A, g). The expression of HA-hPrp31 A216P, as detected by western 
blotting, is reduced by a factor of about 3 compared with the corresponding expression in the 
wild-type (see above). This fact raises the assumption of lower expression efficiency, which 
paradoxically was not detectable by fluorescence microscopy. Quantification of the 
fluorescence signal would be an alternative, and this is discussed below among possible future 
prospects (Section 5.4). Interestingly, mutant HA-hPrp31 A216P is localised in the nucleus 
and itself accumulates in the Cajal bodies (Figure 4-25 A, g, indicated by arrows). This 
accumulation has not been observed for the HA-hPrp31 wild-type. At the same time, HA-
hPrp31 A216P is not capable of reversing the accumulation of hPrp4 in Cajal bodies (Figure 
4-25 A, h). 
Taken together, the presented experiments demonstrate that the phenotype observed 
upon hPrp31 knock-down can be rescued by HA-tagged hPrp31 wild-type protein. The 
mutant hPrp31 A194E shows a strong localisation defect. This mutant appears to have a 
defect in locating to the nucleus, probably because of impaired nuclear import, and remains in 
the cytoplasm. At the same time, hPrp31 A194E is not capable of reversing the accumulation 
of hPrp4 in Cajal bodies. In contrast, mutant hPrp31 A216P is capable of migrating to the 
nucleus. However, this mutant is not able to liberate hPrp4 from the Cajal bodies and itself 
accumulates in Cajal bodies. 
4.4.2. Mutant hPrp31 A216P is incorporated into the tri-snRNP 
and interacts with the U5 snRNP-specific hPrp6 protein 
Previously, it was shown that hPrp31 is required for the formation of the U4/U6.U5 
tri-snRNP and functions as a bridge in the tri-snRNP by interacting directly with the U5-
specific protein hPrp6 (Makarova et al., 2002). 
To analyse the effect of adRP mutants on tri-snRNP formation, immunoprecipitation 
assays followed by northern blot analysis were performed using nuclear extracts from cells 
expressing either the HA-tagged hPrp31 wild-type or the mutant hPrp31 A216P protein 
(Figure 4-26). As the level of expression of mutant hPrp31 A194E was very low, further 
biochemical analysis of this mutant was not possible. Interestingly, yeast two-hybrid analysis 
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revealed recently that mutant hPrp31 A194E shows a significantly reduced binding to the U5 
snRNP-specific protein hPrp6 (Liu, 2005). 
Anti-HA antibodies were used to immunoprecipitate snRNPs from the nuclear extract 
prepared from cells transfected with siRNAs targeting the U4/U6 protein hPrp31 (∆hPrp31) 
and either the wild-type and mutant pTA2-HA-hPrp31. As shown in Figure 4-26 A, lane 3, 
HA-hPrp31 wild-type precipitates the U4, U6, and U5 snRNP via the anti-HA antibody. This 
result therefore demonstrates that the HA-tagged hPrp31 protein is incorporated into the 
U4/U6.U5 tri-snRNP. 
The mutant hPrp31 A216E behaved similarly to the wild-type hPrp31 (Figure 4-26 A, 
lane 6). The HA-tagged mutant hPrp31 A216P was similarly shown to precipitate the U4, U6, 
and U5 snRNPs via the anti-HA antibody. Therefore, the presence of the mutant hPrp31 
A216P did not impair the formation of the U4/U5.U6 tri-snRNP in the nuclear extracts used. 
Unfortunately, the signal of the U5 snRNA detected by northern blot is very weak. This may 
be because HA-hPrp31 in the U4/U6.U5 tri-snRNP is poorly accessible for the α-HA 
antibodies, or it may be because the tag prevents formation of the tri-snRNP. The latter 
problem might be circumvented by the transfection of non–tagged hPrp31 wild-type and 
mutant protein. The high efficiency of the hPrp31 knock-down (95%, see Figure 4-25) would 
allow investigation of the effect of the ectopically expressed proteins, as only a small (and 
negligible) amount of endogenous hPrp31 protein remains in the cells after hPrp31 knock-
down. 
To address the effect of the mutation A216P in hPrp31 on the interaction of hPrp31 
with hPrp6, immunoprecipitation assays using anti-HA antibodies and nuclear extracts from 
cells expressing the HA-hPrp31 wild-type and mutant A216P respectively were performed 
and the precipitated hPrp6 was detected by western blotting. As shown in Figure 4-26 B, lane 
4, wild-type HA-hPrp31 precipitates hPrp6 via the anti-HA antibody. This result demonstrates 
that the HA-tagged hPrp31 protein is in direct contact with hPrp6 and consequently supports 
the bridging of the U4/U6 di–snRNP and the U5 snRNP. The ability of the mutant hPrp31 
A216P to precipitate hPrp6 via the anti-HA antibody was similar to that of the wild-type 
hPrp31. To normalise the result of the experiment, the protein concentration of the nuclear 
extracts was taken into account and not the concentration of the ectopically expressed HA-
hPrp31 wild-type or mutant hPrp31 A216P. The supernatant shows that the amounts of hPrp6 
were equal in all nuclear extracts used (Figure 4-26 B, lower row, lanes 2–5). As expression 
of hPrp31 A216P was reduced by a factor of 5 compared with the expression of the hPrp31 
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wild-type protein (see Figure 4-25 B), and therefore is consequently only one-fifth as much 
hPrp31 A216P as hPrp31 wild-type protein in the extract available for the 
immunoprecipitation, it is not surprising that the amount of precipitated hPrp6 in the western 
blot appears to be about one-fifth of the amount obtained with the wild-type. 
Taken together, these data show that the formation of the tri-snRNP is not affected by 
the point mutation A216P in hPrp31, and this mutation did not prevent the bridging of the 
U4/U6 di–snRNP to the U5 snRNP. This bridging was performed via direct interaction of 
hPrp31 with hPrp6. The pull-down experiments demonstrated that the interaction of hPrp31 
with the U5-specific protein hPrp6 is not impaired by the mutation A216P. This result is 
furthermore supported by yeast two-hybrid analysis, which showed binding of mutant hPrp31 
A216P to protein hPrp6 similar to that of the wild-type hPrp31 (Liu, 2005). 
 
Figure 4-26 hPrp31 A216P is incorporated into the tri-snRNP and interacts with the U5 protein hPrp6.  
A. Anti-HA antibodies were used to immunoprecipitate snRNPs from the nuclear extract prepared from HeLa 
cells 48 h after transfection with siRNAs targeting the U4/U6 protein hPrp31 (∆hPrp31) and the wild-type and 
mutant pTA2-HA-hPrp31. PAS: Protein A-Sepharose incubated with nuclear extract. RNA was isolated from the 
immunoprecipitated snRNPs and characterised by northern blot analysis. B. Anti-HA antibody was used to 
immunoprecipitate proteins from the nuclear extract prepared from HeLa cells 48 h after transfection with 
siRNAs targeting luciferase, the U4/U6 protein hPrp31 (∆hPrp31) and the wild-type and mutant pTA2-HA-
hPrp31. Proteins were isolated from the immunoprecipitated snRNPs and the U5-specific hPrp6 protein 
characterised by western blotting. PAS: Protein A-Sepharose incubated with nuclear extract. 5% supernatant, 




5.1. Regions on the 15.5K protein surface are required for 
complete U4/U6 di–snRNP and box C/D snoRNP 
assembly 
One aim of the work presented in this dissertation was to investigate the role that 
protein–protein interactions play in the 15.5K-mediated assembly of four distinct RNP 
complexes, namely the U4 snRNP, the U4/U6 di-snRNP, the box C/D and box B/C snoRNP.  
It has been noted previously that distinct structures and/or sequences in the RNA are 
required for the specific assembly of each complex (Granneman et al., 2002; Nottrott et al., 
2002; Watkins et al., 2002). The work presented here illustrates the fact that distinct regions 
of the surface of 15.5K are necessary for the assembly of each complex. This suggests that, in 
each case, the formation of the RNP requires a complex recognition process involving both 
protein and RNA.  
5.1.1. Observed effects on complex assembly are specific, due 
to changes on the 15.5K surface 
By using the crystal structure of protein 15.5K bound to the 5' stem-loop of U4 
snRNA (Vidovic et al., 2000) and sequence alignments, regions of conserved amino acids on 
the surface of the protein have been identified and mutated. The changes did not alter either 
the stability or the gross structural organisation of the protein, as each of the mutations 
supported the formation of at least one RNP complex. Analysis of the ability of these mutants 
to support RNP formation revealed that different regions on the surface of the protein are 
required for the assembly of each complex. This implies that, in each of the RNPs, substantial 
and essential contacts are made between this protein and one or more of the complex-specific 
proteins. Importantly, these mutations were not in areas of the protein involved RNA-binding, 
and none of the mutations altered either the affinity or the specificity of protein-binding to the 
three RNAs - U4 snRNA, the U14 box C/D snoRNA or the U3 box B/C RNA – which 
represent the RNA component of the three distinct RNPs. In many cases the binding reactions 
using the mutant 15.5K proteins (Figure 4-5 and Figure 4-6) were analysed by native gel 
electrophoresis in order to confirm that the proteins were stable and retained their RNA-
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binding ability under the assay conditions used. This therefore implies that the observed 
effects are the result of specific changes and are not due to non–specific disruption of the 
overall structure of the protein.  
A detailed analysis of the role of the conserved surface amino acids in protein 
recruitment has been severely hampered by solubility problems observed with a great 
majority of the mutations constructed during this study. Indeed, 21 mutant constructs were 
generated during this study, of which only the five mutants used in this study were soluble 
(see section 4.1.4). 
5.1.2. Differential recognition of the distinct RNAs and protein 
15.5K 
A differential recognition of RNA and 15.5K is not surprising when one considers that 
the proteins involved in each complex are very different, and that they use distinct 
domains/structures to mediate complex formation.  
The only exception to this is the NOP-domain proteins, namely NOP56, NOP58 and 
hPrp31 (Gautier et al., 1997). Interestingly, the recruitment of NOP58, NOP56 to 
U14 snoRNA and the binding of hPrp31 to the U4 snRNA require the highly conserved 
amino acids present in α helix 3. However, NOP56 and NOP58 binding in HeLa nuclear 
extract also required other regions of 15.5K, and at this point it is difficult to separate the 
requirements for binding of the individual snoRNP components.  
Therefore, while it is interesting to speculate that NOP58 or NOP56 and hPrp31 may 
be in contact with the same region of 15.5K, it is at present difficult to draw any conclusions 
about the nature of the protein–protein interactions in box C/D snoRNPs.  
5.1.3. Influence of conserved amino acids on the 15.5K surface 
on the association of the U4/U6di–snRNP specific 
proteins hPrp31 and CypH/hPrp4/hPrp3 
It is clear from the data that much of the surface of protein 15.5K is essential for the 
formation of the U4/U6 snRNP, implying that 15.5K is surrounded by proteins in the 
U4/U6.U5 tri-snRNP. This is consistent with earlier observations, in both HeLa and yeast 
extracts, that 15.5K was not accessible for immunoprecipitation in the tri-snRNP. 
Interestingly, 15.5K-2 inhibits the binding of both hPrp31 and the CypH/hPrp4/hPrp3 
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complex. The binding of these two spliceosomal components has been shown to be 
independent from one another (Nottrott et al., 2002) and since all of these proteins are present 
in the U4/U6.U5 tri-snRNP it is likely that this mutation could disrupt two adjacent protein-
binding sites on the surface of 15.5K. 
5.1.4. Two or more components are involved in box C/D 
snoRNP assembly on the 15.5K protein–box C/D 
snoRNA complex 
The 15.5K mutations that block box C/D snoRNP assembly either totally abolish the 
binding of all proteins (mutants 15.5K-1 and 15.5K-2) or inhibit the recruitment of NOP56 
and TIP49 (mutant 15.5K-5)(see Figure 5-1). This implies that two or more RNP components 
directly bind the 15.5K–box C/D snoRNA complex.  
Indeed, the data could suggest that the binding of NOP58, TIP48, and fibrillarin is 
essential for the subsequent recruitment of NOP56 and TIP49. The data show that recruitment 
of TIP49 and NOP56 are linked as binding of both proteins is disrupted by the same mutation 
(15.5K-5) on the 15.5K surface.  
NOP56 and NOP58, and TIP48 and TIP49 are two pairs of homologous proteins 
(Newman et al., 2000), respectively. This suggests that TIP48 may be involved in the 
assembly of NOP58. 
 
NOP56 and NOP58 are proposed to make specific contact with the box C'/D' and C/D 
motifs respectively, and to interact with one another through a conserved coiled-coil domain 
(Cahill et al., 2002; Aittaleb et al., 2003). On this basis it can well be imagined that NOP56 
recruitment is linked to an interaction with NOP58 bound at the C/D motif. However, the 
finding that α helix 5 of 15.5K is important for the specific recruitment of NOP56, together 
with the efficient binding of TIP49 by NOP56, suggests that NOP56 is in direct contact with 
15.5K bound to the box C/D motif and that its recruitment is not solely due to contact with 





Figure 5-1 Model summarizing required sites in the U14 Box C/D snoRNA–15.5K binary complex.  
The 15.5K protein has been resolved by crystallography in complex with the U4 snRNA nucleotides G26–G35 
and C41–C47 (Vidovic et al., 2000). For visualisation of regions within the U14 Box C/D snoRNA that are 
required for Box C/D snoRNP assembly or contacted by Box C/D specific proteins the region of the U14 
snoRNA, which hybridizes with the 18S rRNA (indicated in grey, 2’-O-methylated nucleotide indicated in 
purple) was modelled and attached to stem II of 15.5K–U4 kink-turn crystal structure. The essential stem II of 
the U14 referring to stem II of the U4 kink-turn is highlighted by the blue coloured nucleotides. Nucleotides 
directly contacted by fibrillarin and NOP58 (Cahill et al., 2002) are indicated by the yellow and green lightnings 
respectively. The mutations in 15.5K-1 (α helix 1), 15.5K-2 (α helix 3), and 15.5K-5 (α helix 5) of the 15.5K 
protein, which blocked Box C/D snoRNP assembly (see Figure 4-5) are highlighted in red, green and yellow in 
the 15.5K crystal respectively. 
 
5.1.5. Direct protein-protein interactions are involved in RNP 
complex formation in the box B/C snoRNP 
The identification of the RNA-independent hU3–55K–15.5K interaction supports the 
idea that protein–protein interactions within each of the complexes are important. A central 
feature of the work presented here was the use of a similar approach to detect direct 
interactions between 15.5K and hPrp31, hPrp3, hPrp4, CypH, NOP56, NOP58, and fibrillarin 
in the absence of RNA. However, no specific interaction could be detected between 15.5K 
and these proteins (data not shown). This implies that the interaction between 15.5K and these 
proteins was not sufficiently stable to allow detection, and that a stable interaction requires the 
presence of both 15.5K and RNA. 
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5.1.6. The eukaryotic proteins L7a, 15.5K, and NHP2 are 
probably derived from a common ancestor 
The data imply that protein 15.5K is involved in numerous conserved interactions in 
the four distinct RNP complexes. The evolutionary pressure required to maintain these 
interactions therefore explains the high degree of conservation of 15.5K in eukaryotes. In 
archaea, a homologous protein, namely L7ae, is present in the ribosome, box C/D RNPs, and 
H/ACA RNPs (Kuhn et al., 2002; Omer et al., 2002; Rozhdestvensky et al., 2003). Therefore, 
protein L7ae performs three functions. It functions as the eukaryotic L7a in the ribosome, as 
15.5K in the box C/D snoRNPs, and as NHP2 in the box H/ACA snoRNPs. This implies that 
the three eukaryotic proteins are derived from a common ancestor. Interestingly, α helix 3 of 
the eukaryotic 15.5K, which is required for snoRNP formation, has a similar amino-acid 
composition in the archaeal L7ae (Figure 5-2), suggesting that this interaction is 
evolutionarily conserved. 
 α1 β1 α2 β2 α3 
 
  10 20 30 40 50 60 70 
  | | | | | | | 
H. sapiens (1) ---MTEADVNPKAYPLADAHLTKKLLDLVQQSCNYKQLRKGANEATKTLNRGISEFIVMAADAEPLEIILHLPL 
S. cerevisiae (1) -----MSAPNPKAFPLADAALTQQILDVVQQAANLRQLKKGANEATKTLNRGISEFIIMAADCEPIEILLHLPL 
C. elegans (1) ---MADDGVNPKAFPLADTNLSQKLMDLVQQAMNYKQLKKGANEATKTLNRGISEIIVMAADAEPLEILLHLPL 
D. melanogaster (1) ----MTEEVNPKAFPLADAQLTAKIMNLLQQALNYNQLRKGANEATKTLNRGLADIVVLAGDAEPIEILLHLPL 
A. thaliana (1) ---MTGEVVNPKAYPLADSQLSITIMDLVQQATNYKQLKKGANEATKTLNRGISEFVVMAADAEPLEILLHLPL 
X. leavis (1) ---MAEPEVNPKAYPLADAQLTKTLLDLVQQAANYKQLRKGANEATKTLNRGISEFIVMAADAEPLEIILHLPL 
L7a H. Archaea  (1) ---MNAMSKASYVKFEVPQDLADKVLEAVRKAKESGKIKKGTNETTKAVERGQAKLVIIAEDVQPEEIVAHLPL 
 
  
 β3 α4 β4 α5 
 
 80 90 100 110 120 
  | | | | | 
H. sapiens (72) LCEDKNVPYVFVRSKQALGRACGVSRPVIACSVTIKEGSQLKQQIQSIQQSIERLLV------ 
S. cerevisiae (70) LCEDKNVPYVFVPSRVALGRACGVSRPVIAASITTNDASAIKTQIYAVKDKIETLLI------ 
C. elegans (72) LCEDKNVPYVFVRSKAALGRACGVTRPVIAASITQNEGSQLKSQIQKIKEDVEKLLI------ 
D. melanogaster (71) LCEDKNVPYVFVRSKQALGRACGVSRPIVACSVTTNEGSQLKSQITSIQQEIERLLV------ 
A. thaliana (72) LAEDKNVPYVFVPSKQALGRACGVTRPVIACSVTSNEASQLKSQIQHLKDAIEKLLI------ 
X. leavis (71) LCEDKNVPYVFVRSKQALGRACGVSRPVISCSVTIKEGSQLKPQIQSVQQAIERLLV------ 
L7a H. Archaea (72) LCDEKKIPYVYVSSKKALGEACGLQVATASAAILEP-G-EAKDLVDEIIKRVNEIKGKTSS-- 
   
Figure 5-2 Sequence alignment of the eukaryotic 15.5K protein with the archaeal ribosomal L7a protein.  
Amino-acid alignment of protein 15.5K from human (H. sapiens), Saccharomyces cerevisiae (Snu13p), 
Caenorhabdidis elegans (Accession no. Q21568), Drosophila melanogaster (Accession no. GH03082), 
Arabidopsis thaliana (Accession no. A71421), and Xenopus laevis (Accession no. AAH46579) with the archaeal 
(Sulsolobus) ribosomal protein L7a sequence using the ClustalV program. Conserved residues are indicated by 
grey boxes and are grouped as described in (Schulz and Schirmer, 1979). Identical and conserved residues are 
indicated in white on black boxes and in black on grey boxes, respectively. Residues specifically conserved in 
protein 15.5K are depicted in white on blue boxes. Amino-acid positions are indicated on the left. The secondary 
structure of the human 15.5K protein (Vidovic et al., 2000) is indicated above the alignment, and amino acids 
involved in RNA-binding are indicated by blue circles. 
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5.2. The U4/U6 di–snRNP and box C/D snoRNP-associated 
protein 15.5K localise to nucleoplasmic foci 
As a part of this study, the in vivo localisation pattern of the U4/U6 snRNP- and 
box C/D-specific protein 15.5K was investigated and the RNAs with which the 15.5K protein 
is complexed in situ were identified. This investigation was performed by using a cultured 
HeLa cell line. 15.5K was analyzed in vivo, either fused to 15.5K antibodies or with an EYFP 
fluorescent protein tag, and the resulting fusion proteins were shown to have similar 
localisation patterns. A stably transformed HeLa cell line that expressed EYFP–15.5K was 
established and used to investigate the specificity of RNA-binding to the endogenous 15.5K.  
The analysis has shown that newly expressed 15.5K accumulates in splicing speckles, 
nucleoli and Cajal Bodies (Figure 4-10). On the basis of the results of previous biochemical 
studies on the structure and the binding specificity of 15.5K, the U4 snRNA is a possible 
candidate target for 15.5K in speckles. 15.5K binds U4 snRNA in vitro via the 5' stem-loop 
sequence (Nottrott et al., 1999; Vidovic et al., 2000). Consistent with this idea, hybridisation 
experiments have shown that the U4 snRNA localised to splicing speckles in HeLa cells; 
these speckles are thought to be sites of storage of mRNA splicing factors (Carmo-Fonseca et 
al., 1992; Lamond and Spector, 2003). However, a permanent localisation of 15.5K in the 
splicing speckles has not been reported before. Leung and Lamond (2002) demonstrated that 
newly imported 15.5K transiently co-localises with splicing factors in splicing speckles. At 
later time points, the signal in speckles was no longer detected and EYFP–15.5K accumulates 
specifically in nucleoli and Cajal bodies.  
The binding studies shown in section 4.2.2 demonstrate that EYFP–15.5K interacts in 
vivo with the U4 snRNA. As the U4 snRNA is associated with the U6 snRNA through an 
extended stretch of RNA base pairs (see 2.1.2.1), the U6 snRNA is co-precipitated with 
protein 15.5K. Likewise, the U5 snRNA is co-precipitated by 15.5K, as it is connected with 
the U4/U6 di–snRNP by a bridge made up of the U4/U6-specific protein hPrp31 and the U5-
associated protein hPrp6 (Makarova et al., 2002). 
Another type of nuclear foci in which protein 15.5K is located are the Cajal bodies, 
which are involved in snRNP biogenesis and in the trafficking of snoRNPs and snRNPs. 
SnoRNPs and snRNPs are thought to move through the Cajal body en route to the nucleoli or 
splicing speckles (Sleeman and Lamond, 1999). Furthermore, there is some evidence that 
Cajal bodies may play a role in U4/U6.U5 tri-snRNP recycling (Schaffert et al., 2004). 
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Consistent with this idea the U4 snRNA, which is complexed with protein 15.5K is located in 
Cajal bodies (Sleeman and Lamond, 1999; Misteli, 2000). 
Furthermore, it was shown that 15.5K is located in nucleoli and co-localises with 
box C/D snoRNP-specific protein NOP56 (Figure 4-10) in nucleoli and Cajal bodies. This 
result is consistent with immuno-fluorescence results of (Leung and Lamond, 2002). It has 
been shown by Narayanan et al. (1999) that wild-type box C/D snoRNAs associate transiently 
with Cajal bodies before they localise to nucleoli and that variant RNAs that lack an intact 
box C/D motif are retained within Cajal bodies. 
Additionally, the data show that 15.5K is complexed with the U3 box C/D snoRNA in 
vivo, which also contains a box B/C motif. This result is consistent with the idea that protein 
15.5K is associated with the box C/D snoRNAs in vitro and in situ (Granneman et al., 2002; 
Leung and Lamond, 2002; Watkins et al., 2002). The protein binds directly the conserved 
box C/D motif and the U3 specific box B/C motif. 
In addition, the in vivo localisation pattern of 15.5K mutants and RNAs complexed 
with 15.5K in situ were studied. The effect of these mutants on complex formation of the 
U4/U6 snRNP and box C/D snoRNPs was investigated in vitro (section 4.1). Mutant 15.5K-2 
is barely expressed in HeLa cells and was prevented from translocating from its site of 
synthesis in the cytoplasm to the nucleus (Figure 4-11). However, no significant difference 
was observed investigating the localisation of the other 15.5K mutants (15.5K-1, 15.5K-3, 
15.5K-4, and 15.5K-5), as they localised to the nucleoli, Cajal bodies and splicing speckles in 
a manner similar to that of the 15.5K wild-type (Figure 4-11, Figure 4-12, and Figure 4-13). 
This effect is likely to be due to the binding of 15.5K to naked RNAs, in which the protein 
acts as a nucleation factor for the recruitment of additional U4/U6 snRNP- and box C/D-
snoRNP-specific proteins associating with the complex. Therefore, it is possible that the 
effect on localisation of the fully assembled RNPs is superimposed by 15.5K bound to naked 
snRNA and box C/D snoRNAs or incompletely assembled RNPs. 
5.3. Requirement for U4 snRNA's kink-turn stem II and the 
Nop domain for the association of the spliceosomal 
hPrp31 protein with the U4 snRNP 
In the next part of this work, the binding of hPrp31 to the U4 snRNA 5′ stem-loop 
complexed with the 15.5K protein was investigated. By using previous hydroxyl-radical 
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footprinting analysis (Nottrott, 2002), detailed information on the relevant RNA-protein 
contacts was obtained. RNA mutational analysis and protein homology comparison revealed 
some essential features of the RNA-protein interaction, viz (i) the requirements made of the 
RNA structure and (ii) the role of the hPrp31 Nop domain as a necessary and sufficient factor 
to mediate stable complex formation. Finally, the results contribute to an understanding of 
how hPrp31 binds specifically to U4 snRNP and how NOP56/NOP58 to the 
box C/D snoRNPs. These issues are discussed in turn below. 
5.3.1. Global RNA shielding by hPrp31 of the U4 snRNA in the 
ternary hPrp31-15.5K-U4 snRNA complex 
In the quest to understand the interaction of hPrp31 with the U4 snRNA in the ternary 
complex hydroxyl radical footprinting experiments from the PhD thesis of Stephanie Nottrott 
(Nottrott, 2002) have been re-examined. In these experiments a direct protein-induced 
shielding of the RNA by hydroxyl radicals can be observed (Figure 4-18). On both sides of 
the kink-turn, directly neighbouring the 15.5K binding site (FP 1 and FP 2), discrete 
footprints were located. First of all, hPrp31 induces protection of the complete penta-loop 
structure and of all the stem II nucleotides that were not in contact with protein 15.5K (FP A). 
Secondly, on the other side of the kink-turn, only a few nucleotides of stem I were found 
protected by hPrp31 (FP B). An additional protection was found between hPrp31 and 
nucleotides G18 and C16 in the U4 snRNA context (FP C), where this region is part of a helix 
extending stem I (Myslinski and Branlant, 1991). If one assumes an ideal RNA helix, then the 
distance of 11 base pairs between FP B and FP C would imply that both footprints are located 
on the same face of the RNA helix, some 25 Å apart. In the context of the U4/U6 snRNA 
duplex, FP C is located at almost identical nucleotides, albeit somehow enlarged. In order to 
obtain a relative placing of FP B and FP C in the U4/U6 snRNA context that would be 
comparable to its placement in the U4 context, a continuity of stem I with helix II is required. 
This can only be achieved by a coaxial stacking of stem I onto the U4/U6 helix II. In fact, this 
has recently been proposed for the U4/U6 three-way junction comprising helix II, stem I and 
helix I (Lescoute and Westhof, 2006). Satisfyingly, the location of FP C is in good agreement 
with cross-links that were previously identified between hPrp31 and U4 snRNA nucleotides 
G18/U19 in the context of the U4/U6.U5 tri-snRNP (Nottrott et al., 2002). These two 
nucleotides are located directly next to the FP C. 
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Interestingly, our data are fully compatible with extensive comparison by RNA 
structure probing of the U4/U6.U5 tri-snRNP (containing hPrp31) and 10S U4/U6 di–snRNP 
(lacking it) (Mougin et al., 2002). For example, sites of strong cleavage by the double-strand 
specific nuclease V1 were observed on stem I of U4/U6 snRNAs, irrespective of the presence 
or absence of hPrp31 (U4-G48 and, to a lesser degree, U4-C49), indicating that hPrp31 makes 
contact with stem I from one side only. This is further corroborated by discrete V1 cleavages 
at the 5′ end of stem I (U4-U21 and U4-C22), which were only observed in the absence of 
hPrp31 (Mougin et al., 2002). In sum, these observations suggest that what was observed in 
the U4/U6 complex is directly applicable to the situation in the tri-snRNP. 
Having identified the hPrp31 sites of protection from hydroxyl radicals in the 
U4 snRNA, next it has been speculated how the experimental binding sites could be arranged 
in 3D. For this purpose it has been resorted to the crystal structure of the 15.5K–U4 snRNA 
kink-turn (Vidovic et al., 2000). Through the formation of the kink-turn, stem II would be 
forced into an angle of about 30° relative to the helix axis of stem I (Vidovic et al., 2000). 
Stem I of the U4 snRNA 5′ stem-loop was now simulated by adding an idealised RNA A-
form helix on to the stump of stem I in the crystal structure (Figure 5-3). The experimentally 
determined protection sites were then mapped onto this model. Clearly, hPrp31 would touch 
the RNA in two patches, namely FP C and FP B, and at the same time it would bury whatever 
is exposed of stem II and the penta-loop in FP A (Figure 5-3). From this model it becomes 
clear that hPrp31 approaches the 15.5K-U4 snRNA complex from one side only. 
From the footprint it has been concluded that the relative orientation of hPrp31 to the 
RNA elements should be topologically equivalent between U4 snRNA and the U4/U6 snRNA 
duplex. If one would think of the entire helix II and the coaxially stacked stem I as a single 
idealised RNA helix, then hPrp31 would shield the upper half of this big helix in FP C and 
FP B. This asymmetric binding would be translated into an asymmetric architecture of the 
whole particle. Though highly simplified, this model, in conjunction with the three-way 
junction model (Lescoute and Westhof, 2006), provides readily testable constraints for the 
relative positioning of helix I of the U4/U6 snRNA duplex. This is currently being done by a 




Figure 5-3 Model demonstrating contacted sites of hPrp31 in the U4 snRNA-15.5K binary complex.  
The 15.5K protein has been resolved by crystallography in complex with the U4 snRNA nucleotides G26–G35 
and C41–C47 (Vidovic et al., 2000). For visualisation of regions within the U4 snRNA that are in contact with 
protein hPrp31 an ideal A-form helix was attached to stem I of 15.5K-U4 kink-turn crystal structure. The helix 
sequence used (5′ half, 5′-CCUUCCUUGGAU-3′, 3′ half, 5′-AUCCAAGGAAGG-3′) differs from the wild-type 
U4 snRNA sequence. Footprints of hPrp31 in the U4 snRNA are indicated by the green coloured nucleotides and 
are labelled FP A–C as in the text and in Figure 4-18. The green dashed line indicates the terminal penta-loop 
which was not resolved in the original crystal structure (Vidovic et al., 2000). 
5.3.2. RNA structural requirements for binding of hPrp31 to 
the 15.5K protein–U4 snRNA binary complex 
A systematic mutational analysis revealed a highly differentiated requirement for the 
various RNA structural elements. A battery of U4 snRNA 5′ stem-loop mutants was assayed 
in an electrophoretic mobility-shift assay (EMSA) for overall kinetic stability in ternary-
complex formation. 
The complete 5′ terminal nucleotides (A1–U19), including those nucleotides that were 
in contact with U6 snRNA in the ternary complex (FP C), were found to be inessential. 
Although no binding of the U4–2 had previously been observed (Nottrott et al., 2002), it 
seems likely that the difference in the assay systems accounts for this discrepancy. The 
previous pull-down assay involved a wash step at 500 mM salt, whereas in the present study 
the ternary complex was never subjected to more than 150 mM salt. In addition, the EMSA 
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may detect kinetically stable complexes, which cannot survive the continuous dilution of a 
pull-down assay. 
Although the region of contact between hPrp31 and the kink-turn is only very short 
(FP B), the 8-bp stem I was required for efficient hPrp31 binding to the ternary complex. 
Neither the removal of the upper part (five base pairs and the bulge), nor the removal of a 
bottom part consisting of four base pairs only, was tolerated (Figure 4-19). The 
U4atac snRNA, which also supports ternary-complex formation, does not contain the bulged 
adenosine and has a different stem I sequence, but stem I is of identical length (Figure 5-4). 
This comparison suggests that the length of eight base pairs, but not the sequence of stem I, is 
critical for the binding of hPrp31 to the binary complex. This is further corroborated by a 
phylogenetic analysis, which showed that stem I is, with so far only one exception, exactly 
8 bp long (sequences in this region are collated for 13 organisms in Figure 5-4). Consistent 
with this length requirement, the above-mentioned protection from V1 nuclease cleavage at 
nucleotides U21 and C22 suggest that hPrp31 protein is in contact with the first base pairs of 
stem I. This contact does not result in protection of ribose, since the hydroxyl-radical footprint 
is restricted to the other end of the stem I (FP B). It will be interesting to determine the nature 
of the RNA-protein contacts involved. This will be particularly interesting in view of the 
box C/D discrimination discussed below. 
Paradoxically, the large penta-loop structure, of which every ribose is in contact with 
hPrp31, is not required for binding. This is the more surprising because one of the two UV 
cross-linking sites of hPrp31 on U4 snRNA maps to this region (Nottrott et al., 2002). 
Further, in the U4atac snRNA penta-loop, which has a different sequence, similar cross-links 
are observed to hPrp31 (Kühn-Hölsken et al., 2005). These observations suggest that the 
penta-loop is in close contact with the ribose-phosphate backbone. Various contacts can be 
detected by UV cross-linking, depending on which base is in contact with the protein surface. 
Since this RNA-protein interaction pattern is not required for primary recognition in the 
ternary complex, it is presumably important in one of the dynamic functional states of 
U4 snRNA during the splicing cycle. 
Another interesting feature of the penta-loop deletion mutant (U4-B) is that the 
binding of protein 15.5K to the truncated U4 5′ stem-loop structure was hardly detectable by 
EMSA, even though ternary-complex formation was unaffected (Figure 4-20, lanes 18 and 
19). Thus, it appears that transient and/or weak binding of this protein to the mutant RNA are 
dramatically stabilised by interaction with hPrp31. 
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Since it is known that hPrp31 binds neither the U4 snRNA (Nottrott et al., 2002) nor 
the 15.5K protein (immunoprecipitation data, not shown) on its own, it appears as if hPrp31 
simultaneously recognises the protein and RNA components of the transient binary complex. 
It is conceivable that hPrp31 simultaneously recognises a composite RNA/protein surface of 
the binary 15.5K–U4 snRNA complex. 
The length of stem II turned out to be of crucial importance for hPrp31 binding to the 
binary complex. Binding was completely abolished by extending the stem by a single 
Watson-Crick base pair, irrespective of the presence or absence of the penta-loop (Figure 
4-20). These findings imply that hPrp31 can accommodate at most two base pairs of stem II 
in a binding site; a third base pair interferes sterically with productive binding. This binding 
site thus contributes significantly to the specificity of the RNA-protein recognition. 
Interestingly, a phylogenetic comparison of the penta-loops from human, rat, mouse, chicken, 
and fly U4 snRNA s revealed that in both U4 and U4atac snRNAs no Watson-Crick base pair 
can be formed at the bottom of the penta-loop. This restricts the length of stem II strictly to 
two base pairs, lending further support to the model for molecular recognition outlined above. 
Exceptions are found only in nematode U4 snRNA, which were able to form a C-G pair at the 
top of the penta-loop, and in yeasts, which have a six-membered loop. The latter may have 
special requirements, in that the six-membered loop ends with an A-U base pair (Figure 5-4). 





Figure 5-4 Secondary structure of the U4 or U4atac snRNA 5' stem-loops for selected organisms.  
Gene bank (http://www.ncbi.nlm.nih.gov) accession numbers are given in brackets. H. sapiens U4 (NR_002759) 
and U4atac (U62822), M. musculus U4 (M18004), R. norvegicus U4 (M26115), G. gallus U4 (K00476), D. 
melanogaster U4 (NR_001679) and U4atac (AC007532, positions 155309–155468), C. elegans U4 (X07828), A. 
lumbricoides U4 (L22250), P. sativum U4 (X15932), A. thaliana U4 (X67146) and U4atac (see reference (Wang 
and Brendel, 2004), S. cerevisiae U4 ( M17238). U4 sequences from the yeast strains listed in the bottom row 
are taken from supplemental reference (Bon et al., 2003). Base pairs are denoted by the following nomenclature: 
solid lines for W-C base pairs, solid dots for non–canonical base pairs except for sheared G-A base pairs, which 
are indicated by open circles. 
5 Discussion 
 132 
5.3.3. Different and shared binding requirements between 
hPrp31 and the box C/D snoRNP proteins NOP56 and 
NOP58 
The nucleolar box C/D snoRNPs and the spliceosomal U4 snRNP share a common 
core RNP structure, consisting of the 15.5K protein bound to an internal RNA loop. hPrp31 
selects exclusively U4 snRNA, whereas NOP56/NOP58 selects only the box C/D snoRNP 
structure, with the ultimate result that two particles with completely different biological 
properties and functions are produced. The binding requirements of hPrp31 suggest how this 
discrimination may be achieved on a molecular level. Stems I and II, flanking the 15.5K-
induced kink-turn, are undoubtedly the two important RNA structural determinants that are 
differentially recognised by the different Nop domains (Figure 5-5). 
 
Figure 5-5 Schematic representation of the U4/U6 snRNA and U14 box C/D snoRNA.  
The secondary structures of the U4/U6 snRNA (Brow and Guthrie, 1988) and U14 box C/D snoRNA (Watkins 
et al., 2000; Watkins et al., 2002) are shown on the left and right, respectively. The two flanking stems I and II 
that together with the internal loop form the k-turn are boxed in black. Conserved boxes C and D of the 
U14 snoRNA are indicated in black on a grey background. Base pairing interactions are indicated as in Figure 
4-18. The two helical structures formed between U14 snoRNA and the 18S rRNA, which are essential for 
modification and processing are indicated. 
As outlined above, the stem II binding site of hPrp31 can only accommodate a two-
base-pair-long stem, probably with further restrictions imposed by the closeness of the 15.5K 
protein. In contrast, in the box C/D snoRNA this stem is a conserved three-base-pair-long 
stem with a closing A-U pair (Watkins et al., 2002). In fact, the addition of a Watson-Crick 
base pair to the U4 stem II (mutants U4-7 and U4-8, Figure 4-21) resulted in the loss of 
hPrp31 binding. Therefore, stem II can be viewed as a major discrimination element. 
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Moreover, box C/D snoRNAs have strict sequence requirements for stem II, where a central 
G-C base pair was found to be essential (Watkins et al., 2002). The other discrimination 
element is probably stem I. A four-base-pair-long stem I on box C/D snoRNAs is sufficient 
for NOP56/NOP58 binding, while in the U4 snRNA context this is clearly not sufficient. 
5.3.4. The hPrp31 Nop domain is necessary and sufficient for 
hPrp31 binding to the U4 snRNA-15.5K binary complex 
The Nop domain, initially identified on the basis of sequence alignment (Makarova et 
al., 2002) is here defined more precisely by comparing secondary-structure predictions 
(Figure 4-22) and using the recently published crystal structure of the archaeal Nop5p 
homologue (Aittaleb et al., 2003). The studies show that this domain on its own is both 
necessary and sufficient for binding to the binary 15.5K-U4 snRNA complex. In particular, 
the determinants for recognition of stem II are entirely contained within it. Of the two cross-
linking sites of hPrp31 on U4 snRNA, the one mapping to the penta-loop was retained in the 
RNA construct that could be cross-linked to the Nop domain (Figure 4-23). Therefore, it is 
reasonable to infer that the Nop domain also contains elements of the binding site that are in 
contact with the penta-loop. The penta-loop cross-link itself maps to H270 of hPrp31 (Nottrott 
et al., 2002; Kühn-Hölsken et al., 2005), a residue located in the Nop domain. Interestingly, 
the homologous position in the archaeal Nop5p crystal structure maps to a flexible loop (cf. 
Figure 4-22, dashed grey line). While further studies were not attempted, it is tempting to 
speculate that this unordered loop becomes ordered upon penta-loop binding. On the other 
hand, the penta-loop, which was found to be unstructured in the binary 15.5K-U4 5′ stem-
loop structure (Vidovic et al., 2000), may likewise become structured upon ternary-complex 
formation. This flexibility would be consistent with the above idea that the penta-loop binds 
in a manner largely independent of sequence. 
The observed complex formation suggests that the stem I determinants are likewise 
contained in the hPrp31 Nop domain. This interesting domain thus recognises three different 
RNA structural elements, of which stem I and stem II are required for complex formation. In 
addition, preliminary evidence (Schultz et al., 2006a) indicates that recognition specificity is 
also influenced by recognition between the proteins hPrp31 and 15.5K in the context of 
ternary-complex formation, adding a further element of complexity to the process of binding 
of hPrp31 to the 15.5K–U4 snRNA 5′ stem-loop. 
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Recently, two mutations responsible for the autosomal form of the disorder retinitis 
pigmentosa were mapped to the gene encoding the hPrp31 protein (Vithana et al., 2001). 
While nothing is known about the molecular details of the effect of these mutations, it is 
important to note that they map onto (mutation A216P) or adjacent to (mutation A194E) the 
Nop domain that in this work was found necessary and sufficient for hPrp31 binding to the 
15.5K–U4 snRNA binary complex. It seems possible that the mutations affect the binding of 
hPrp31 to U4 snRNP and may thus exert a subtle influence on tri-snRNP stability. Studies are 
currently under way to investigate these mutations in the assay system. 
5.4. Analysis of retinitis pigmentosa causing mutations in 
the U4/U6 specific hPrp31 protein on cellular 
localisation and tri-snRNP formation 
In this work, the effects of hPrp31 adRP point mutations A194E and A216P causing 
the autosomal dominant form of retinitis pigmentosa (see 2.1.4) on the localisation of protein 
hPrp31 within human cells and on tri-snRNP formation have been studied by combining 
RNAi depletion methods with fluorescence microscopy and biochemical studies using HA-
tagged hPrp31, wild-type and mutants. 
Recent findings show that when the cells are depleted of hPrp31 protein by RNAi 
knock-down, the formation of U4/U6.U5 tri-snRNP is inhibited, and stable U4/U6 di–snRNPs 
and U5 snRNPs accumulate in the cell (Schaffert et al., 2004). This demonstrated for the first 
time in vivo that the U4/U6 protein hPrp31 is essential for the interaction of the U4/U6 di–
snRNP with the 20S U5 snRNP, and it is consistent with previous studies performed in vitro 
(Makarova et al., 2002). Interestingly, under conditions where tri-snRNP formation was 
inhibited, both U4/U6-specific proteins and U4 and U6 snRNAs accumulate in Cajal bodies 
(Schaffert et al., 2004). 
The “rescue” experiments presented here (4.4.2) demonstrate that the wild-type 
phenotype in HeLa cells depleted of hPrp31 can be restored by expressing HA-tagged hPrp31 
wild-type protein (Figure 4-25). The U4/U6 di–snRNP-specific protein hPrp4 is liberated 
from the Cajal bodies and tri-snRNP formation is restored (see Figure 4-25 and Figure 4-26). 
This result therefore strengthens the hypothesis (Schaffert et al., 2004) that tri-snRNP 
formation takes place in Cajal bodies as the expression of exogenous protein hPrp31 is able to 
restore tri-snRNP formation and wild-type phenotype. 
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Mutant A194E gave a staining pattern quite different from that of wild-type hPrp31, 
with signal throughout the cytoplasm and rather less intense staining in the nucleus (Figure 
4-25). This might be due to a reduced solubility of the mutant A194E. The sub-cellular 
localisation shows that A194E mutation interferes with, but does not completely prevent, the 
translocation of protein from its site of synthesis in the cytoplasm to the nucleus. 
Interestingly, protein hPrp31 has been shown to interact with importin (β1) for translocation 
to the nucleus. However, neither the A194E nor the A216P mutation has any affect on this 
interaction (Wilkie et al., 2006). Furthermore, hPrp31 A194E is not capable of reversing the 
accumulation of hPrp4 in Cajal bodies, and the results presented here indicate that mutation 
A194E results in mis-location of the protein. Some soluble protein does reach the nucleus, as 
seen from the confocal images. It is possible that the reduced solubility of the mutant protein 
may result in an insufficiency of splicing activity in cells with a very high metabolic demand, 
and this remains the most likely explanation for the retinitis pigmentosa disorder. The 
problem may alternatively lie in the efficiency of the targeting mechanism by which the 
protein is translocated from its site of synthesis in the cytosol into the nucleus. 
This conclusion is supported by the analysis, which showed that fewer mutant than 
wild-type protein was present in the nucleus (Figure 4-25). It may be that the mutant protein 
is more susceptible to mis-folding and thus produces insoluble aggregates in the cytosol. This 
mis-folding may result in a protein with lost function and to an insufficiency of splicing 
function. This splicing insufficiency might lead to a reduction in the concentrations of certain 
key proteins and, finally, cause cell photoreceptor degeneration.  
In contrast, mutant hPrp31 A216P is capable of migrating to the nucleus. However, 
this mutant is unable to liberate hPrp4 from the Cajal bodies, and itself accumulates in Cajal 
bodies (Figure 4-25). As detected by Western blotting the expression of HA-hPrp31 A216P is 
reduced by a factor of about three compared with the wild-type expression (Figure 4-25). 
Results furthermore show that the formation of the tri-snRNP is not affected by the point 
mutation A216P in hPrp31, and the mutation did not prevent the bridging of the U4/U6 di–
snRNP to the U5 snRNP (Figure 4-26). Bridging of U4/U6 di–snRNP and the U5 snRNP 
takes place by direct interaction of hPrp31 with hPrp6. The pull-down experiments presented 
here demonstrate that the interaction of hPrp31 with the U5-specific protein hPrp6 is not 
impaired by the mutation A216P (Figure 4-26). This result is furthermore supported by yeast 
two-hybrid analysis, which showed binding of mutant hPrp31 A216P to protein hPrp6 similar 
to that of the wild-type hPrp31 (Liu, 2005). 
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Taken together, the results presented in section 4.4 suggest a decrease in concentration 
of functional hPrp31 protein in the nucleus. Such as, inactivation of the Nop domain, could 
cause an insufficiency of splicing function. The Nop domain has been shown to be necessary 
for hPrp31 binding to the U4 snRNP (see 4.3.3) and consequently has a key function in 
tri-snRNP formation (Makarova et al., 2002; Schaffert et al., 2004). One effect of the reduced 
amount of functional hPrp31 protein in the nucleus may be a reduction in the concentrations 
of certain key proteins in the cell. Further investigation in the mammalian system will be 
needed to examine the basic cause of the disorder retinitis pigmentosa. 
5.5. Future Prospects 
The assembly of the spliceosomal U4/U6 di–snRNP and the box C/D snoRNPs has 
been shown to be highly complex and to involve a hierarchical assembly pathway (Nottrott et 
al., 2002; Watkins et al., 2002). This process is initiated by the 15.5K protein, acting as a 
primary RNA-binding protein. At the beginning of this study it was unknown how 15.5K 
directs the assembly of the complex. However, the results presented here demonstrate that 
protein-protein contacts are essential for RNP formation in each complex, and they suggest 
that the formation of each RNP involves the direct recognition of specific elements in both 
15.5K protein and the specific RNA.  
The results presented in this work provide a basic idea of the three-dimensional 
architecture of the U4/U6 di–snRNP and the box C/D snoRNPs (see section 4.1 and 4.3) to 
which further studies such as X-ray crystallography could fall in line. 
In the case of the U4/U6 di–snRNP-specific hCypH/hPrp4/hPrp3 complex, four 
different regions on the surface of protein 15.5K influenced the assembly (see section 4.1.3). 
However, it remains unknown which region on the 15.5K surface makes contact with which 
of the three trimeric-complex proteins. Knowledge of this would provide further essential 
information about the three-dimensional structure of the U4/U6 di–snRNP and, probably, 
about the function of each of the proteins in the U4/U6 di–snRNP.  
Similar considerations will also apply to the box C/D snoRNP assembly, which is also 
known to take place in a hierarchical manner (Watkins et al., 2002). Mutants in different 
regions of the 15.5K surface have been shown to disrupt the association of complex-specific 
proteins, fibrillarin, NOP56, NOP58, TIP48 and TIP49 (see section 4.1.4). However, it is not 
known which region on the 15.5K surface makes contact with which of the box C/D-specific 
proteins. Therefore, the use of recombinant proteins would be helpful in finding out which 
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box C/D-specific protein is in contact with which region on the 15.5K surface. This could at 
the same time yield information about the order of events in the formation of the 
box C/D snoRNP complex, which would improve our understanding about hierarchical 
complex assembly pathways. 
The complex, hierarchical assembly of the U4/U6 di–snRNP and of the 
box C/D snoRNPs are probably dynamic processes. The association of a single protein may 
change the structure of the RNP and at the same time the conformation of the RNA. These 
dynamic rearrangements within the RNA could be investigated in NMR studies by 
assembling the complexes in a stepwise manner. Knowledge about RNA-RNA 
rearrangements within the U4/U6 di–snRNP and the box C/D snoRNPs is of major interest on 
understanding of their function in the different processing pathways in which these complexes 
are involved. 
In the work described in this dissertation, structural features of the U4 snRNA and the 
protein hPrp31 necessary for the binding of hPrp31 to the U4/U6 snRNP were identified (see 
section 4.3). By employing point and deletion mutants of U4 snRNA and deletion mutants of 
protein hPrp31, a minimal U4 snRNA–15.5K–hPrp31 trimeric-complex was identified. The 
results provide a minimal complex that would be suitable for crystallisation; it consists of the 
U4 5' stem-loop and the hPrp31 Nop domain. Crystallisation of the complex would give 
further information about the three-dimensional structure of the U4 snRNP. This is a matter of 
particular interest in comparison with the box C/D snoRNPs as hPrp31 and the 
box C/D snoRNP-specific proteins NOP56 and NOP58 are homologous proteins sharing the 
conserved Nop domain. Conserved Nop domains of hPrp31 and NOP56/NOP58 have to 
recognise on the one hand but have to discriminate on the other hand between the distinct 
15.5K-RNA complexes. 
Protein hPrp31 is also of clinical interest as two mutations (A194E, A216P) in the 
human hPrp31 gene (PRPF31) are correlated with the autosomal dominant form of retinitis 
pigmentosa (see section 2.1.4). Using fluorescence microscopy and biochemical methods it 
has been shown here how hPrp31 mutations influence the localisation of hPrp31 in vivo and 
how they influence U4/U6.U5 tri-snRNP formation (see section 4.4). However, whether both 
mutations have any influence on splicing remains unknown. Therefore, an understanding of 
the effect of mutations A194E and A216P on splicing could be of value in explaining the 
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This section lists the 
abbreviations used in the present 
dissertation. Standard, internationally 
used abbreviations and physical units 
are not included. 
3´-SS 3´-terminal splice site 
5´-SS 5´- terminal splice site 
α anti or alpha 
aa  amino acid 
A Ampere 
Ac Acetate 
APS Ammonium persulfate 
ATP Adenosinetriphosphate 
BSA Bovine serum albumin 
bp  base pair 
C Cytidine 
cpm counts per minute 
d Deoxy 
D Dalton 
DMEM Dulbecco’s Minimal Essential 
Medium 






EtBr  ethidium bromide 
EtOH Ethanol 





hn heterogeneous nuclear 
kDa Kilo 
LB  Luria Bertani medium 
M molar 









PAGE polyacrylamide gel 
electrophoresis 
PBS phosphate-buffered saline 
PCA mixture of phenol, chloroform 
and isoamyl alcohol 
PCR polymerase Chain Reaction 
PK Proteinase K 





RIPA Radio Immuno Precipitation 
Assay 
RNasin RNase inhibitor 
RNP Ribonucleoprotein 
RRM RNA recognition motif 
RT room temperature 
RT-PCR  Reverse transcription PCR 
S Svedberg-Unit (1 x 10-13 
seconds) 
sec seconds 
SDS  sodium dodecyl sulfate 
SF Splicing factor 
sn small nuclear 
sno small nucleolar 
7 Appendix 
 II 
snRNP  small nuclear ribonucleoprotein 
particle 
SR serin-(arginine)-rich 






U Unit (Unit of enzyme activity) 
U snRNP  uridine-rich small nuclear  
ribonucleoproteine particle 
v/v volume per volume 
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